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Abstract 
The in utero environment is a critical determinant of the immediate and future health of the 
developing fetus. In Australia, two of the most commonly used drugs during pregnancy are alcohol 
and nicotine. Prolonged periods of gestational exposure to alcohol and nicotine, separately, have 
been associated with a range of adverse outcomes in the offspring, in both humans and experimental 
animal models. The consequences of ethanol and nicotine exposure restricted to early gestation on 
resultant offspring are poorly characterised, and few animal models exist to build greater 
understanding. Moreover, the immediate molecular changes associated with exposures to ethanol 
and/or nicotine restricted to early gestation has yet to be described. 
 This thesis utilised mouse models of early gestational ethanol and/or nicotine exposure to explore 
the impact of each of these exposures on offspring growth, as well as their associated transcriptional 
and epigenetic changes. In each model, pregnant C57BL/6 dams were provided with ad libitum 
access to solutions of 10% ethanol and/or 100 µg/ml nicotine from fertilisation (0.5 dpc) to mid-
gestation (8.5 dpc). The exposure window utilised in each of the models is developmentally 
equivalent to the first three to four weeks of a human pregnancy. 
Previously, our laboratory identified reduced growth, microcephaly, and gene expression changes in 
the liver and hippocampus of the postnatal offspring of the model of prenatal ethanol exposure 
utilised in this thesis. In contrast, at mid-gestation (9.5 dpc), there was no evidence of 
developmental delay (somite number), reduced growth (crown-rump length), or microcephaly. 
Further, a genome-wide gene expression microarray (targeting 30 855 genes) and a screen of the 
expression of 641 microRNAs, identified only one gene (Bcl11b) as differentially expressed in male 
9.5 dpc whole embryos following the ethanol exposure. These data suggest that there is a delay 
between the ethanol exposure and the onset of adverse phenotypes – arguing that the embryo is 
somehow able to form a memory of the ethanol exposure. The absence of widespread 
transcriptional changes suggests that changes in embryonic mRNA and microRNA expression are 
unlikely to be major contributors to the memory of the exposure.  
A early gestational model of nicotine exposure was newly established in this thesis. This nicotine 
exposure resulted in an average serum cotinine (metabolite of nicotine) concentration similar to that 
reported in humans who smoke 10 to 15 cigarettes per day. This exposure was sufficient to induce a 
reduction in body size both at mid-gestation and postnatally, but not at late gestation. Furthermore, 
the increased expression of Zscan10 in the whole male 9.5 dpc embryo was identified and validated 
across multiple cohorts. Zscan10 encodes for a transcription factor expressed throughout 
development, with a proposed role in the regulation of progenitor cells. The increased expression of 
Zscan10 in the nicotine-exposed embryos was associated with a reduction in DNA methylation at a 
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putative promoter region. These findings demonstrate the capacity for a moderate dose of nicotine 
to have both molecular and phenotypic consequences in the offspring, raising questions as to the 
safety of nicotine usage during early pregnancy. 
A model of concomitant ethanol and nicotine exposure was also newly established in this thesis. 
When compared to the nicotine-only model, there was no evidence for an exacerbation of the 
phenotype of reduced growth. It is possible that had other phenotypes been assayed, an interactive 
effect may have been observed. The exact conditions under which a dual exposure to ethanol and 
nicotine can result in interactive effects on offspring phenotype are at present unclear; however, the 
individual dosages of ethanol and nicotine, as well as the timing of the exposure are likely to be of 
importance. 
This thesis adds to a growing body of literature suggesting that moderate environmental exposures 
restricted to early pregnancy have the capacity to result in both short- and long-term consequences 
on the developing embryo. The findings from the ethanol model highlight that the absence of an 
overt embryonic phenotype does not necessarily preclude the development of other phenotypes later 
in life. This is the first time in which a nicotine exposure, when restricted to early gestation, has 
been demonstrated to have the capacity to influence future phenotype. The high rate of women who 
cease drinking alcohol and smoking tobacco upon pregnancy confirmation within the Australian 
community highlights the willingness of women in our society to make lifestyle modifications to 
protect the health of their baby. If the potentially detrimental impact of early-gestational exposures 
were better understood, this would enable not only women planning a pregnancy to make more 
informed decisions as to the lifestyle choices they make during the peri-conceptional period, but 
would also allow for better risk mitigation in individuals who were inadvertently exposed prior to 
pregnancy recognition. 
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1 Introduction
1.1 Early-life exposures can influence later health
The gestational environment in which the fetus develops - as postulated by the Developmental Ori-
gins of Health and Disease hypothesis - is a crucial determinant of both its immediate and future
health. There have been a number of human epidemiological studies identifying a relationship be-
tween early-life environment and later health. A relationship between adverse early-life environments
and adult cardiovascular disease was suggested when David Barker identified that the local authority
areas within England and Wales with high infant mortality rates in 1921 - 1925 subsequently had in-
creased levels of mortality from ischaemic heart disease in 1968 - 1975 (Barker and Osmond, 1986).
The Dutch Winter Famine occurred in the last six months of the second world war was relatively
well-defined in nature, therefore allowing for the identification of consequences resultant of exposure
to maternal undernutrition at various windows of time during pregnancy (Ravelli et al., 1976). In
this cohort, men who were exposed to famine during the first two trimesters of gestation were found
to have increased levels of obesity at age 19, whereas men exposed during the final trimester and/or
the first few months of life had reduced levels of obesity at age 19 when compared to control indi-
viduals not exposed to the famine (Ravelli et al., 1976). Subsequently, numerous other longitudinal
cohort studies have been established, further strengthening the hypothesis that a range of early-life
environments in humans is associated with long-term health (recently reviewed in Ganu et al., 2012;
Hanson and Gluckman, 2014, and Heindel et al., 2016). While these are striking correlations, hu-
man studies have many confounding variables (e.g., variable exposure severity and window, effects
of socio-economic status, heterogeneous genetic background), and consequently, it can be difficult to
claim that early-life environments have a causal relationship with adult health.
The contribution of these confounding variables to phenotypic outcome can be greatly reduced by
utilising animal models. Animal studies have expanded upon the foundations established by the hu-
man epidemiological studies and identified adverse phenotypic consequences associated with a range
of prenatal exposures including but not limited to those of ethanol (Kaminen-Ahola et al., 2010b),
hypoxia (reviewed in Golan and Huleihel, 2006), cigarette smoke (Leichter, 1989; Esposito et al.,
2008), nicotine (Holloway et al., 2005), glucocorticoid exposure (Moritz et al., 2011), maternal un-
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dernutrition (Kwong et al., 2000), maternal obesity (Nicholas et al., 2013), and high-fat diet (reviewed
in Williams et al., 2014). Furthermore, due to the capacity to harvest tissue samples from all organs at
all ages, these animal studies have also allowed for a greater understanding of the molecular changes
associated with these exposures.
1.1.1 Potential mechanisms underlying the programming of disease-risk by
early-life exposures
The exact mechanism by which the early-life environment programs disease-risk into the developing
fetus is poorly understood. One of the hypotheses for how this occurs, is that the early-life exposure
perturbs normal organ development during fetal development, in turn leading to impaired organ func-
tion and thus disease later in life (Desai and Hales, 1997; Ingelfinger and Woods, 2002; Hyatt et al.,
2008).
Another potential mechanism underlying this programming is that the early-life exposure modulates
the epigenome, which in turn may have consequences on gene expression, thereby influencing later
disease-risk (reviewed in Yamada and Chong, 2016). Epigenetics is the study of heritable changes in
gene expression, which occur without changes to the underlying DNA sequence. Epigenetic mecha-
nisms encompass DNA methylation, histone modifications, and the expression of non-coding RNAs
(reviewed in Yamada and Chong, 2016). Although under tight regulation, the epigenetic state of the
genome is sensitive to perturbations in the environment. So sensitive is the epigenome to environ-
mental factors, it has been described to be the interface between the environment and the genome
(Richards, 2006). Maternal dietary levels of compounds such as folic acid, vitamin B12, choline and
betaine during gestation have been shown to permanently affect epigenetic states and gene expression
in the developing fetus in a mouse model (Waterland and Jirtle, 2003). Similarly, exposure during
gestation to environmental toxins such as the fungicide Vinclozolin has been shown to elicit a pheno-
typic response which correlated with epigenetic alterations (Anway et al., 2005). Even the use of in
vitro culture techniques have been reported to alter the epigenome resulting in transcriptional changes
(Dean et al., 1998). Given the sensitivity of the epigenome to the environment, it is highly possible
that changes to the epigenome may contribute to some of the aberrant programming events resultant
of early-life exposures.
During embryogenesis, there are two major periods of epigenetic reprogramming. These reprogram-
ming events are necessary to allow cells of the early embryo to achieve a state of pluripotency, a
requirement of embryogenesis (Bhutani et al., 2010). In the preimplantation embryo, a genome-wide
demethylation event occurs (reviewed in Reik et al., 2001), with methylation re-established in a de
novo manner from implantation (approximately 4.5 dpc) onwards (Monk et al., 1987). A second ma-
jor reprogramming event occurs later in development during gametogenesis (reviewed in Reik et al.,
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2001). It could be hypothesised that the epigenome is most susceptible to environmental exposures
during these periods of epigenetic reprogramming (reviewed in Yamada and Chong, 2016).
1.2 Gestational alcohol and tobacco usage in Australia
Alcohol and tobacco were identified as two of the drugs most commonly used during pregnancy in a
survey of women pregnant in Australia in 2013, with 56% and 17.4% of the surveyed women drinking
alcohol or smoking tobacco, respectively, at any point during pregnancy (Australian Institute of Health
and Welfare, 2014). The rates of high-risk drinking and smoking are not homogenous throughout the
general population, with prevalence rates of each of these behaviours considerably higher amongst
individuals of the lowest socio-economic status as well as within the Indigenous Australian population
(Australian Institute of Health and Welfare, 2014).
A study on 92 Australian cases of Fetal Alcohol Syndrome (discussed in more detail in Section 1.3.1)
between 2001 and 2004 found that 78.3% of affected children had also been exposed to a secondary
drug (e.g., nicotine, marijuana, and heroin) during gestation (Elliott et al., 2008). Of these, nicotine
was the most frequently identified as being used with alcohol, with 67.4% of affected children also
being identified as exposed to nicotine during pregnancy (Elliott et al., 2008), despite only 17.3% of
mothers who were surveyed Australia-wide, who gave birth in 2003, admitting to smoking cigarettes
during their pregnancies (Laws et al., 2006). A recent study which enrolled pregnant women from
north-east New South Wales and south-east Queensland from 2007 - 2011 found that women who
smoked during pregnancy were more likely to also consume alcohol both at any level, and in a high-
risk manner during pregnancy (Cameron et al., 2013), with similar trends identified in a cohort of
women in Michigan (USA) (Flynn et al., 2003). As alcohol and tobacco are often used simultane-
ously, it is therefore critical to understand the consequences not only of each exposure in isolation,
but also the consequences resultant of a co-exposure during pregnancy.
1.3 Consequences of prenatal ethanol exposure
1.3.1 Phenotypic consequences of prenatal ethanol exposure
Evidence in humans
The maternal consumption of alcohol during pregnancy can lead to a spectrum of alcohol related
disorders in the offspring, which collectively are classified under the term of Fetal Alcohol Spectrum
Disorders (FASDs). Of the FASDs, Fetal Alcohol Syndrome (FAS) is used to describe patients who
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present on the most severe end of the spectrum (Hoyme et al., 2005). Fetal Alcohol Syndrome is char-
acterised by abnormal neural development, growth retardation, and craniofacial abnormalities which
can be attributed to a known or suspected exposure to alcohol in utero (Astley, 2004). More recently,
it is becoming apparent that the phenotypic consequences of prenatal ethanol exposure are not re-
stricted to these phenotypes, with a recent literature review identifying greater than 400 conditions
to be comorbid with FASDs (Popova et al., 2016). FASDs have also been associated with a num-
ber of secondary disabilities including disrupted school experiences, experiencing trouble with the
law, confinement, inappropriate sexual behaviours, and alcohol or drug related problems (Streissguth
et al., 2004). A high proportion (23.3%) of youth who had been convicted of criminal offences and
remanded to the Inpatient Assessment Unit in British Columbia (Canada) in a one year period (from
1995-1996) were assessed as having an alcohol-related diagnosis (Fast et al., 1999).
The prevalence of Fetal Alcohol Syndrome (FAS) varies considerably between communities. In a
high-risk community in South Africa, the prevalence in first graders was as high as 65.2 - 74.2 per
1000 children (Viljoen et al., 2005). In Australia, the prevalence of FAS in children under the age of
5 between 2001 and 2004 was estimated to be 0.037 per 1000 non-Indigenous children, or 1.46 per
1000 Indigenous children (Elliott et al., 2008). The authors of this study did indicate that these figures
are likely to be underestimated due to difficulties associated with diagnosis. Even fewer studies have
attempted to estimate the prevalence of FASD, but it has been estimated in one study that prevalence
in the US and some Western European countries of FASD is between 2 - 5 % (May et al., 2009).
Evidence in animal models
Animal studies have successfully recapitulated the three main diagnostic feature of FAS: abnormal
neural development (Zhang et al., 2015), growth retardation (Kaminen-Ahola et al., 2010b; Probyn
et al., 2012; Gardebjer et al., 2014) and craniofacial abnormalities (Sulik et al., 1981; Anthony et al.,
2010; Kaminen-Ahola et al., 2010b). In addition to these, the usage of animal models has allowed for
the investigation of a wide range of other phenotypes resultant of prenatal ethanol exposure: impair-
ments to behaviour (Sanchez Vega et al., 2013), glucose metabolism (Harper et al., 2014), adiposity
(Dobson et al., 2012), renal (Gray et al., 2010) and cardiovascular (Ren et al., 2002) function, lung
development (Probyn et al., 2013), hypothalamic-pituitary-adrenal function (Lan et al., 2009), and
even osteoarthritis risk (Ni et al., 2015).
Collectively, both human and animal studies suggest that prenatal exposure to ethanol can result in
a vast array of adverse consequences affecting a range of organ systems, which can have profound
effects on quality of life.
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1.3.2 Cellular and molecular changes associated with prenatal ethanol expo-
sure
The usage of animal models have allowed for a greater understanding of the mechanisms by which
prenatal ethanol exposure can affect the developing fetus. Increased apoptosis, specifically in the
neural crest cells was reported following the injection of 42 mM ethanol into the yolk sacs of chick
embryos (Cartwright et al., 1998), as well as in mouse embryos at 10 dpc following the acute exposure
of dams to ethanol from 8.5 dpc to 9.5 dpc (Wang and Bieberich, 2010). Mitochondrial dysfunction
(Ramachandran et al., 2001) has been proposed to be one of the possible mediators of this ethanol
induced apoptosis. This theory is supported by other studies which have reported an increase in
reactive oxygen species and oxidative DNA damage following ethanol culture of embryonic midbrain
cells (Da Lee et al., 2005). Similarly, increases in various markers of oxidative stress were observed
in 19 dpc fetuses following an acute in utero exposure over two days between 17 dpc and 18 dpc in
Sprague-Dawley rats (Henderson et al., 1995). Together, these results show a likely role for oxidative
stress contributing to apoptosis following prenatal alcohol exposure.
Aside from cell death, a number of other biological processes are also affected by ethanol. A re-
duction of cellular proliferation has been reported following ethanol culture of the mid-brain from
mice aged 12 dpc (Jing and Li, 2004). In utero ethanol exposure of Sprague-Dawley rats resulted
in diminished fetal glucose uptake, which correlated with a decrease in fetal brain weight (Singh
et al., 1989). A study using cell culture found that cell-cell adhesion was affected following the ad-
dition of ethanol to cells (Ramanathan et al., 1996). Furthermore, transcriptional changes have also
been identified in various models of prenatal ethanol exposure affecting numerous signaling cascades
critical for normal embryogenesis: the sonic hedgehog signaling cascade (Ahlgren et al., 2002; Li
et al., 2007; Vangipuram and Lyman, 2012), the Wnt/β catenin signalling pathway (Serrano et al.,
2010; Vangipuram and Lyman, 2012; Tong et al., 2013), and the Notch signalling pathway (Sathyan
et al., 2007; Tong et al., 2013). Collectively, these studies indicate that alcohol is likely to act via a
combination of mechanisms to induce fetal teratogenesis.
Epigenetic changes have also been identified in various models of prenatal ethanol exposure. Ex-
posure of pregnant mice on gestational days 9 to 11 resulted in decreased DNA methyltransferase
activity in the fetus, and the subsequent global hypomethylation of DNA (Garro et al., 1991). Em-
bryos exposed to ethanol in vitro for two days from embryonic day 8.25 had a higher frequency of
neural tube defects and, in those embryos with defects, a higher number of genes with DNA methy-
lation changes in the promoter region was observed (Liu et al., 2009). An inverse correlation was
also observed between the methylation state of the promoter region and mRNA expression (Liu et al.,
2009). Furthermore, previous work from our laboratory has reported altered DNA methylation at
numerous loci following in utero ethanol exposure for the first eight days of gestation in the mouse
(Kaminen-Ahola et al., 2010b; Zhang et al., 2015). At one of the genes at which DNA methyla-
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tion was identified to be altered (Slc17a6), post-translational histone modifications were also altered
(Zhang et al., 2015), suggesting that multiple epigenetic modalities are likely to be sensitive to ethanol
exposure.
A vast array of cellular and molecular perturbations following ethanol exposure during either mid-
or late gestation have been identified in various animal models. However, little is known as to the
immediate molecular perturbations following an ethanol exposure during early gestation. While the
model previously developed in our laboratory did utilise an in utero model of early gestational ethanol
exposure, only the long-term consequences were assayed (Kaminen-Ahola et al., 2010b; Zhang et al.,
2015). As such, further work is required to understand the molecular changes immediately follow-
ing the early-gestational exposure which may precede the previously identified long-term postnatal
outcomes.
1.3.3 Impact of prenatal ethanol exposure on offspring growth
Evidence in humans
Growth deficiency is one of the criterion necessary for the diagnosis of Fetal Alcohol Syndrome in
the Washington four-digit diagnostic code (Astley, 2004). This reduction in body size of children
prenatally exposed to ethanol can be detected in infancy, and then persists throughout childhood into
adolescence (Streissguth et al., 1985; Day et al., 1989, 1999, 2002). Although Day and colleagues
were able to detect persistent growth restriction from infancy through to adolescence, the life-long
nature of the growth restriction has yet to be validated in other independent longitudinal cohorts.
Evidence in animal models
The capacity for ethanol to result in reduced body size has been validated in a number of animal mod-
els; however, the exact nature of the impact of ethanol exposure on growth appears to vary between
experimental models. In a rat model of ethanol exposure using a liquid diet (from three weeks prior
to conception and lasting throughout gestation), a reduction in offspring body weight was observed at
both postnatal day 1 and 22 (Witek-Janusek, 1986). In contrast, in a similar rat model, again using an
ethanol exposure by liquid diet (from prior to conception and then throughout gestation), a reduction
in fetal body size was observed at gestational day 18, but this reduction was transient in nature - with
a reduction in body size no longer apparent by gestational day 21 (Robinson and Seelig, 2002). A
transient ethanol-induced growth restriction was also identified in another rat model of ethanol expo-
sure (administered by liquid diet for the entirety of gestation), in which the reduction in fetal weight
present at gestational day 20 was no longer apparent at postnatal day 30 (Probyn et al., 2012). In
the same study, the ethanol-exposed rats had a reduced crown-rump length at eight months of age
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(Probyn et al., 2012). Furthermore, the head and brain are not spared from the effects of prenatal
ethanol exposure, with reduced head size reported in both humans (Day et al., 1989; Elliott et al.,
2008; Feldman et al., 2012) and animal models (Maier et al., 1997; Kaminen-Ahola et al., 2010b).
These studies highlight the complex, and often temporally-specific nature of ethanol-induced growth
restriction.
Potential mechanisms underlying ethanol-induced growth restriction
The mechanisms for this ethanol-induced reduction in growth are poorly understood. Children who
were exposed to ethanol in utero were found to secrete less growth hormone than non-exposed chil-
dren of normal body size, but of comparable levels to non-exposed small-for-gestational-age children
(Hellström et al., 1996). Furthermore, there was a greater increase in the levels of insulin-like growth
factor I (IGF-I) in prenatally ethanol-exposed children at age 3 and 4 when compared to non-exposed
children (Aros et al., 2011). In this study, there was a correlation between IGF-I levels and body size
(body mass index, height, and weight) in the healthy children at age three; however, this correlation
between IGF-I and body size was lost in the ethanol-exposed children at age three (Aros et al., 2011),
suggesting that not only did prenatal ethanol exposure perturb IGF-I levels, but the ethanol exposure
was also able to perturb the relationship between IGF-I and body size (Aros et al., 2011). The rate
of postnatal growth of mice lacking a functional copy of IGF-1 was reduced when compared with
wildtype mice (Baker et al., 1993), suggesting that a deficiency in IGF-1 is likely to lead to growth
restriction. However, it is presently unknown what effect an over-expression of IGF-1, such as that ob-
served by Aros et al., 2011, has on growth. Prenatal ethanol exposure has consequences on both pre-
and postnatal growth; however, the exact mechanism behind this is poorly understood. Further study
is required to better understand not only the role of IGF-1 in ethanol-associated growth restriction,
but also to identify other potential genes and mechanisms underlying the growth restriction.
1.4 Consequences of prenatal tobacco and nicotine exposure
Maternal tobacco smoking during pregnancy is associated with a range of adverse outcomes on the
offspring, both during pregnancy and well into postnatal life. Children whose mothers smoked during
their pregnancies are at increased risk of reduced birth weight (Butler et al., 1972; Lieberman et al.,
1994; Ward et al., 2007), cognitive impairments (Julvez et al., 2007), behavioural problems (Weitzman
et al., 1992), asthma (Jaakkola and Gissler, 2004), altered immune function (Noakes et al., 2006),
aberrant metabolic profiles (reviewed in Behl et al., 2013), offspring nicotine dependence (Buka et al.,
2003), spontaneous abortion (Kline et al., 1977), stillbirth (reviewed in Marufu et al., 2015), and
Sudden Infant Death Syndrome (Anderson et al., 2005).
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Tobacco smoke is comprised of over 5 000 chemicals, many of which are known to be toxic to humans
(Talhout et al., 2011). Furthermore, the very act of smoking results in exposure to carbon monoxide
and tissue hypoxia (Sagone et al., 1973; Jensen, 1991) - a condition which in and of itself, is known
to be of detriment to the developing fetus (reviewed in Golan and Huleihel, 2006 and Hutter et al.,
2010). Given the complex composition of tobacco smoke, understanding the mechanisms by which
tobacco exposure influences fetal health is challenging.
One of the chemicals found in tobacco smoke is nicotine, which has been identified to be a repro-
ductive or developmental toxicant (U.S. Food and Drug Administration, 2012). Despite the diffi-
culty in legally obtaining them in Australia, the usage of e-cigarettes, which deliver vaporised nico-
tine, increased amongst current and recent ex-smokers between 2009 and 2013 in Australia (Yong
et al., 2015) - an increase likely driven in part by the perception that they are safer than conventional
cigarettes (Czoli et al., 2016).
Consequently, it is vital to better understand the consequences of prenatal nicotine exposure, both
within the context of smokers, as well as the growing number of individuals choosing to use nicotine
alone (either by e-cigarette or nicotine replacement therapy).
1.4.1 Phenotypic consequences of prenatal nicotine exposure
Evidence in humans
While a number of studies have assessed the safety of nicotine replacement therapies in smokers rel-
ative to tobacco use only in the context of smoking cessation during pregnancy, each of these studies
are confounded by the relatively poor rate of smoking cessation observed, with the majority of women
using nicotine replacement therapy in each of the studies continuing to smoke throughout pregnancy
(Oncken et al., 1996; Wisborg et al., 2000; Pollak et al., 2007). At time of writing, two studies have
been published which identified non-smoking pregnant women who used nicotine replacement ther-
apies. A study which included 76, 768 pregnancies from the Danish National Birth Cohort identified
a greater risk of congenital malformations following the use of nicotine substitutes (gum, patches,
and inhalers) than with tobacco products in the first 12 weeks of pregnancy (Morales-Suárez-Varela
et al., 2006). In the same Danish cohort, while not statistically significant, there was a trend towards
a dosage-dependent inverse relationship between the number of nicotine therapy replacement types
used simultaneously in the first 27 weeks of gestation and offspring birthweight (Lassen et al., 2010).
In this cohort, preterm delivery was slightly more prevalent within nicotine substitute users (4.1%)
than women using neither nicotine nor tobacco products (3.2%), but whether the difference between
these particular groups was statistically significant was not reported (Lassen et al., 2010). Together,
these studies suggest that exposure to nicotine alone is associated with risks to the developing fetus
(Morales-Suárez-Varela et al., 2006; Lassen et al., 2010).
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Evidence in animal models
There is a growing body of evidence from animal models that many of the phenotypes resultant from
prenatal cigarette smoke exposure can also be induced by nicotine alone. Prenatal exposure to nicotine
has been reported to result in changes to offspring growth (Wang et al., 2008), metabolic outcomes
(Gao et al., 2005; Holloway et al., 2005; Somm et al., 2008, 2009; Ma et al., 2014; Xu et al., 2015),
cognitive behaviour (Ernst et al., 2001; Alkam et al., 2013), locomotor activity (Pauly et al., 2004),
nicotine preference (Klein et al., 2003), genital development (Gyekis et al., 2010), vulnerability to
hypoxia (Li et al., 2012), asthma (Rehan et al., 2012), neuroanatomy (Chen et al., 2005; Mychasiuk
et al., 2014), and immune function (Basta et al., 2000). Given the increasing usage of nicotine sub-
stitutes within the Australian population, it is imperative to better establish the safety, or lack thereof
for the use of these products during pregnancy.
1.4.2 Cellular and molecular changes associated with prenatal nicotine expo-
sure
Nicotine is a ligand for the nicotinic acetylcholine receptor (nAChR). The earliest published reports
of the expression of genes comprising the subunits for this receptor in the mouse are from 10.5 dpc
(approximately mid-gestation) onwards (Michalk et al., 2008). Prior to the expression of this receptor,
it is likely that nicotine affects the embryo by indirect mechanisms. Maternal nicotine administration
to rats during the first five days of gestation can result in delayed embryo implantation, due in part to a
disturbance in maternal progesterone secretion (Yoshinaga et al., 1979). In addition, nicotine admin-
istration can also result in diminished oviducal blood flow to the preimplantation embryo (Mitchell
and Hammer, 1985), which in turn could impair embryo development.
Nicotine has been demonstrated to affect a number of cellular processes in the developing embryo.
Dose-dependent increases in oxidative stress leading to apoptosis were described in mouse embryos
cultured in nicotine for 48 hours from both gestational day 8.5 (Zhao and Reece, 2005) and gestational
day 9.5 (Roy et al., 1998). At gestational day 11.5 in the mouse, specific neuronal regions (e.g.,
the hindbrain) appeared to be more sensitive to nicotine-induced apoptosis than others, with this
sensitivity to nicotine hypothesised in Roy et al., 1998 to correlate with increased nicotinic receptor
expression. The suggestion that prenatal nicotine exposure can result in apoptosis is not restricted
to cultured embryos; following an in utero exposure to nicotine from gestational days 4 - 18 in the
mouse, increased expression of c-fos mRNA, which encodes for a protein associated with apoptosis,
was observed in the fetal brain at gestational day 18 (Slotkin et al., 1997). Interestingly, when the
same exposure was terminated at gestational day 12, no changes in c-fos expression was observed
in the fetal brain at gestational day 18 (Slotkin et al., 1997). Whether the lack of expression change
six days after an exposure restricted to early gestation was reflective of an immediate but transient
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increase in expression, or whether the developing embryo has greater sensitivity to nicotine later in
gestation has yet to be determined. These studies collectively suggest that prenatal nicotine exposure
can result in increased apoptosis in the developing embryo by a variety of mechanisms, however
further work is required to better understand the processes involved.
Transcriptional changes have been reported in various tissues of rodent offspring subjected to a prena-
tal nicotine exposure. The altered expression of Cyp2a3 and Cyp2b1 mRNA (which encode proteins
involved in the metabolism of nicotine into cotinine) in the lungs of the resultant pups was reported
following the administration of nicotine to pregnant rats through both gestation and postnatally (up to
weaning) (Gamieldien and Maritz, 2004). In addition, prenatal nicotine exposure in rats has also been
identified to result in the reduction of the expression of various nAChR subunit mRNAs in the ventral
tegmental area of the adolescent offspring (Chen et al., 2005). As previously discussed, increased
c-fos mRNA expression was observed in the fetal brain at gestational day 18 following a prenatal
nicotine exposure (Slotkin et al., 1997). While it is clear that prenatal nicotine exposure can result in
late gestational and postnatal gene expression changes, whether gene expression changes also occur
earlier in gestation have yet to be reported.
In addition to transcriptional changes, changes to the epigenome following prenatal nicotine expo-
sure have also been reported. Following in vivo gestational nicotine exposure in rats, the offspring
at postnatal day 21 were found to have global changes in the level of DNA methylation (testicu-
lar and ovarian tissue), histone 3 acetylation (lung and testicular tissue), and histone 4 acetylation
(lung, testicular, and ovarian tissue) (Rehan et al., 2012). Another study identified downregulation of
angiotensin type 2 mRNA in male postnatal day 10 rat pups, which was correlated to increased methy-
lation at the promoter region of this gene, following gestational exposure to nicotine (Li et al., 2012).
No literature has been published to date linking immediate transcriptional and epigenetic changes in
the early embryo following an in vivo nicotine exposure.
1.4.3 Impact of prenatal nicotine on offspring growth and adiposity
Growth in humans
To date, one study has suggested that nicotine replacement therapies in the first 27 weeks of gestation
can result in reduced birth weight in humans (Lassen et al., 2010). In contrast, numerous animal
models have indicated that prenatal nicotine exposure can influence offspring growth in early life.
Growth in animal models
The offspring of Swiss-Webster mice provided with ad libitum access to 100 µg/ml of nicotine in
water for two weeks prior to conception and then for the entirety of gestation were found to have
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reduced body weight at gestational day 17 (Rowell and Clark, 1982). In a similar model, birth weight
was reduced in the offspring of pregnant Wistar dams subcutaneously injected with nicotine from two
weeks prior to conception, continuing throughout pregnancy and lactation (Holloway et al., 2005).
Reduced offspring growth was apparent even in models in which exposure was restricted to mid- to
late gestation; Wistar rat fetuses had reduced body weight in late gestation (gestational days 15, 18,
and 21) following twice daily maternal subcutaneous injections of nicotine from gestational day 8
until the end of pregnancy (Wang et al., 2008). Similarly, growth restriction during postnatal weeks
1 and 24 was observed in Wistar rat pups prenatally exposed to nicotine from gestational days 11 -
21 (administered by twice daily subcutaneous injections) (Xu et al., 2015). In contrast, birth weight
of offspring of Sprague-Dawley dams fitted with osmotic minipumps from gestational day 4 until the
end of gestation was no different to that of controls (Somm et al., 2008). Exactly why the offspring
from this model displayed no change in birth weight when others utilising a similar dosage and ex-
posure window did identify changes (Wang et al., 2008) is unclear. The delivery of the nicotine by
osmotic minipump is likely to result in a steady-state chronic exposure, rather than acute fluctua-
tions in circulating nicotine concentration as would occur following subcutaneous injections, and it is
possible that this difference in delivery method may contribute to the lack of effect on birth weight.
In the absence of knowledge of maternal serum nicotine or cotinine concentrations, the differences
in strain, nicotine dosages and administration methods utilised in each model complicates the direct
comparison of one study to another (Matta and Elberger, 2007). Nonetheless, these studies suggest
that nicotine exposure for either the entirety of gestation, or from mid-gestation are likely to result in
reduced fetal growth. At present it is unclear whether an exposure to nicotine restricted to just early
gestation will elicit similar results.
Later-life adiposity in animal models
An increasing number of studies are reporting an increased risk of adiposity later in life following a
prenatal exposure to nicotine. Although having lower birth weights, Wistar rat pups subjected to a
prenatal nicotine exposure (subcutaneous nicotine injections to pregnant dams from two weeks prior
to conception through to weaning) had body weights comparable to that of their control counterparts
by weaning (Holloway et al., 2005), and were significantly heavier than control offspring by postnatal
week 10 - an increase likely to be reflective of the observed increase in fat pad mass (Gao et al.,
2005). In the Sprague-Dawley rat model in which nicotine was delivered by osmotic minipump from
gestational day 4 throughout gestation (discussed above), the nicotine-exposed offspring had increases
in both body weight and epididymal white adipose tissue at weaning (but not at birth) (Somm et al.,
2008). Whether this increased tendency towards adiposity can also occur with a prenatal nicotine
exposure restricted to just early gestation has yet to be determined.
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There are a number of potential mechanisms by which this increase in adiposity following a prenatal
nicotine exposure may occur. Rat offspring prenatally exposed to nicotine (as discussed above) dis-
played increased expression of adiponectin - a regulator of insulin sensitivity - in epidydymal white
adipose tissue, with a corresponding reduction in insulin sensitivity (Somm et al., 2008). The increase
in insulinemia may contribute to the increased adiposity observed in this model (Somm et al., 2008),
as insulin has known roles in stimulating adipogenesis (Zhang et al., 2009). Furthermore, Wistar
rats exposed to prenatal nicotine exposure (from gestational day 11) were also found to have distur-
bances in their hypothalamus-pituitary-adrenal axis (Xu et al., 2013) - the dysregulation of which is
associated with obesity (reviewed in Bose et al., 2009). More study is required however, to further
elucidate the mechanisms behind these increased tendencies towards adiposity present following a
prenatal nicotine exposure.
1.5 Consequences of concomitant exposure to ethanol and to-
bacco products
Evidence in humans
Given the high proportion of children with FAS exposed to nicotine products (Elliott et al., 2008),
it could be hypothesised that this dual exposure could potentiate the growth restriction associated
with FAS. A study that utilised data from 655 758 singleton pregnancies in Missouri, USA found an
increased risk of infants being identified as small for gestational age when exposed to both alcohol
and tobacco products during gestation when compared to either exposure alone (Aliyu et al., 2009).
Similar results identifying a potentiating effect of alcohol on the effect of tobacco on newborn size in
humans have been found in studies on cohorts from Denmark (Olsen et al., 1991), England (Wright
et al., 1983; Brooke et al., 1989; Haste et al., 1991), and the USA (Sokol et al., 1980; Day et al.,
1992). However, a similar study on a US cohort was only able to identify a synergistic effect of
prenatal alcohol and tobacco exposure on birthweight in infants of mothers greater than 30 years of
age (Jacobson et al., 1994). In addition to affecting growth, a synergistic affect of alcohol and tobacco
use was identified on attention and reaction time in 454 4-year old children (Streissguth et al., 1984),
raising the possibility that other phenotypes may also be affected. Further work is required to elucidate
the exact circumstances in which a synergistic effect between alcohol and tobacco may occur.
Evidence in animal models
The potentiating effect of co-exposure to cigarette smoke and ethanol on growth has been validated
in an experimental study, which gave pregnant rats ad libitum access to 30% ethanol, and 2 hours
daily cigarette-smoke exposure for the first 20 days of gestation. When offspring were assessed at
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gestational day 20, a significant decrease in fetal weight was observed in both the ethanol-only and
cigarette-only groups compared to controls, while an even greater effect was observed in offspring of
the combined exposure (Leichter, 1989).
Another study which administered daily intraperitoneal ethanol injections (maternal blood alcohol
concentration > 300 mg/dl) and exposed pregnant dams to the smoke of 1.5 cigarettes/day in outbred
Swiss albino mice from 6 - 17 dpc identified resorptions in 5% of tobacco-treated offspring, 31%
of ethanol-treated offspring and 67% in the combined exposure offspring. Interestingly, cleft palates
were observed at a greater frequency in the ethanol-treated offspring when compared to combination
treated offspring. The authors did postulate that this could be explained by the embryonic lethality of
offspring with severe malformations, so only the moderately affected offspring would survive to be
assayed at 17 dpc (Peterson et al., 1981).
An experimental study compared the incidence of limb defects in mouse embryos following acute
high dose exposure of pregnant dams to cigarettes and/or ethanol on gestational day 10. Cigarette
or ethanol exposure alone resulted in low incidences of defects (0% and 1%, respectively), whereas
exposure to both cigarettes and ethanol resulted in a higher rate of limb defects (43%) in resultant em-
bryos (Fazel, 1996). Together, these findings further support the hypothesis that there is a synergistic
interaction between ethanol and tobacco products with teratogenic consequences.
1.6 Consequences of concomitant exposure to ethanol and nico-
tine
Evidence in humans
While there is a reasonable body of evidence to suggest a potential synergistic interaction between
ethanol and tobacco products during pregnancy, whether a similar interaction occurs between ethanol
and nicotine is less well described. To the best of our knowledge, at time of writing no human studies
had been published investigating the consequences following concomitant alcohol and nicotine usage
(in the absence of tobacco) during pregnancy.
Evidence in animal models
The combined exposure of ethanol and nicotine has been documented in a number of experimental
animal studies, however, the results are conflicting. Offspring from pregnant rats that were admin-
istered nicotine (3.0 mg/kg body weight twice daily via intraperitoneal injection) with access to a
liquid diet containing 10% ethanol for the first 21 days of gestation were identified to have greater
rates of stillbirth and neonatal death than in offspring exposed to either ethanol or nicotine alone
14 INTRODUCTION
(Martin et al., 1982). A similar study which administered nicotine (2 mg/kg body weight/day by os-
motic minipump) from 3 dpc to birth and ethanol (4 g/kg body weight/day by daily gavage, maternal
peak blood alcohol concentration of approximately 150 mg/dl) reported no differences in the rates of
incidence of stillbirth in resultant offspring when compared to the control group, or either exposure
in isolation (Matta and Elberger, 2007). It is difficult to directly compare the results of these studies,
as the first utilised acute dosages of nicotine with chronic ethanol administration while the opposite
is true for the latter study. A further study administered nicotine (16.7 mg/kg body weight/day via
subcutaneous injection) and ethanol (1.41 g/kg body weight/day via intraperitoneal injection) daily to
pregnant rats from 8.5 - 11.5 dpc and identified a number of gross dysmorphologies common to both
the nicotine-only and dual exposed groups, but not present in the control or ethanol-only offspring at
11.5 dpc (Woo and Persaud, 1988). Given the relatively low dose of ethanol used, and the high dose
of nicotine it was unsurprising perhaps that the authors identified little difference between the dual
exposure and nicotine-only exposed embryos (Woo and Persaud, 1988). Despite difficulties in the
direct comparison of studies, it would appear that the combined exposure of nicotine and ethanol can
result in embryonic and fetal death and gross dysmorphology, the extent of which is dependent on the
timing and dosage of each chemical.
Collectively, the animal studies suggest that nicotine may have the capacity to potentiate the pheno-
typic consequences of a prenatal ethanol exposure; however, the molecular changes resulting from
such exposures have yet to be described. Furthermore, it is also necessary to verify the results ob-
tained from animal models of concomitant ethanol and nicotine use in a human population to better
understand the risks associated with a co-exposure.
1.7 Consequences of early gestational exposure to ethanol and/or
nicotine or tobacco
Close to half of pregnancies were identified to be unplanned in a survey of non-Indigenous Western
Australian women giving birth from 1995 - 1997 (Colvin et al., 2007). Furthermore, a more recent
study identified that of the Australian women giving birth in 2010, 48.3% of those surveyed confirmed
their pregnancies six or more weeks after conception (Callinan and Room, 2012). The high proportion
of women who stop drinking or smoking upon pregnancy confirmation (Australian Institute of Health
and Welfare, 2014) highlights their willingness to modify behaviours to optimise pregnancy outcomes.
However, despite the best intentions of women, many conceptuses are likely to have been exposed
during the very early stages of gestation prior to pregnancy confirmation. Therefore, there is a clear
need for studies examining the consequences of an exposure to nicotine and/or ethanol restricted to
just early gestation.
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Early gestational ethanol exposure
In humans, little is known regarding the consequence of an ethanol exposure only in early gestation.
The amount of alcohol consumed during early gestation has been reported to increase the risk of oral
cleft (DeRoo et al., 2008) and low birth weight (Little et al., 1986). Neither of these studies controlled
for drinking later in pregnancy, and as a consequence it is difficult to be certain whether similar results
would be identified in women who drank only in early pregnancy. To the best of our knowledge, no
studies have reported on the consequences of alcohol consumption during early pregnancy only.
Recently, a number of animal models of ethanol exposure restricted to the periconceptional and early
gestational periods have been developed. One of these models utilised pregnant Sprague-Dawley
rats subjected to a periconceptional ethanol exposure (ad libitum access to 12.5% v/v ethanol in
a liquid diet from four days before conception until four days after conception) (Gardebjer et al.,
2014). This periconceptional exposure alone was sufficient to result in fetal growth restriction at
gestational day 20 (Gardebjer et al., 2014), as well as impairments in glucose homeostasis at 6 months
of age (Gardebjer et al., 2015). The challenge inherent in periconceptional animal models that rely on
voluntary consumption is that as well as the exposure to the dam, the stud is often exposed too, and
thus it can be difficult to discern with confidence maternal versus paternal effects.
Previously, our laboratory developed a C57BL/6 mouse model of early gestational ethanol exposure
(ad libitum access to 10% v/v ethanol from fertilisation (0.5 dpc) to 8.5 dpc (Kaminen-Ahola et al.,
2010b). The exposure window utilised in this model is developmentally equivalent to the first 3 - 4
weeks of a human pregnancy (Otis and Brent, 1954) - well before most Australian women will confirm
their pregnancies (Callinan and Room, 2012). It has previously been identified using this model, that
ethanol exposure even when restricted to this very early time in pregnancy was sufficient to result in
changes to behaviour (Sanchez Vega et al., 2013), brain structure (Marjonen et al., 2015), craniofacial
morphology (Kaminen-Ahola et al., 2010b), and postnatal growth (Kaminen-Ahola et al., 2010a).
Furthermore, various transcriptional and epigenetic changes were also identified in various postnatal
tissues following the exposure (Kaminen-Ahola et al., 2010b,a; Marjonen et al., 2015; Zhang et al.,
2015). As all of these previous studies investigated only the postnatal offspring, it is impossible to
determine whether these phenotypes were present from the time of exposure, or whether there was a
latency in their onset. The molecular changes identified postnatally are informative for the phenotypic
changes that may be present at those ages. The identification of molecular changes closer to the
time of exposure may be more informative as to the molecular pathways which may be perturbed
as an immediate consequence of such exposure, potentially leading to a greater understanding of the
mechanism underlying these previously identified phenotypes.
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Early gestational maternal smoking
A number of studies have been conducted in humans exploring the impact of maternal smoking during
the first trimester and fetal outcomes. Babies of women who smoked only during the first trimester
were found to have a similar risk of being small-for-gestational-age as babies of non-smoking mothers
(Lieberman et al., 1994). Similar results were identified in two subsequent studies; birth weight of
babies born to mothers who stopped smoking during early pregnancy (either following confirmation
of pregnancy (Dejmek et al., 2002), or during the first trimester (Prabhu et al., 2010)) were found to
be comparable to those born to non-smoking mothers. In one of these studies however, it was found
that despite being born of normal size, the children of mothers who stopped smoking during the first
trimester were at increased risk of being diagnosed with asthma by age two when compared to the
children of non-smokers (Prabhu et al., 2010), suggesting that this early exposure may not be without
consequence.
The capacity for early gestational exposure to an extract from tobacco smoke to alter neurodevelop-
mental outcomes was recently reported in a Sprague-Dawley rat model (Slotkin et al., 2016). In this
study, pregnant dams were exposed to tobacco smoke extract by infusion minipumps for the first ten
days of gestation, resulting in perturbations to both the cholinergic and serotonergic systems in the
postnatal offspring (Slotkin et al., 2016).
At present, little is known as to the molecular changes underlying the phenotypic consequences of
maternal smoking during early gestation.
Early gestational nicotine exposure
There is even less known as to the consequences of an early gestational nicotine exposure. Delayed
embryo implantation has been reported following twice daily subcutaneous injections of nicotine
for the first five days of gestation in Charles River CD rats (Yoshinaga et al., 1979). Whether this
early gestational nicotine exposure also resulted in other phenotypes, or even whether this delay in
implantation resulted in developmental delay or growth restriction at later times in pregnancy is as
yet, unknown.
Early gestational concomitant exposure to ethanol and nicotine
To date, the phenotypic consequences of a concomitant early gestational exposure to ethanol and
nicotine have yet to be described. The growing number of nicotine substitute users in Australia (Yong
et al., 2015) coupled with the fact that many Australian women will not confirm their pregnancies
until 6 or more weeks into gestation (Callinan and Room, 2012) means that pregnancies inadvertently
exposed to both alcohol and nicotine during early gestation are likely to be an ongoing issue. It is
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therefore critical to gain a better understanding of both the phenotypic and molecular consequences
of an early gestational in utero exposure to nicotine in combination with alcohol.
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1.8 Hypothesis and aims of this thesis
1.8.1 Hypothesis
Exposure to ethanol and/or nicotine during preimplantation epigenetic reprogramming will disrupt
the epigenome, which will have an effect on both mRNA and miRNA expression, in turn resulting in
phenotypic changes in the embryo. The concomitant exposure to both ethanol and nicotine will have
a synergistic effect on phenotype, whereas either exposure alone will be less severe.
1.8.2 Aims
1. Establish mouse models of early gestational nicotine exposure and of early gestational dual
ethanol/nicotine exposure
2. Assay consequences of prenatal exposure to ethanol and/or nicotine on growth in both the mid-
gestational (9.5 dpc) and postnatal offspring
3. Profile transcriptional changes (mRNA and miRNA) in the mid-gestational (9.5 dpc) in the
embryo following the prenatal exposure to ethanol or nicotine
4. Assay epigenetic marks that are associated with transcripts of interest identified in Aim 3
2 Materials and Methods
2.1 Materials
2.1.1 Chemicals and reagents
All the major chemicals and reagents used in this project, along with the suppliers, are shown below.
All chemicals are molecular biology grade unless otherwise stated.
Acetic acid glacial, Sigma-Aldrich
Agar, Sigma-Aldrich
Agarose, Sigma-Aldrich
Anti-Digoxigenin-AP, Fab fragments, from sheep, Roche
Ampicillin, Sigma-Aldrich
β -mercaptoethanol, Sigma-Aldrich
Blocking Reagent, Roche
Bovine Serum Albumin Fraction V from bovine serum, Roche
5-Bromo-4-chloro-3-indolyl phosphate disodium salt (BCIP), Sigma-Aldrich
Bromophenol blue, Sigma-Aldrich
CHAPS, Sigma-Aldrich
Chloroform isoamyl alcohol, Fluka
10 mM dNTP mix, Invitrogen
10 x Dulbecco’s Phosphate Buffered Saline (dPBS), Gibco
Ethanol, Ajax Finechem
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Ethylene diaminetetra acetic acid disodium dihydrate (EDTA), Sigma-Aldrich
Formamide, Sigma-Aldrich
Glutaraldehyde, Sigma-Aldrich
Glycerol, Sigma-Aldrich
Heparin sodium salt from porcine intestinal mucosa, Sigma-Aldrich
Horse serum, Sigma-Aldrich
Isopropanol, Sigma-Aldrich
Isopropyl β -D-thiogalactoside (IPTG), Sigma-Aldrich
Lysing Matrix D Bulk, MP Biomedicals
Methanol, Sigma-Aldrich
(-)-Nicotine free base 98 - 100%, Sigma-Aldrich
4-Nitro blue tetrazolium chloride, solution, Roche
Magnesium chloride, Sigma-Aldrich
Paraformaldehyde, Sigma-Aldrich
Phenol (pH 7.9), Sigma-Aldrich
Platinum SYBR Green qPCR SuperMix-UDG, Invitrogen
Random Primers, Invitrogen
RNA from yeast, Sigma-Aldrich
Sodium chloride, Sigma-Aldrich
Sodium citrate dihydrate, Sigma-Aldrich
Sodium dodecyl sulfate 10% solution (lauryl sulphate sodium salt) (SDS) (ultra-pure grade),
Sigma-Aldrich
SYBR safe DNA gel stain, Life Technologies
Tris-hydroxymethyl-aminomethane (Tris base) (ultra pure grade), Invitrogen
TritonX-100, Sigma-Aldrich
Tryptone, Sigma-Aldrich
Tween-20, Sigma-Aldrich
Water (0.1 µm filtered), Sigma-Aldrich
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Xylene cyanol, Sigma-Aldrich
Yeast extract, Sigma-Aldrich
2.1.2 Buffers and solutions
All solutions and buffers and their concentrations are listed below. They were all prepared using
milli-Q water unless otherwise stated.
1 x Dulbecco’s Phosphate Buffered Saline (dPBS)
10% (v/v) of 10 x dPBS, 90% water
10% ethanol
10% (v/v) ethanol, 90% reverse osmosis water
10 x Loading dye
0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol, 49.5 mM Tris (pH 7.6), 60% glycerol
20 x Saline Sodium Citrate buffer (SSC), pH 7.0
17.53% sodium chloride (w/v), 8.82% sodium citrate dihydrate (w/v)
250 x nicotine stock solution
25.25 mg/ml free base nicotine, 22.5% (v/v) ethanol, in reverse osmosis water
50 x TAE
2 M Tris base, 1 M glacial acetic acid, 0.5 M EDTA (pH 8.0)
DNA lysis solution
50 mM Tris (pH 8.0), 10 mM EDTA, 100 mM NaCl, 1% SDS
LB medium
1% tryptone (w/v), 0.5% yeast extract (w/v), 1% sodium chloride (w/v)
LB agar
1% tryptone (w/v), 0.5% yeast extract (w/v), 1% sodium chloride (w/v), 1.5% (w/v) agar
NTMT
100 mM Tris (pH 9.5), 100 mM NaCl, 50 mM magnesium chloride, 0.1% Tween-20
PBTX
1% Triton-X 100 in dPBS
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Prehybridisation solution
50% formamide, 5 x SSC, 2% blocking powder, 0.1% TritonX-100, 0.5% CHAPS, 1 mg/ml yeast
RNA, 5 mM EDTA, 50 mg/ml heparin
Solution 1
50% formamide, 5 x SSC, 0.1% Triton-X 100, and 0.5% CHAPS
TBTX
50 mM Tris chloride, 150 mM sodium chloride, 0.1% TritonX-100
2.1.3 Enzymes
EcoRI, New England Biolabs
NotI, New England Biolabs
Proteinase K from Tritirachium album, Roche
RNase (from bovine pancreas), Roche
RNase-OUT, Invitrogen
SalI, New England Biolabs
T7 RNA polymerase, Roche
Superscript III Reverse Transcriptase, Invitrogen
2.1.4 Commercial kits
Alcohol Reagent and Control Set, Pointe Scientific Inc.
AllPrep DNA/RNA/miRNA Universal kit, QIAGEN
EpiTect Bisulfite Kit, QIAGEN
HotStarTaq Plus Master Mix Kit, QIAGEN
HyperLadder II, Bioline
MangoMix, Bioline
Mouse/Rat Cotinine ELISA Kit, Calibotech Inc.
pGEM-T easy vector, Promega
Platinum SYBR qPCR SuperMix-UDG, Invitrogen
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QIAprep Spin Miniculture Kit, QIAGEN
QIAQuick Gel Extraction Kit, QIAGEN
RNA 6000 Nano Kit, Agilent
TaqMan Array Rodent MicroRNA A+B Cards Set v3.0, Applied Biosystems
TaqMan Fast Advanced Master Mix, Applied Biosystems
TaqMan MicroRNA Reverse Transcription Kit, Applied Biosystems
2.1.5 Oligonucleotides
The oligonucleotides used in this project are listed in Table A1. Oligonucleotides were purchased
from either Sigma-Aldrich or Integrated DNA Technologies.
2.1.6 Mouse strains and housing conditions
Mouse cohorts included in this thesis were generated and maintained across two separate campuses of
Mater Research Institute: Aubigny place (Mater Hill), South Brisbane and the Translational Research
Institute (TRI), Woolloongabba.
The University of Queensland Animal Ethics Committee provided ethical approval for the use of mice
in this project. Approval numbers are as follows:
• MMRI/120/12/NHMRC
• MMRI/TRI/426/13/NHMRC/BREED
• MMRI/TRI/430/13
Inbred C57BL/6J mice (Animal Resource Centre, Perth, Australia) were housed on a 12 hour light-
dark cycle. All mice had ad libitum access to standard laboratory chow (at Aubigny place: GoldMix
p/n 126575 [protein: 18.0%, fibre: 5%, fat: 3%]), and at the TRI: Specialty Feeds Meat Free Rat
and Mouse Diet [protein: 20.0%, crude fibre: 4.8%, fat: 4.8%]). When not being mated, female and
male mice were caged separately. All environmental factors including cage type, temperature, and
environmental enrichment were standardised.
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2.2 General methods
2.2.1 Extraction of nucleic acid from tissues
Genomic DNA and total RNA extraction from whole 9.5 dpc embryos
The QIAGEN AllPrep DNA/RNA/miRNA Universal kit was used to isolate total RNA and genomic
DNA in accordance with the manufacturer’s instructions. Samples (individual embryos) in 600 µl
of Buffer RLT Plus were homogenised by mechanical disruption using a 21.5-gauge needle fitted
to a syringe. At the final step, RNA was eluted out of the membrane with 50 µl of RNase-free
water (provided with the kit, non-DEPC treated) and stored at -80°C, and DNA was eluted out of the
membrane with 100 µl of RNase-free water and stored at -80°C.
Genomic DNA and total RNA extraction from testes
The QIAGEN AllPrep DNA/RNA/miRNA Universal kit was used to isolate total RNA and ge-
nomic DNA in accordance with the manufacturer’s instructions for lipid-rich tissues. Testes were
homogenised by mechanical disruption with Lysing Matrix D Bulk (MP Biomedicals) using the
FastPrep-24 Instrument (MP Biomedicals). At the final step, RNA was eluted out of the membrane
with 50 µl of RNase-free water (provided with the kit, non-DEPC treated) and stored at -80°C, and
DNA was eluted out of the membrane with 100 µl of RNase-free water and stored at -80°C.
Genomic DNA extraction from yolk sacs and tail tips
Proteolytic digestion of samples was achieved by overnight incubation at 55°C in lysis solution con-
taining approximately 1 mg/ml of proteinase K. Following digestion, samples were incubated at 37°C
with 0.1 µg of RNase. Equal volumes of phenol:chloroform (5 mins) and chloroform (5 mins) were
sequentially added, with the organic phase being discarded following vigorous shaking for the afore-
mentioned times, with a 5-minute centrifugation conducted between each step. DNA was precipitated
by the addition of an equal volume of isopropanol. The precipitated DNA was pelleted by centrifu-
gation, then washed with 70% ethanol. Samples were air-dried and resuspended in 50 µl of Milli-Q
water.
Determination of total RNA and genomic DNA concentration and integrity
Generally, total RNA and genomic DNA were analysed using the NanoDrop 1000 to provide an
indicator of concentration and purity.
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Agilent RNA 6000 Nano Kits, and the Agilent Bioanalyzer 2100 were also utilised to determine
sample concentration, and most importantly, RNA integrity for the microarray experiment. These
kits were used as per the manufacturer’s guidelines and involve electrophoretic separation on chips
to determine the range of RNA fragment sizes and the 18S to 28S ribosomal band ratio. A software
algorithm then calculates the RNA Integrity Number (RIN). Samples with RINs of 1 are the most
degraded, and those with RINs of 10 are most intact.
2.3 Prenatal exposure to ethanol and/or nicotine
In all models used in this project, inbred nulliparous C57BL/6J mice were time mated (females at
6 - 7 weeks of age, males at 8 weeks of age), with the day of vaginal plug detection designated as
0.5 dpc. Mice were subsequently randomly allocated to one of the control, ethanol, nicotine, or dual
ethanol/nicotine treatment groups from 0.5 to 8.5 dpc. Every 24 hours during the exposure period,
bottle contents were changed, and voluntary consumption (ml) in all groups recorded. At 8.5 dpc
all dams were then reverted back to the standard bottle with water. Mice were provided free access
to standard rodent chow at all times. All treatment solutions were made up in reverse osmosis (RO)
water. All dams were subjected to only one cycle of exposure.
The prenatal ethanol exposure model used in this project is as previously described (Kaminen-Ahola
et al., 2010a,b; Sanchez Vega et al., 2013). During the exposure period from 0.5 to 8.5 dpc, ethanol-
treated dams were provided with ad libitum access to 10% (v/v) non-denatured ethanol.
The prenatal nicotine exposure model was newly developed in this project. Ad libitum access to 100
µg/ml freebase nicotine was provided during the exposure period.
The dual ethanol/nicotine (EtOH/NIC) model, also developed during this project combines the ethanol-
and nicotine-only models, providing mice with ad libitum access to a solution comprising both 10%
ethanol and 100 µg/ml freebase nicotine over the exposure period.
2.4 Assays for serum ethanol and cotinine concentrations
Levels of serum alcohol and cotinine (the major primary metabolite of nicotine) were evaluated over a
24-hour period using commercially available kits (Alcohol Reagent and Control Set [Pointe Scientific
Inc., A7504-39] and the Mouse/Rat Cotinine ELISA Kit [Calbiotech Inc., CO096D-100]).
Female 7 week old C57BL/6 mice were provided with either control, ethanol, nicotine, or dual
ethanol/nicotine solutions. On the second day of exposure, mice were sacrificed by carbon dioxide
asphyxiation followed by cervical dislocation. Blood was collected by cardiac punctures performed
using a 26 gauge needle attached to a 1 ml syringe. For each of the exposure models, blood from five
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mice at 12 time-points over a 24-hour period was collected by cardiac puncture. Two control mice
(provided with water) were also included alongside each of the exposures. Each mouse was sampled
only once. Whole blood was clotted at 4°C for between 30 mins and 4 hours, then centrifuged at
1500 rcf at room temperature for 20 minutes. The supernatant (the serum fraction) was then stored in
aliquots at -80°C.
2.4.1 Assay for serum ethanol concentration
Serum ethanol concentrations were determined using the Alcohol Reagent and Control Set (Pointe
Scientific Inc., A7504-39). Using alcohol dehydrogenase and NAD this assay is able to detect ethyl
alcohol in whole blood and serum, and has been recently cited a number of times in the literature
(Lauing et al., 2008; Oldenburg et al., 2009). The reaction volume of this assay was scaled down to
30% of the recommended volume (i.e., 300 µl instead of 1000 µl), but was otherwise performed in
accordance with the manufacturer’s instructions.
2.4.2 Assay for serum cotinine concentration
Serum cotinine concentrations were assayed using an enzyme-linked immunosorbent assay (ELISA)
for cotinine (Mouse/Rat Cotinine ELISA Kit [Calbiotech Inc., CO096D-100]). This kit has also
been used in a number of publications to assay serum cotinine concentrations following nicotine
exposure (Raval et al., 2009; Moreno-Gonzalez et al., 2013). Reactions were conducted as per the
manufacturer’s instructions.
2.5 Phenotyping and collection of 9.5 dpc embryos
2.5.1 Embryo dissection
Pregnant dams were sacrificed by carbon dioxide asphyxiation followed by cervical dislocation at 9.5
dpc, one day following the termination of exposures. Embryos and their yolk sacs were dissected out
of the uterine horns and decidua into dPBS with the aid of an Olympus stereomicroscope. Embryos
were photographed then snap frozen in liquid nitrogen and stored at -80°C. Yolk sacs were placed in
DNA lysis solution and proteinase K (10 µg/ml), incubated at 55°C overnight, then stored at -20°C.
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2.5.2 Measurement of embryo size at 9.5 dpc
Embryo size was quantified at 9.5 dpc by measuring crown-rump length and head length. Photographs
of embryos were taken with a camera attached to an Olympus stereomicroscope, and measurements
obtained using an image analysis software, CellSens (Olympus Inc.). Each embryo was measured
twice (on left and right side) by two people (LY and SC), one of whom was blinded to the treatment
group (SC).
2.5.3 Measurement of somite number at 9.5 dpc
Somite numbers were counted under the stereomicroscope by one person at the time of dissection.
Somite counting accuracy was validated in a randomly selected subset of control and ethanol-exposed
embryos by first counting somite number at dissection, and then again after staining using an RNA-
riboprobe for Uncx4.1 (a somitic marker) using a whole mount in situ hybridisation technique. After
staining, somites were counted by two individuals (LY and SC), both of whom were blinded to the
treatment history of the embryos.
Whole mount in situ hybridisation
The plasmid DNA for the Uncx4.1 riboprobe (Furtado et al., 2008) was a gift from Richard Harvey. It
contains a 1200 bp fragment of Uncx4.1 cDNA. Digoxigenin-labeled antisense probes were synthe-
sised from plasmid linearised with SalI digestion, then transcribed in vitro using T7 RNA polymerase
(Roche) as per manufacturer’s instructions. The sense probe was synthesised from plasmid linearised
using NotI then transcribed with Sp6 RNA polymerase.
Whole mount in situ hybridisation was performed on inbred C57BL/6 embryos as below. Embryos
were dissected out into dPBS, then fixed in 4% paraformaldehyde for at least 2 hours. Unless other-
wise indicated all steps in this protocol were conducted while rocking. Embryos were then dehydated
into 100% methanol then stored until required at 4°C. They were then washed with PBTX (PBS with
1% Triton-X 100) three times for 10 minutes each then treated with Proteinase K (10 µg/ml) for a fur-
ther 10 mins. They were again washed at twice at room temperature with PBTX for 5 minutes each,
then re-fixed with 0.2% glutaraldehyde/4% PFA in PBTX for 20 mins. Again they were washed twice
at room temperature with PBTX for 10 minutes then incubated at 65°C for 2 hours in prehybridisation
solution (50% formamide, 5 x SSC, 2% blocking powder (Roche), 0.1% TritonX-100, 0.5% CHAPS,
1 mg/ml yeast RNA, 5 mM EDTA, and 50 mg/ml heparin).
Probe was added and embryos were incubated at 65°C overnight. Embryos were washed at 65°C
for 5 minutes in each of 100% Solution 1 (50% formamide, 5 x SSC, 0.1% Triton-X 100, and 0.5%
CHAPS), followed by 75% Solution 1: 25% 2 x SSC, 50% Solution 1: 50% 2 x SSC, 25% Solution
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1: 75% 2 x SSC, then twice for 10 minutes at 65°C each with a solution containing 2 x SSC and
0.1% CHAPS, and then a further twice at 65°C for 15 minutes in a solution containing 0.2 x SSC
and 0.1% CHAPS, all at 65°C. Embryos were then washed twice with TBTX (50 mM Tris.Cl, 150
mM NaCl, 0.1% TritonX-100) at room temperature. They were then pre-blocked with 10% horse
serum and 2% BSA for 1 hour at room temperature. This solution was replaced with the preabsorbed
antibody solution (see below). Following overnight incubation at 4°C, embryos were washed 5 times
with TBTX with 0.1% BSA at room temperature for 30 minutes each wash. They were then incubated
overnight with TBTX and 0.1% BSA at 4°C. The next day embryos were washed twice in TBTX at
room temperature for 15 minutes, then a further 3 times in NTMT for 10 minutes.
NBT and BCIP were added to facilitate the colour development. Once adequate colour development
had occured the reaction was terminated by washing for 5 minutes in NTMT then PBTX for 20
minutes. They were then washed twice in PBS with 0.1% TritonX-100, then again for several days at
4°C. Embryos were then fixed in 4% PFA overnight at 4°C, then stored at 4°C in PBS.
Preabsorbed antibody: 1.5 mg of embryo powder and 0.5 ml of 10% horse serum/2% BSA in TBTX
and 1 µl of anti-DIG antibody (Roche) were incubated at 4°C for 2 hours. This was then centrifuged
at 4°C and the supernatant diluted to 2 ml using 10% horse serum/2% BSA in TBTX to prepare the
preabsorbed antibody solution.
2.6 Phenotyping and collection of 17.5 dpc fetuses
2.6.1 Dissection of fetuses at 17.5 dpc
Pregnant dams were sacrificed by carbon dioxide asphyxiation followed by cervical dislocation at
17.5 dpc. Fetuses and their placentae were dissected out of the uterine horns and decidua into dPBS.
Fetuses were euthanised by decapitation, and a tail tip obtained to allow for later sex determination
by PCR.
2.6.2 Measurement of fetal size at 17.5 dpc
Fetal size was quantified at 17.5 dpc by measuring both weight and crown-rump length. Placental
size was quantified at 17.5 dpc by measuring both weight and diameter.
All weight measurements were taken using the same balance (TX323L, Shimadzu). Morphometric
measurements were conducted by LY, with each fetus measured twice (on left and right side).
Samples were photographed using a camera attached to an Olympus stereomicroscope, and measure-
ments obtained using an image analysis software, CellSens (Olympus Inc.).
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2.7 Dissection of testes from male mice
Testes were collected from male mice aged 10 - 11 months of age after euthanasia by carbon dioxide
asphyxiation, and immediately snap frozen in liquid nitrogen.
2.8 Postnatal body weight measurement
Mice were weaned on postnatal day 21 and caged with between two and four mice of the same sex
per cage. Mice were uniquely ear notched, and body weight was measured weekly. Litters were
randomly allocated at weaning to either a high-fat diet (High Fat Rodent Diet Based on D12451,
SF04-001, Specialty Feeds) or a low-fat control diet (Low Fat Rodent Diet Based on D12450B, SF13-
081, Specialty Feeds), which contains the same ingredients and is closely matched in composition to
the high-fat formula. Mice had free access to water and their allocated diet at all times.
2.9 Body composition analysis by dual-energy X-ray absorptiom-
etry
At 10 - 11 months of age, a subset of the mice maintained on either a high-fat or low-fat diet were
euthanised using carbon dioxide asphyxiation, and body composition measured using the Lunar PIX-
Imus X-ray densitometer (conducted by Dr Suyinn Chong). Image analysis was conducted using the
manufacturer’s software.
2.10 Polymerase Chain Reaction (PCR)
2.10.1 Sly/Xlr PCR to determine the genetic sex of embryos
Embryonic sex was determined by testing for the presence of a Y-specific gene (Sly) and an X-specific
gene (Xlr) by polymerase chain reaction (PCR) in genomic DNA isolated from either yolk sacs (for
9.5 dpc embryos) or tail tips (for 17.5 dpc fetuses) (McFarlane et al., 2013). Briefly, this involves using
a single primer pair which amplifies fragments from both the X (Xlr) and the Y (Sly) chromosomes.
The resultant amplicons from each chromosome are distinct in size, allowing for the determination
of the chromosomal origin of each amplicon. If the yolk sac was unavailable, or yielded inconclusive
results, DNA extracted from the whole embryo used.
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Each reaction comprised approximately 2 µl of the sample (lysate or genomic DNA), 12.5 µl of
MangoMix (Bioline, which includes DNA polymerase, MgCl2 and dNTPs), and 0.2 µM of each of
the primers, SX_F and SX_R (Table A1). PCR was then conducted in Eppendorf Mastercycler Pro
Thermal Cyclers. Following an initial denaturation at 94°C for 3 minutes, 35 cycles of denaturation
(94°C, 15 seconds), annealing (57°C, 15 seconds), and extension (72°C, 15 seconds) were conducted,
followed by a final extension step (72°C, 5 minutes). A heated lid was used at all times.
The PCR product was visualised on a 1.5% TAE gel (stained with 1 x SYBR Safe DNA Gel Stain,
Life Technologies). The expected product size of amplicons originating from the Y chromosome (Sly)
was 280 bp, while the amplicon from the X chromosome (Xlr) was 685 bp.
2.10.2 RT-PCR to detect multiple transcripts of Zscan10
RT-PCR to detect multiple Zscan10 transcripts were conducted as previously published (Zhang et al.,
2006). cDNA was synthesised from total RNA extracted from male 9.5 dpc embryos using Super-
script III Reverse Transcriptase, random primers, dNTPs, and RNaseOUT (all from Invitrogen), as
per manufacturer’s guidelines. Briefly, 10 ng of cDNA was amplified in 25 µl of MangoMix (Bi-
oline, which includes DNA polymerase, MgCl2 and dNTPs), and 0.2 µM of each of the primers
Zfp206_F_Zhang2006 and Zfp206_R_Zhang2006 (Table A1). PCR was conducted in Eppendorf
Mastercycler Pro Thermal Cyclers (heated lid used at all times). Following an initial denaturation of
95°C for 2 minutes, 35 cycles of denaturation (94°C, 30 seconds), annealing (51°C, 30 seconds), and
extension (72°C, 1 minute) were conducted, followed by a final extension step (72°C, 5 minutes).
The PCR products were visualised on a 2% TAE gel (stained with 1 x SYBR Safe DNA Gel Stain, Life
Technologies). To confirm their identities, each of the three visible bands were cloned and sequenced.
Each of the three bands on the gel were gel-purified using the QIAQuick Gel Extraction Kit (QIA-
GEN). Purified PCR product was ligated into a pGEM-T Easy vector (Promega) as per manufacturer’s
instructions, with resultant plasmids transformed into competent cells. Colonies were selected for by
Ampicillin resistance as well as by blue/white screening using the X-Gal/IPTG system. Up to four
colonies were picked for each sample, which were then cultured overnight. Plasmids were extracted
using the QIAprep Spin Miniculture Kit (QIAGEN) as per manufacturer’s instructions.
Extracted plasmids were digested using EcoRI to screen for plasmids with the expected insert size.
Plasmids containing an insert of the expected size were sequenced using the M13 reverse primer
(Table A1) by the Australian Genome Research Facility sequencing facility.
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2.11 Microarray-based whole genome expression analyses
Genome-wide gene expression was assayed using the Illumina MouseWG-6 v2.0 BeadChip mRNA
microarray platform (conducted by the Australian Genome Research Facility). Briefly, 12 male 9.5
dpc embryos were selected from each of the control, ethanol, and nicotine-only exposure groups and
assayed individually. 1µg of total RNA (isolated from whole embryos as per Section 2.2.1 was used
as a template. cRNA synthesis and subsequent microarray preparation was conducted according to
the manufacturer’s instructions. The lowest RIN of any RNA sample utilised for this experiment was
8.2. Data analysis was conducted as detailed in Section 2.15.3.
2.12 Quantitative reverse transcriptase polymerase chain reac-
tion (qRT-PCR)
2.12.1 qRT-PCR based arrays for miRNAs using TaqMan Array Rodent Mi-
croRNA A+B Cards Set v3.0
The same samples were utilised for this assay as were used for the microarray-based whole genome
expression analyses (Section 2.11). cDNA was synthesised from total RNA using the TaqMan Mi-
croRNA Reverse Transcription Kit using the Megaplex Pools for microRNA Expression Analysis
Protocol (Part Number 4399721 Rev. C 07/2010). qRT-PCR was conducted using TaqMan Array
Rodent MicroRNA A+B Cards Set v3.0 (catalogue number 4444909, Applied Biosystems), with the
TaqMan Gene Expression Master Mix, as per the manufacure’s instructions on the Applied Biosys-
tems 7900. Following an initial UNG incubation of 50°C for 2 minutes and a polymerase activation
step of 94.5°C for 10 minutes, 37 cycles of denaturation (97°C, 5 seconds) and annealing/extension
(59.7°C, 45 seconds) were conducted. Data analysis was conducted using the software recommended
by the manufacturer (ExpressionSuite Software v1.0.4, Applied Biosystems).
2.12.2 qRT-PCR for validation of differential miRNA expression
Candidate miRNAs of interest were validated in an independent cohort from which the initial screen
were conducted. qRT-PCR was conducted using the same TaqMan primer/probe pairs utilised in
the TaqMan array cards. Briefly, cDNA was synthesised from 500 ng of total RNA extracted from
male 9.5 dpc embryos using the TaqMan MicroRNA Reverse Transcription Kit (catalogue number
4366596, Applied Biosystems), as per the manufacturer’s instructions. qRT-PCR was conducted using
the TaqMan Fast Advanced Mastermix (catalogue number 4444963, Applied Biosystems), as per the
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manufacturer’s instructions on the Applied Biosystems Viia7 Real-Time PCR System. Following
an initial UNG incubation of 50°C for 2 minutes and a polymerase activation step of 95°C for 20
seconds, 40 cycles of denaturation (95°C, 1 second) and annealing/extension (60°C, 20 seconds)
were conducted. qRT-PCRs were conducted in triplicate. No template controls were conducted in
duplicate for each miRNA. Data analysis was conducted as detailed in Section 2.15.4.
2.12.3 qRT-PCR to measure mRNA expression
cDNA was synthesised using Superscript III Reverse Transcriptase, random primers, dNTPs, and
RNaseOUT (all from Invitrogen), as per manufacturer’s guidelines. qRT-PCRs were conducted using
the Invitrogen Platinum SYBR Green qPCR SuperMix-UDG as per manufacturer’s instructions on
the Applied Biosystems Viia7 Real-Time PCR System. Following an initial UNG incubation of 50°C
for 2 minutes and a denaturation of 95°C for 2 minutes, 40 cycles of denaturation (95°C, 15 seconds)
and annealing/extension (60°C, 30 seconds) were conducted, followed by a melt curve stage. qRT-
PCRs were conducted in triplicate, with a no reverse transcriptase control included for each sample.
No template controls were conducted in quadruplicate for each gene. Data analysis was conducted as
detailed in Section 2.15.4 and 2.12.3. Primers used are listed in (Table A1).
Selection of reference genes for gene expression analysis
Reference genes for the whole embryo at 9.5 dpc
Reference genes were selected by conducting an analysis of the stability both within and between
treatment groups of the microarray-based expression of five commonly used reference genes (Gusb,
Hprt1, Hsp90ab1, Gapdh, and Actb). NormFinder v0.953 (Andersen et al., 2004) identified the most
stably expressed genes both within and across the three treatment groups (ethanol, nicotine, and
control). For all treatment groups, it was determined that in this tissue (whole embryo at 9.5 dpc),
Hsp90ab1 was the most constant, followed by Gapdh. For all gene expression assays of the 9.5 dpc
whole embryo in this project, these two genes were used to normalise the data.
Reference genes for the adult testis
Gapdh and Actb were selected for use as reference genes in adult testes, as per previous literature
(Fullston et al., 2013; Gong et al., 2014).
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2.13 Agouti viable yellow mouse coat colour phenotyping
Coat colour of mice prenatally exposed to either nicotine or water and carrying the Avy allele was
assessed at weaning (postnatal day 21). Mice were categorised into one of seven categories based on
the percentage of their coat colour that was yellow or agouti: category 1 (100% yellow), category 2
(95 - 99% yellow), category 3 (75 - 94% yellow), category 4 (25 - 74% yellow or 25 - 75% agouti),
category 5 (75 - 94% agouti), category 6 (95 - 99% agouti), and category 7 (100% agouti). In the final
analysis, the seven categories were combined into three broad categories: Yellow (categories 1 and
2), Mottled (categories 3 - 5), and Pseudoagouti (categories 6 and 7).
Data analysis was conducted using the χ2 test.
2.14 Clonal bisulfite sequencing
Bisulfite sequencing was conducted to determine the methylation levels of individual cytosines within
CpG dinucleotides at regions of interest within Zscan10.
2.14.1 Bisulfite conversion of genomic DNA
1 µg of genomic DNA from each embryo was subjected to bisulfite conversion using the Epitect
Bisulfite Kit (QIAGEN) as per the manufacturer’s instructions.
2.14.2 Semi-nested PCR of bisulfite-converted DNA
Semi-nested PCR was conducted to amplify the regions of interest (putative promoter regions 1 and
2 and the CpG-island) from bisulfite-converted DNA. Semi-nested primers (Table A1) were designed
using MethPrimer (Li and Dahiya, 2002).
In the first round PCR for the putative promoter region 1 and the CpG-island, each reaction comprised
1.5 µl of bisulfite-converted DNA, 12.5 µl of 2 x MangoMix (Bioline), and 0.2 µM of each of the
relevant primers (Table A1). PCR was conducted in Eppendorf MasterCycler Pro Thermal Cyclers.
Following an initial denaturation of 94°C for 2 minutes, 30 cycles of denaturation (94°C, 30 seconds),
annealing (55°C (promoter region 1) or 51°C (CpG island), 30 seconds), and extension (72°C, 30
seconds) were conducted, followed by a final extension step (72°C, 5 minutes). A heated lid was used
at all times. To reduce the effects of PCR bias, samples were subjected to PCR in duplicate. For each
set of PCRs, a no template control was included.
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In the second round of PCR for the putative promoter region 1 and the CpG-island, each reaction
comprised 1 µl of the product resultant of the first round of PCR, 25 µl of 2 x MangoMix (Bioline),
and 0.2 µM of each of the relevant primers (Table A1). PCR conditions were as per those utilised in
the first round of PCR.
In the first round of PCR for the putative promoter region 2, each reaction comprised 1.5 µl of
bisulfite-converted DNA, 12.5 µl of 2 x HotStarTaq Plus Master Mix, and 0.2 µM of each of the
relevant primers (Table A1). PCR was conducted in Eppendorf MasterCycler Pro Thermal Cyclers.
Following an polymerase activation step of 95°C for 5 minutes, 30 cycles of denaturation (94°C, 60
seconds), annealing (51°C, 60 seconds), and extension (72°C, 60 seconds) were conducted, followed
by a final extension step (72°C, 10 minutes). A heated lid was used at all times. To reduce the effects
of PCR bias, samples were subjected to PCR in duplicate. For each set of PCRs, a no template control
was included.
In the second round of PCR for the putative promoter region 2, each reaction comprised 1 µl of the
product resultant of the first round of PCR, 25 µl of 2 x HotStarTaq Plus Master Mix, and 0.2 µM of
each of the relevant primers (Table A1). PCR conditions were as per those utilised in the first round
of PCR.
Gel purification of PCR products
The second round PCR was run on an agarose gel (2% TAE gel, stained with 1 x SYBR Safe DNA Gel
Stain, Life Technologies) and products of the appropriate size (putative promoter region 1: 439 bp,
putative promoter region 2: 526 bp, CpG-island: 581 bp) were then gel-purified using the QIAQuick
Gel Extraction Kit (QIAGEN).
2.14.3 Cloning and Sanger sequencing of purified PCR product
Purified PCR product was ligated into a pGEM-T Easy vector (Promega) as per manufacturer’s in-
structions, with resultant plasmids transformed into competent cells. Colonies were selected for by
Ampicillin resistance as well as by blue/white screening using the X-Gal/IPTG system. Up to four
colonies were picked for each sample, which were then grown overnight. Plasmids were extracted
using the QIAprep Spin Miniculture Kit (QIAGEN) as per manufacturer’s instructions.
Extracted plasmids were digested using EcoRI to screen for plasmids with the expected insert size.
Plasmids containing an insert of the expected size were sequenced using the M13 reverse primer by
the Australian Genome Research Facility sequencing facility.
Individually sequenced clones were analysed using BiQ Analyzer (Bock et al., 2005). To eliminate the
risk of PCR bias, if more than one clone from each PCR reaction had identical cytosine methylation
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patterns, all but one of these were excluded. Clones identified to have a bisulfite conversion rate of
less than 90% were also excluded.
2.15 Statistical analyses
2.15.1 χ2 test
The χ2 test for independence was used to calculate the probability that two variables are independent.
This is achieved through the comparison of the distribution of the observed values with the values that
were expected. A p-value can then be generated, reflecting the likelihood of the difference observed
being due to chance. A p-value of 0.05 or less considered to be statistically significant in this thesis.
The χ2 test was conducted using Microsoft Excel.
2.15.2 Standard Student’s t-test
The Standard Student’s t-test assesses whether the means of two groups of data differ from one an-
other. A p-value reflects the likelihood of the difference observed being due to chance. That is, a
p-value of 0.05 indicates that this result is likely to be a false positive 1 in 20 times. A probability of
0.05 or less is considered to be statistically significant.
One of the assumptions of this t-test is equal variance. To assess whether the data fulfilled this criteria,
an F-test was carried out on all data prior to performing the t-test. If data lacked equal variance, then
the t-test for unequal variance was utilised. All t-tests described in this thesis were two-tailed.
These analyses were carried out either in the open source statistical program, R (version 2.13.1) or
using GraphPad Prism 6.
2.15.3 Analysis of genome-wide gene expression data
Statistical analyses were performed using R project software, in collaboration with Elizabeth Mason
(The Australian Institute of Bioengineering and Nanotechnology, The University of Queensland).
Probes were first filtered based on their detection p-values (p < 0.01 in at least 75% of samples in
at least one of the two groups being compared). Expression values were quantile normalised, then
a differential gene expression analysis conducted using a Wilcox rank sum t-test. The Wilcoxon
rank sum test was used as a normal distribution could not be assumed. Probes were considered to
be differentially expressed if their absolute fold change (between ethanol or nicotine and control)
was greater than 1.5 fold, and had an uncorrected p-value of less than 0.05. The p-value following
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Bonferroni multiple testing correction was also calculated, however the corrected p-value was not
used to define probes to be differentially expressed.
The correlation between the expression of each gene identified to be differentially expressed and the
crown-rump length, normalised to somite count was then calculated for each embryo. Correlations
were calculated using both the Pearson’s and Spearman’s methods. Genes with a correlation coeffi-
cient of greater than 0.5 in the control embryos only were considered to be correlated to phenotype.
Final filtering of the gene list involved the exclusion of genes with probes which bound in intronic or
unannotated regions, or which had multiple probes with conflicting expression data.
2.15.4 Analysis of qRT-PCR
Any CT values obtained in the qRT-PCR reactions (conducted in triplicate) that differed from any of
the others by more than 0.5 of a CT were excluded. Analysis was subsequently conducted using the
2-∆∆CT method, as detailed below (Livak and Schmittgen, 2001).
First the ∆CT of all of the samples were determined. For every gene of interest in every sample, the
following equation was applied:
∆CT = x¯CT [Geneo f Interest]− x¯CT [Housekeeper Gene] (2.1)
The ∆CT obtained above was then normalised to the average of the reference population (the control
samples). For every sample:
∆∆CT = ∆CT [Sample]− x¯∆CT [Re f erencePopulation] (2.2)
The primer efficiency was estimated to be 2, and thus to obtain the relative fold change, the following
equation was applied:
Fold change= 2−∆∆CT (2.3)
3
Establishment of mouse models of
gestational ethanol and/or nicotine
exposures
3.1 Introduction
Alcohol and tobacco were the two most commonly used drugs during pregnancy in Australia in 2013
(Australian Institute of Health and Welfare, 2014). Gestational exposure to alcohol and tobacco in-
dividually, have been identified to be detrimental to the developing fetus in both humans and animal
models.
Maternal consumption of alcohol during pregnancy can lead to a spectrum of alcohol related disorders
in the offspring (collectively termed FASDs), with FAS being used to describe patients who present
with more severe symptoms (Stratton et al., 1996; Hoyme et al., 2005; Chudley et al., 2005; Astley,
2004). More recently, a literature review identified over 400 conditions to be comorbid with Fetal
Alcohol Spectrum Disorders in humans (Popova et al., 2016). Experimental animal models have
shown the capacity for prenatal ethanol exposure to result in a range of phenotypes in the offspring.
These phenotypes include abnormal neural development and behaviour (Sanchez Vega et al., 2013;
Zhang et al., 2015), growth retardation (Kaminen-Ahola et al., 2010b; Probyn et al., 2012; Gardebjer
et al., 2014) and craniofacial abnormalities (Sulik et al., 1981; Anthony et al., 2010; Kaminen-Ahola
et al., 2010b), metabolic perturbations (Dobson et al., 2012; Harper et al., 2014), as well as the
abnormal development and function of the renal, cardiovascular and pulmonary systems (Ren et al.,
2002; Gray et al., 2010; Probyn et al., 2013).
Maternal tobacco smoking can also increase the risk of children developing abnormalities affecting a
range of organ systems, including effects on growth, metabolism, behaviour, and perturbations in the
cardiovascular, renal, pulmonary, and gastrointestinal systems (reviewed in Mund et al., 2013). Nico-
tine, the major addictive component of tobacco, is a known reproductive or developmental toxicant
(U.S. Food and Drug Administration, 2012). Experimental studies using animal models have found
that prenatal exposure to nicotine alone can result in phenotypes in the offspring including those of
growth restriction (Wang et al., 2008), morphological malformations (Kang and Svoboda, 2003) and
behavioural changes (Alkam et al., 2013; Pauly et al., 2004).
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A number of studies in humans have collectively suggested that prenatal exposure to alcohol and
tobacco products may have a synergistic effect on newborn size (Aliyu et al., 2009; Olsen et al.,
1991; Brooke et al., 1989; Haste et al., 1991). These studies are supported by experimental studies
using animal models which have identified synergistic effects on fetal size, fetal dysmorphology, and
embryonic lethality (Leichter, 1989; Peterson et al., 1981; Fazel, 1996). While a number of studies
have reported synergistic effects between alcohol and nicotine in exposed offspring (Martin et al.,
1982; Woo and Persaud, 1988), not all studies have (Matta and Elberger, 2007). These discordances
are likely due to differences in exposure dosage, timing, method of administration, as well as outcome
assayed.
Of concern are findings that 56% of women who were pregnant in 2013 in Australia drank alco-
hol prior to pregnancy confirmation, while 17.4% smoked tobacco prior to pregnancy confirmation
(Australian Institute of Health and Welfare, 2014). While most of the studies outlined above have
examined the consequences of exposures either throughout pregnancy or late in gestation, the con-
sequences of ethanol and/or nicotine exposure restricted to early gestation, such as the time prior to
pregnancy confirmation, are poorly understood.
Our laboratory has previously developed a prenatal ethanol exposure model, in which the expo-
sure window covers this period of preimplantation epigenetic reprogramming (Kaminen-Ahola et al.,
2010a,b; Sanchez Vega et al., 2013; Zhang et al., 2015). However, to the best of our knowledge
no such models exist for either nicotine alone, or nicotine in combination with ethanol. Conse-
quently, in this chapter I describe the establishment of both an early gestational nicotine, and dual
ethanol/nicotine exposure models. I also further characterise the previously established ethanol model.
3.2 Results
3.2.1 Establishment of inbred mouse models of early gestational ethanol and/or
nicotine exposures
An ethanol-only model has previously been established and published by our laboratory (Kaminen-
Ahola et al., 2010b). In this chapter, mouse models of early gestational exposures to nicotine either
alone, or in combination with ethanol were established. The period of exposure for these models
(0.5 - 8.5 dpc) was chosen such that it would span preimplantation epigenetic reprogramming, and is
developmentally equivalent to the first three to four weeks of human gestation (Otis and Brent, 1954).
In all models inbred nulliparous C57BL/6J mice were time mated (females: 6 - 7 weeks of age,
males: 8 weeks of age), with the day of vaginal plug detection designated to be 0.5 dpc. Following
plug detection, dams were randomly allocated to a treatment group and depending on the group,
provided with solutions of either 10% (v/v) ethanol, 100 µg/ml nicotine or a dual 10% (v/v) ethanol/
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100 µg/ml nicotine solution from 0.5 to 8.5 dpc. At 8.5 dpc dams of treatment groups were then
reverted back to water. At all times during gestation, dams had free access to standard rodent chow.
Control dams were provided with ad libitum access to reverse osmosis (RO) water for the duration of
the experiment.
The dosage of 100 µg/ml freebase nicotine was selected as not only have C57BL/6 mice previously
been reported to voluntarily consume this dosage (Robinson et al., 1996; Maier et al., 2011), it has also
been identified to not result in any overt signs of toxicity (Maier et al., 2011). Furthermore, previous
literature suggests that in utero exposure to this dosage of nicotine at various times in pregnancy is
sufficient to result in various physiological changes in postnatal life (Wongtrakool et al., 2012a,b).
The concentrations of ethanol and nicotine used in the dual ethanol/nicotine model are the same as
those used in the ethanol-only and nicotine-only models.
3.2.2 Maternal ad libitum drinking behaviour over the exposure period
In each of the models used in this thesis, mice are provided with ad libitum access to treatment so-
lutions. While an advantage of this method of administration is a reduction in handling and thus
stress in the dams, inherent in this approach is the impossibility of controlling the volume each mouse
consumes of their allocated treatment solution. Consequently, the volume of the treatment solution
consumed in each model was measured every 24 hours to examine the consistency and reproducibil-
ity of our voluntary consumption strategy over different days and in different mice. No significant
differences in liquid consumption (ml) were observed between the control and ethanol-exposed dams
(Figure 3.1A), consistent with previous literature utilising the model (Kaminen-Ahola et al., 2010b).
In contrast, average daily maternal consumption (ml) was significantly reduced in both the nicotine
(14.9%) and dual ethanol/nicotine (12.8%) dams as compared to control dams (Figure 3.1A). As preg-
nancy status had no effect on consumption of any of the solutions (data not shown), consumption data
of all dams irrespective of pregnancy status were included in these results.
Up to six independent cohorts of mice (depending on the treatment group) named A - F were generated
for this thesis; therefore it was necessary to compare maternal drinking behaviour between cohorts
to account for possible cohort-specific effects. Water consumption in control dams was relatively
unchanged across cohorts, with the exception of cohort F, which consumed significantly less water
than those in cohorts A and B (Figure 3.1B). In the nicotine-exposed dams, the only significant cohort-
specific effects observed were between cohorts A and B, whereby consumption was greater in cohort
A than in cohort B (Figure 3.1C). No differences in consumption of the dual ethanol/nicotine solution
was observed between cohorts (Figure 3.1D). As only one cohort of ethanol mice were included in
this thesis, no comparisons between cohorts could be made.
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Figure 3.1: (A) Average daily liquid consumption (ml) of dams from all cohorts (A - F) over the
exposure period (0.5 - 8.5 dpc). Average daily consumption (ml) of water (B), nicotine solution (C),
and dual ethanol/nicotine solution (D) by dams in each of the individual cohorts used in this thesis.
Mean ± S.D. indicated. *: p<0.05, **: p<0.01, ***: p<0.001, and ****: p<0.0001, as determined by
one-way ANOVA with Tukey’s multiple comparison test.
3.2.3 Maternal weight gain over the exposure period
Maternal weight gain during the exposure period from 0.5 dpc to 8.5 dpc was measured as a general
indicator of health. There was no detectable difference in maternal weight gain, relative to starting
weight, over the exposure period between the controls and any of the treatment groups (Figure 3.2)
(Student’s t-test , p>0.05). This lack of difference in maternal weight gain was consistent in each
of the individual cohorts included in this thesis (data not shown). These results suggest that despite
the nicotine and dual ethanol/nicotine dams consuming slightly less than the controls (Figure 3.1A),
and cohort-to-cohort fluctuations in consumption in the control and nicotine exposures (Figure 3.1B,
Figure 3.1C), these exposures had no major impact on maternal health and pregnancy progression.
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Figure 3.2: Maternal weight gain, expressed as a ratio of weight (g) at 8.5 dpc to weight (g) at 0.5
dpc in pregnant dams provided with ad libitum access to water, 10% ethanol, 100 µg/ml nicotine, or
a combination of both the ethanol and nicotine solutions. Mean ± S.D. indicated.
3.2.4 Maternal serum alcohol and cotinine concentrations
Inter-species differences in the metabolism of both ethanol and nicotine have been reported between
mice and humans, with mice metabolising both of these drugs at a faster rate than humans (Dole
and Gentry, 1984, and reviewed in Matta and Elberger, 2007). As such, while the calculation of
dosage based on total volume consumed is useful for comparisons within a species, understanding the
effective dosages of these exposure models in the context of human health requires the measurement
of circulating levels of these drugs. To achieve this, levels of serum alcohol and cotinine (the major
primary metabolite of nicotine) were evaluated over a 24-hour period between day two and three of
exposure. For each of the exposure models, blood from five mice at each of 12 time-points over the
24-hour period, was collected by terminal cardiac puncture. Two control mice (provided with RO
water) were also included alongside each of the exposures, but only measured at two time-points
(07:00 and 19:00).
Serum ethanol concentrations were determined using the Alcohol Reagent and Control Set (Pointe
Scientific Inc., A7504-39). Using alcohol dehydrogenase and NAD this assay is able to detect ethyl
alcohol in whole blood and serum, and has been recently cited a number of times in the literature
(Lauing et al., 2008; Oldenburg et al., 2009). Serum cotinine concentrations were assayed using an
enzyme-linked immunosorbent assay (ELISA) for cotinine (Mouse/Rat Cotinine ELISA Kit [Cal-
biotech Inc., CO096D-100]). This kit has also been used in a number of publications to assay serum
cotinine concentrations following nicotine exposure (Raval et al., 2009; Moreno-Gonzalez et al.,
2013).
42 ESTABLISHMENT OF MOUSE MODELS
A B
C D
Figure 3.3: Serum ethanol [(A), (B)] and cotinine [(C), (D)] concentrations over a 24 hour period in
female C57BL/6 mice following exposures as labelled. Each circle represents the average of duplicate
readings from an individual mouse (black = treatment, and white = control mice). Mice were on a
12-hour light-dark cycle, with the shaded area from 19:00 to 07:00 identifying the dark cycle. The
red line in each panel indicate the daily average concentration calculated from all mice assayed for
that exposure (excluding the controls).
In all three models, serum ethanol and/or cotinine concentrations tended to be higher during the dark
phase than during the light phase of the light-dark cycle (Figure 3.3).
In the ethanol-only model, the peak serum ethanol concentration measured was 203 mg/dl (Fig-
ure 3.3A). In contrast, the peak ethanol concentration in the EtOH/NIC-exposed mice was 130 mg/dl
(Figure 3.3B). The average serum ethanol concentration over all time points in the ethanol-only model
(24 mg/dl) was almost double that of the dual exposure (12 mg/dl), despite the difference in daily con-
sumption between the ethanol-only and the dual exposure mice being only 14.7% (Figure 3.1). These
results suggest that in addition to the effect of consuming slightly less ethanol, there appears to be an
3.2. RESULTS 43
interaction between nicotine and ethanol in the dual model resulting in a reduced effective exposure
relative to the ethanol-only model.
In the nicotine-only model, the peak cotinine concentration measured was 689 ng/ml with the average
from all nicotine-exposed mice being 179 ng/ml (Figure 3.3C). In the dual ethanol/nicotine model,
the peak cotinine concentration was 781 ng/ml, and the average concentration across all time-points
was 172 ng/ml (Figure 3.3D). There was no significant difference in the average serum cotinine con-
centrations over the 24-hour period between the nicotine-only and the dual ethanol/nicotine exposure
groups (p>0.05).
3.2.5 Consequences of prenatal exposure to ethanol and/or nicotine on gross
morphology and viability of offspring
Once the effective dosages of both ethanol and nicotine were determined in each of the exposure
models, the effect of each exposure on gross morphology and offspring survival was assayed both
pre- and postnatally.
Embryos were assayed shortly following the termination of the exposure at mid-gestation (9.5 dpc), in
two independent cohorts. Data from both cohorts were combined in this section as no cohort-specific
effects were detected with regards to gross morphology or survival characteristics (data not shown).
At 9.5 dpc, no gross morphological abnormalities were apparent in embryos from any of the exposure
groups (data not shown). Further, there were no differences in either the number of viable or resorbed
embryos (deciduas without a viable embryo) in each litter between the control and any of the treatment
groups at 9.5 dpc (Figure 3.4). Implantation sites at which resorptions occurred very early in gestation
may no longer be obvious at 9.5 dpc, and the only evidence of these occurrences would be a change
in total number of implantation sites. However, even when the total number of implantation sites (i.e.,
the sum of viable embryos and resorbed embryos) were compared between groups no differences
were detected (Figure 3.5), indicating that none of the exposures altered embryonic viability at 9.5
dpc or earlier.
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Figure 3.4: The number of viable embryos and resorbed decidua that were identified at 9.5 dpc in
each litter. Mean ± S.D. indicated.
Figure 3.5: Total number of implantation sites observed at 9.5 dpc in each litter. Mean ± S.D.
indicated.
Offspring of the nicotine, dual ethanol/nicotine and control dams were also assayed at weaning (post-
natal day 21). The ethanol exposure utilised in this thesis has previously been described to not im-
pact on postnatal litter size (Kaminen-Ahola et al., 2010b). Neither the nicotine-only nor the dual
ethanol/nicotine exposure was associated with any gross malformations at this age (data not shown).
Offspring were not counted prior to weaning (21 days of age) due to the potential risk of stressing the
dam, which may adversely impact on maternal care. The postnatal data was also derived from two
independent cohorts, which due to the lack of cohort-specific effects on survival (data not shown), are
presented together in this section. At postnatal day 21, litter size following prenatal exposure to either
nicotine alone, or in combination with ethanol was not significantly different to that of the controls
(Figure 3.6). These data indicate that the prenatal exposures had no effect on postnatal survival.
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Figure 3.6: Number of live pups in each litter at postnatal day 21 following prenatal exposure to either
nicotine, or dual ethanol/nicotine. Mean ± S.D. indicated.
3.3 Discussion
The consequences of early gestational ethanol and nicotine exposure on resultant offspring are poorly
characterised, and few animal models exist to facilitate greater understanding. In this chapter, I es-
tablished a mouse model of early gestational nicotine exposure and another modelling a dual early
gestational ethanol and nicotine exposure. These models were characterised by quantifying the av-
erage volume of 10% (v/v) ethanol and 100 µg/ml nicotine consumed in each model, the resultant
maternal serum ethanol and cotinine concentrations, and gross consequences on both maternal and
offspring health. In addition to the two new models, these outcomes were also examined in a previ-
ously established mouse model of early gestational ethanol (10% v/v) exposure.
The use of an inbred mouse strain (C57BL/6) in each of the models described in this chapter reduces
the contribution of genetic heterogeneity between individuals to the response to ethanol and/or nico-
tine. Further, C57BL/6 mice have previously been identified to voluntarily consume both ethanol and
nicotine, and even display a susceptibility towards ethanol-induced teratogenesis compared to other
rodent strains (Rodgers, 1966; Meliska et al., 1995; Ogawa et al., 2005).
The exposure window in each of the models, from 0.5 to 8.5 dpc, was selected with the primary
intention of covering preimplantation epigenetic reprogramming (reviewed in Yamada and Chong,
2016). Furthermore, the selected exposure window is developmentally equivalent to the first three to
four weeks of human gestation (Otis and Brent, 1954). As this is a period of time when many women
have yet to confirm their pregnancies (Callinan and Room, 2012), it is likely that a large proportion
of women will inadvertently use either ethanol or nicotine products during this period.
Consistent with previous literature, C57BL/6 dams voluntarily consumed each of the treatment so-
lutions at the selected dosages (Kaminen-Ahola et al., 2010b; Robinson et al., 1996; Maier et al.,
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2011). In both the nicotine-only and control groups, variation was observed in mean daily consump-
tion between some cohorts. In the nicotine-only groups, there were two cohorts in which consumption
significantly differed from that of each other; however, in this instance it must be noted that the mag-
nitude of this difference was small, with the mean of the second cohort within one standard deviation
of the mean of the first (Figure 3.1C). Likewise, when consumption in control dams was compared
between cohorts, dams in one cohort (F) consumed on average, significantly less than two of the other
cohorts (15.9% reduction compared to cohort A, and 13.8% reduction compared to cohort B) (Fig-
ure 3.1B). In this instance, one likely impact of reduced water consumption is maternal dehydration,
which if severe enough could lead to reduced maternal body weight. However, as no such impact on
maternal body weight was observed (Figure 3.2), this reduced water consumption specific to cohort
F is unlikely to have had significant impact. The absence of any changes in maternal weight gain
over the exposure period in any of the treatment groups compared to control (Figure 3.2) indicates the
absence of any overt impact of any of these exposures on gross maternal health or wellbeing. The lack
of toxicity observed is consistent with previous literature using similar dosages of ethanol and nico-
tine (Kaminen-Ahola et al., 2010b; Maier et al., 2011). It has previously been reported that nicotine,
at dosages higher than that utilised in this thesis, can reduce food consumption and body weight in
C57BL/6 mice (Mangubat et al., 2012; Huang et al., 2015). The dosage utilised in the nicotine model
in this thesis has previously been identified to not influence either food intake or body weight (Huang
et al., 2015). Consistent with these previous findings, maternal body weight of nicotine-exposed dams
was unchanged relative to that of control dams (Figure 3.2), and it is therefore unlikely that reduced
maternal food consumption is mediating the nicotine-induced effects on the fetus.
Given that nicotine and ethanol metabolism vary considerably between mouse and humans, to enable
comparisons between the two species it was necessary to measure the resultant serum ethanol and
cotinine (the primary metabolite of nicotine) concentrations in each exposure. As embryos during
the window of exposure (0.5 - 8.5 dpc) have yet to develop a circulatory blood supply (McGrath
et al., 2003), ethanol and cotinine concentrations were measured in maternal serum. Furthermore, the
measurement of serum ethanol and cotinine levels in the dam enables the comparison of the effective
dosage in these models to those reported not only in other rodents, but also in humans.
The peak maternal serum ethanol concentration measured in the ethanol-only model was 203 mg/dl,
with an average serum ethanol concentration of 24 mg/dl (Figure 3.3A). While this peak serum ethanol
concentration is approximately four times the legal driving limit in Australia (50 mg/dl (Queensland
Government, 2013)), it is important to note that on average, the ethanol concentration was under the
legal driving limit. In contrast, in the dual ethanol/nicotine model, both the peak (130 mg/dl, i.e.,
2.3 times the legal driving limit) and average (12 mg/dl) serum ethanol concentrations were con-
siderably lower than for the ethanol-only model (Figure 3.3B). The magnitude of this reduction in
serum ethanol concentration was greater than could be explained by the reduction in ethanol vol-
ume consumed (Figure 3.1A). There are a number of mechanisms which may however, explain the
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reduction in blood alcohol concentration. Cytochrome P450, family 2, subfamily e, polypeptide 1
(Cyp2e1) metabolises ethanol, and has previously been demonstrated to be upregulated in response
to both ethanol and nicotine exposure (Howard et al., 2001, 2003). Cyp2e1 mRNA was not detected
in the whole embryo at 9.5 dpc (data not shown); however, it is possible that maternal Cyp2e1 levels
may have been affected. Consequently, it is possible that maternal Cyp2e1 levels may have been
greatest in the dual exposure model, with a resultant increase in ethanol metabolism which would
lead to the observed reduction in blood alcohol concentration. Alternatively, it has been reported that
blood alcohol concentration is decreased when nicotine is administered simultaneously with ethanol
via intragastric infusion in neonatal rats (Chen et al., 2001). Similar phenomena were also reported in
humans with cigarette smoking resulting in lower peak blood alcohol concentrations (Johnson et al.,
1991). Others have found that nicotine can delay gastric emptying (Gritz et al., 1988; Johnson et al.,
1991), which in turn may lead to increased first-pass metabolism by alcohol dehydrogenases present
in the gastrointestinal system (Julkunen et al., 1985; DiPadova et al., 1987). Ethanol metabolised
by first-pass metabolism would not enter into systemic circulation and would not contribute to blood
alcohol concentration.
Serum cotinine concentrations were comparable in both the nicotine-only and the dual ethanol/nicotine
models. The average serum cotinine concentrations (172 and 179 ng/ml) obtained in this study are
similar to that measured in humans who self-report consuming 10 - 15 cigarettes per day, defined as
light smokers (Lawson et al., 1998). Two similar models of oral ad libitum access to freebase nicotine
at a concentration of 100 µg/ml in female C57BL/6 have been previously reported. In the first, the
authors sweetened the nicotine solution with 2% saccharin and reported an average cotinine concen-
tration of 91.0 ng/ml in plasma collected between 8:00 and 9:00 in the morning (Sparks and Pauly,
1999), while the second did not sweeten the nicotine solution and reported an average steady-state
cotinine concentration of 100 ng/ml in serum collected in the early morning (Maier et al., 2011). In
the present study, the average serum cotinine concentrations over the 24-hour period was 179 ng/ml,
which is significantly higher than those reported previously. Despite previous studies reporting a
steady-state of cotinine (Sparks and Pauly, 1999; Maier et al., 2011), it is evident from the 24-hour
experiment presented in this chapter that the cotinine concentrations collected in the early morning are
not representative of the cotinine concentrations throughout the entire day, with substantially higher
concentrations measured during the dark phase of the light-dark cycle (Figure 3.3C), when mice are
more active (Harri et al., 1999). When the data was re-analysed, such that it only included samples
harvested from 8:00 to 9:00 am (Sparks and Pauly, 1999), the average concentration was instead
91.0 ng/ml, concordant with that previously reported. These findings suggest that perhaps the actual
nicotine exposures occurring in previously established ad libitum oral dosage models in the literature
may have been previously underestimated, and that assaying at only one time during the day may be
insufficient to gain an understanding of the exposure.
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When offspring of each of these models were assayed, none of the exposures resulted in changes to
gross morphology or survival at either 9.5 dpc or at postnatal day 21. This lack of effect on gross
morphology and viability reinforces and is consistent with the findings that the dosages used in these
models resulted in moderate, rather than severe exposures. Further, there appears to be no synergistic
effect on either of these parameters as a result of both nicotine and ethanol exposure. Previously,
one model of prenatal exposure to cigarette smoke and ethanol in rats was identified to result in
a synergistic effect on the number of viable offspring (Leichter, 1989), whereas other dual exposure
models reported no difference in neonatal death (Matta and Elberger, 2007) or gross dysmorphologies
(Woo and Persaud, 1988). The different dosages and administration methods utilised in each of these
models however, precludes the direct comparison of one study to another, especially in the absence of
any indication as to the resultant blood ethanol and/or cotinine concentrations in any of the models.
In this chapter, I established two new mouse models of nicotine-only and dual ethanol and nicotine
exposures. These models, alongside the previously established ethanol-only model constitute moder-
ate exposures and lacked overt consequences on maternal heath. Additionally, none of the exposures
were severe enough to induce changes in either viability or gross morphology of resultant offspring.
Both maternal ethanol consumption and smoking have however, been individually associated with a
reduction in offspring size (Butler et al., 1972; Streissguth et al., 1985; Witek-Janusek, 1986; Day
et al., 1989; Lieberman et al., 1994; Day et al., 1999, 2002; Robinson and Seelig, 2002; Ward et al.,
2007; Probyn et al., 2012). Furthermore, a number of studies have identified a potentiating effect of
alcohol on the effect of tobacco products on newborn size in humans (Aliyu et al., 2009; Brooke et al.,
1989; Haste et al., 1991; Olsen et al., 1991). Consequently, the following chapter of this thesis will
focus on examining whether prenatal ethanol and/or nicotine affects offspring growth.
4 Effects of prenatal exposure to ethanoland/or nicotine on growth
4.1 Introduction
Prenatal exposure to ethanol, tobacco smoke and nicotine have been extensively associated with re-
duced offspring growth (Aliyu et al., 2009; Kaminen-Ahola et al., 2010a; Rowell and Clark, 1982;
Wang et al., 2008, 2009). Furthermore, both maternal ethanol consumption (Kaminen-Ahola et al.,
2010a) and maternal smoking (Delpisheh et al., 2008) have also been reported to result in micro-
cephaly. Despite maternal tobacco smoking during gestation being associated with reduced birth
weight (Butler et al., 1972; Lieberman et al., 1994; Ward et al., 2007), these exposures have also
been associated with increased adiposity later in life in both humans and experimental animal studies
(recently extensively reviewed in Behl et al., 2013). Many of the experimental animal studies which
have previously reported these associations used models in which the exposures occurred either in
late gestation (Wang et al., 2008), for the majority of gestation (Rowell and Clark, 1982; Somm et al.,
2008; Wang et al., 2009), or lactation as well as gestation (Gao et al., 2005; Holloway et al., 2005).
Few studies have examined whether the phenotypes of reduced growth, later-life adiposity, and mi-
crocephaly can be detected following exposure to ethanol or nicotine restricted to just early gestation.
Our laboratory has previously described postnatal phenotypes of both reduced body weight and mi-
crocephaly in the model of early gestational ethanol exposure utilised in this thesis (Kaminen-Ahola
et al., 2010b). However, whether these phenotypes are present prenatally, from the time of exposure,
or whether there is a latency in the onset of these phenotypes has yet to be determined. To the best
of our knowledge, the capacity for nicotine exposure restricted to early gestation to affect offspring
growth or body composition, let alone head size has yet to be characterised.
There is evidence in human studies to suggest that concurrent maternal alcohol consumption and
tobacco smoking throughout pregnancy can have a greater effect on birth weight than either single
exposure (Aliyu et al., 2009; Brooke et al., 1989; Haste et al., 1991; Olsen et al., 1991). Whether
ethanol exposure restricted to early gestation can potentiate the effect of nicotine on these parameters
has also yet to be determined.
In this chapter, growth of offspring exposed to early gestational ethanol, nicotine, or the dual ethanol/nicotine
exposures are assayed both shortly following the termination of the exposures at mid-gestation and
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postnatally. The capacity for both the early nicotine and the dual ethanol/nicotine exposures to result
in increased adiposity postnatally is also explored.
4.2 Results
4.2.1 Rationale for the use of individual animals as experimental units
One of the dogmas within the field of DOHaD is that embryos from the same dam are all exposed
to the same intrauterine environment. Following from this, in the field of DOHaD it is common to
sample only a few offspring per litter, with the assumption that the findings from these individuals are
representative of the characteristics of their littermates (Haseman and Hogan, 1975). However, there
is an increasing body of evidence to suggest that there is greater intra-litter variability than inter-litter
variability in fetal outcomes following many prenatal exposures (van der Schoot, 1992; Howdeshell
and Saal, 2000; Barlow et al., 2003; Godin et al., 2010; Kietzman et al., 2014; Han et al., 2016).
These findings suggest that contrary to the dogma, embryos from the same dam are often exposed to
different intrauterine environments.
There are a number of factors that may contribute to the intra-litter differences in intrauterine environ-
ment. Uterine blood flow between individual conceptuses within a litter is highly variable (Buelke-
Sam et al., 1982), which would result in not only variable nutrient and oxygen delivery to each em-
bryo, but also variable delivery of the drug of interest (e.g., ethanol or nicotine). More locally, the
development of a given embryo can be influenced by fetus-to-fetus steroid transport from adjacent
littermates (Even et al., 1992; Clark et al., 1993). In turn, this local variation in steroid hormone
concentrations may modulate not only the normal developmental trajectory of each embryo, but also
the impact of an exposure of interest (Howdeshell and Saal, 2000). In recognition of this, it has been
argued that sampling a subset of each litter is likely to lead to erroneous findings, with greater accu-
racy achieved when each fetus is considered as an individual experimental unit (Elswick et al., 2000;
Haseman and Hogan, 1975). Consequently, in this thesis I chose to consider each embryo to be an
individual experimental unit. Furthermore, no litter effects were observed in any of the parameters
assayed in this thesis, suggesting that the assessment of multiple embryos per litter is unlikely to have
led to erroneous results.
4.2.2 Embryonic size at 9.5 dpc following prenatal exposure to ethanol and/or
nicotine
Crown-rump length, which is a measure of embryonic size (Chan et al., 2002; Denny et al., 2013; Lee
et al., 1995; Naruse-Nakajima et al., 2001; Parnell et al., 2006; Schneider et al., 2012) was measured
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at 9.5 dpc to assess whether embryonic growth was affected by any of the exposures used in this
project (black line, Figure 4.1). Given the potential for the head to be disproportionately affected by
these exposures, head length was also measured in embryos at 9.5 dpc (green line, Figure 4.1). Pho-
tographs of embryos were taken with a camera attached to a dissecting microscope, and measurements
obtained using an image analysis software, CellSens (Olympus Inc.). Measurements were taken by
two individuals; one who was blinded to treatment group (SC), and one who was not (LY). When
the crown-rump length obtained by the two individuals were compared, they were highly concordant
(r2=0.9943 (cohort A) and r2=0.9906 in (cohort B), Pearson’s correlation coefficient). As embryonic
development and size is known to be influenced by gender (Seller and Perkins-Cole, 1987), male and
female embryos were analysed separately.
Figure 4.1: Analysis of embryonic size at 9.5 dpc. Crown-rump length (black line) was measured
between the most rostral and caudal points of the embryo. Head length (green line) was measured
between the most dorsal and anterior points of the head of the embryo. Scale bar represents 1 mm.
No significant difference in embryonic size was observed between the control and ethanol-exposed
embryos (Figure 4.2A); however, a reduction in embryonic size was observed in both the nicotine
(significant in both males and females) and the dual ethanol/nicotine (EtOH/NIC)-exposed embryos
(significant only in males) (Figure 4.2A). There was no significant difference in magnitude of growth
restriction between the nicotine-only and the EtOH/NIC-exposed groups (Figure 4.2A), suggesting
that the addition of ethanol failed to exacerbate the nicotine-induced reduction in embryonic size at
9.5 dpc. Furthermore, head size remained proportionate in size to the rest of the body following all
exposures (Figure 4.2B).
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Figure 4.2: (A) Crown-rump length (µm) and (B) head length (µm) normalised to crown-rump length
(µm) of embryos at 9.5 dpc following prenatal exposure to ethanol and/or nicotine. Embryos in this
figure were generated from cohort A (Chapter 3). Morphometric measurements in this figure were
obtained by LY, with similar results obtained from a second investigator blinded to embryo treatment
group (SC) (Figure A1). Mean ± S.D. is indicated. **: p<0.01, ***: p<0.001 as determined by a
Student’s t-test. Control males: n=17 (6 litters), ethanol males: n=22 (7 litters), nicotine males: n=22
(6 litters), EtOH/NIC males: n=13 (5 litters), control females: n=24 (7 litters), ethanol females: n=20
(7 litters), nicotine females: n=16 (6 litters), and EtOH/NIC females: n=21 (6 litters).
One possibility was that the reduction in embryonic size following the nicotine and dual ethanol/nicotine
exposures was a consequence of developmental delay. To assess embryonic age, somites (an indicator
of developmental progression) were counted in embryos at time of dissection under a light micro-
scope. There was no significant difference in somite number in embryos from any of the treatment
groups when compared to the control group (Figure 4.3A), suggesting that none of the exposures
resulted in developmental delay at 9.5 dpc. Furthermore, the reduced embryonic size phenotype
persisted even when crown-rump length (µm) was normalised to somite number (Figure 4.3B), sug-
gesting that even slight differences in age were not responsible for the differences in size.
4.2. RESULTS 53
A limitation to this experiment was that the person counting the somites (LY) was not blinded to the
treatment group of the samples. To address this limitation, a subset of embryos for which somite
counts were conducted by LY at dissection were stained using whole mount in situ hybridisation for
a somitic marker (Uncx4.1, representative embryo in Figure A3) and re-counted by two individuals
who were blinded to the treatment group of the embryos (LY and SC). When the somite count from
the stained embryos were compared to those generated at time of dissection by a linear regression
analysis, a high concordance was found (r2=0.75, Figure A4). These data suggest that knowledge
of group in this instance did not significantly influence somite count, and consequently the lack of
developmental delay is unlikely to be due to investigator bias.
A
B
Figure 4.3: (A) Somite number at dissection of embryos at 9.5 dpc. (B) Crown-rump length nor-
malised to the somite number for each embryo at 9.5 dpc. Embryos in this figure were generated
from cohort A (Chapter 3). Morphometric measurements in this figure were obtained by one inves-
tigator (LY), with similar results obtained from a second investigator blinded to embryo treatment
group (SC) (Figure A2). Mean ± S.D. indicated. *: p<0.05, **: p<0.01, ***: p<0.001 as determined
by a Student’s t-test. Control males: n=17 (6 litters), ethanol males: n=22 (7 litters), nicotine males:
n=22 (6 litters), EtOH/NIC males: n=13 (5 litters), control females: n=24 (7 litters), ethanol females:
n=20 (7 litters), nicotine females: n=16 (6 litters), and EtOH/NIC females: n=21 (6 litters).
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Validation: nicotine-induced reduction of embryonic size
To test the reproducibility of the nicotine-induced reduction in embryonic size, embryos generated in
an independent cohort (referred to as cohort B) were assayed.
Consistent with cohort A, there was no difference in somite number in nicotine-exposed embryos
when compared to control embryos at 9.5 dpc in cohort B (Figure 4.4A). Furthermore, there was a
trend towards reduced embryonic size in males only (p=0.07) (Figure 4.4B).
A
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Figure 4.4: (A) Somite number at dissection of embryos at 9.5 dpc. (B) Crown-rump length nor-
malised to the somite number for each embryo at 9.5 dpc. Embryos in this figure were generated
from cohort B (Chapter 3). Morphometric measurements in this figure were obtained by one inves-
tigator (LY), with similar results obtained from a second investigator blinded to embryo treatment
group (SC) (Figure A5). p-values as determined by a Student’s t-test are displayed. Control males:
n=43 (12 litters), nicotine males: n=28 (9 litters), control females: n=40 (13 litters), and nicotine
females: n=28 (8 litters).
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4.2.3 Postnatal body weight following prenatal exposure to nicotine
To investigate whether the nicotine-induced effect on growth persisted postnatally, body weight was
measured weekly from weaning (postnatal week three) to six months of age in nicotine-exposed and
control mice. Again, males and females were analysed separately.
A reduction in body weight was apparent in males three weeks of age, but did not become statistically
significant until nine weeks of age (Figure 4.5). This statistically significant reduction in body weight
in males then persisted until the end of the experiment at 24 weeks (6 months) of age (Figure 4.5).
The reduction in female body weight was statistically significant only at weaning (three weeks);
however, for the remainder of the experiment, the average body weight of nicotine-exposed female
mice remained slightly lower than that of control mice (Figure 4.5).
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Figure 4.5: Postnatal body weight (g) following prenatal nicotine exposure (cohort B). Mean ± S.D. indicated. *: p<0.05 as determined by a
Student’s t-test in males (blue) or females (red). Control males: n=13-15 (5-6 litters), nicotine males: n=12 (3 litters), control females: n=23-24
(5 litters), and nicotine females: n=12-13 (3 litters).
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4.2.4 Fetal and placental morphometrics at 17.5 dpc following prenatal expo-
sure to nicotine
Both at mid-gestation (9.5 dpc) and from postnatal week three onwards, there appears to be an in-
creased tendency for reduced growth following prenatal nicotine-exposure, which is more apparent in
males. Thus far, the prenatal and postnatal data appear to be grossly concordant in both their direc-
tionality and sexually dimorphic nature. To investigate whether the postnatal reduced body weight is
likely to be related to reduced prenatal growth, body weight and crown-rump length were measured
at an intermediate time-point at the end of gestation (17.5 dpc). As previous experiments identified
a high degree of concordance between measurements obtained from investigators blinded and un-
blinded to treatment group, only one person (LY) who was unblinded to treatment group conducted
measurements in this experiment.
At 17.5 dpc, there was no difference in fetal weight (Figure 4.6A) or crown-rump length (Figure 4.7A,
Figure 4.7B). Furthermore, at this age, no effect on the placenta was observed following the nicotine
exposure, when measured by either weight (Figure 4.6B) or placental diameter (Figure 4.7C, Fig-
ure 4.7D).
A B
Figure 4.6: Fetal and placental characteristics at 17.5 dpc following prenatal nicotine exposure. (A)
Fetal weight (g), and (B) placental weight (g). Mean ± S.D. indicated. Control males: n=37 (8
litters), nicotine males: n=30 (7 litters), control females: n=26 (8 litters), and nicotine females: n=24
(7 litters).
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Figure 4.7: (A) Crown-rump length (black line) was measured between the most rostral and caudal
points of the fetus. (B) Crown-rump length (µm) at 17.5 dpc following prenatal nicotine exposure. (C)
Placental diameter was defined as the widest dimension across the placenta. (D) Placental diameter
(µm) at 17.5 dpc following prenatal nicotine exposure. Mean ± S.D. indicated. Scale bar in each
figure represents 2 mm. Control males: n=37 (8 litters), nicotine males: n=30 (7 litters), control
females: n=26 (8 litters), and nicotine females: n=24 (7 litters).
4.2. RESULTS 59
4.2.5 Postnatal body composition following prenatal exposure to nicotine or
ethanol and nicotine
Exposure to cigarette smoke or nicotine during gestation has been associated with increased risk of
later obesity in various animal studies (reviewed in Behl et al., 2013). To investigate whether the
nicotine-exposed and dual ethanol/nicotine-exposed mice in our models were at increased risk of
obesity, a new cohort of mice (cohort D) were generated from which offspring were weaned onto
either a high-fat diet (23.50% total fat, Specialty Feeds SF04-001), or a low-fat diet (5.30 % total
fat, Specialty Feeds SF13-081) and body weight assayed at regular intervals until 24 weeks of age.
In a subset of these mice, body composition was also measured using the Lunar PIXImus X-ray
densitometer at 10 - 11 months of age.
Males weaned onto the low-fat diet, had a trend towards reduced body weight between week 3 and
24, with the reduction being significant at weeks 8 and 9 (Figure 4.8). While the overall trends were
similar to what was observed in cohort C, this reduction in body weight appeared to be of a lesser
magnitude than that previously observed in cohort C. The female nicotine-exposed mice weaned onto
a low-fat diet, had a statistically significant increase in body weight at weeks 3 and 4 (Figure 4.8).
This trend reversed later in life, with the nicotine-exposed mice tending to have lower body weights
for the remainder of the experiment (Figure 4.8). The reduced body weights in the nicotine-exposed
mice were statistically significant from week 8 - 11, and again at week 18 (Figure 4.8). Overall, these
results are consistent with the findings in cohort C in which female nicotine-exposed mice tended to
have lower body weights than control mice. The dual ethanol/nicotine-exposed mice in which body
weight was assayed for the first time in this cohort had significantly increased body weight compared
to control mice at week 5 (females only) (Figure 4.8). For the remainder of the experiment however,
the ethanol/nicotine-exposed mice of both sexes tended to have lower body weights than that of the
controls in both males and females (Figure 4.8).
Neither of the prenatal exposures in this cohort (nicotine or dual ethanol/nicotine) significantly influ-
enced susceptibility of the offspring to a high-fat diet (Figure 4.9).
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Figure 4.8: Postnatal body weight (g) in mice following either a prenatal nicotine or a dual
ethanol/nicotine exposure then weaned onto a postnatal low-fat diet (LFD). Mean ± S.D. indicated.
*: p<0.05 as determined by a Student’s t-test in prenatally-exposed males (green) or females (or-
ange/purple) as compared to their respective control group. Control males: n=13 (4 litters), nicotine
males: n=19 (3 litters), EtOH/NIC males: n=12 (4 litters), control females: n=9-10 (3 litters), nicotine
females: n=5 (3 litters), and EtOH/NIC females: n=17-22 (5 litters).
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Figure 4.9: Postnatal body weight (g) in mice following either a prenatal nicotine or a dual ethanol/nicotine exposure then weaned onto a postnatal
high-fat diet (HFD). Mean ± S.D. indicated. *: p<0.05 as determined by a Student’s t-test in prenatally-exposed females (orange/purple) as
compared to the control group. Control males: n=11 (3 litters), nicotine males: n= 9 (3 litters), EtOH/NIC males: n=12 (3 litters), control
females: n=10 (3 litters), nicotine females: n=14 (3 litters), and EtOH/NIC females: n=11 (3 litters).
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To assess whether the mice had altered adiposity, Dual X-ray Absorptiometry (DXA) scans were con-
ducted using the PIXImus system. This system allowed for the collection of data pertaining to lean
mass, fat mass, and bone mineral density in each mouse (Figure A6, Figure A7). In mice weaned
onto a low-fat diet, no significant differences in percentage fat were observed in either males (Fig-
ure 4.10A) or females (Figure 4.10B) between controls and either of the prenatal treatment groups.
Furthermore, neither prenatal exposure influenced susceptibility to diet-induced adiposity in either
sex (Figure 4.10A and Figure 4.10B).
A B
Figure 4.10: Percentage body fat following prenatal exposure to nicotine or ethanol/nicotine followed
by postnatal high/low-fat diet in (A) males (control LFD: n=4 (4 litters), nicotine LFD: n=4 (2 litters),
EtOH/NIC LFD: n=4 (2 litters), control HFD: n=4 (3 litters), nicotine HFD: n=4 (3 litters), and
EtOH/NIC HFD: n=4 (3 litters)), and (B) females (control LFD: n=4 (2 litters), nicotine LFD: n=4 (3
litters), EtOH/NIC LFD: n=4 (4 litters), control HFD: n=4 (2 litters), nicotine HFD: n=4 (3 litters),
and EtOH/NIC HFD: n=4 (2 litters)). Mean ± S.D. indicated.
4.3 Discussion
Gestational exposures to both ethanol and nicotine individually, can have consequences on the growth
of offspring (Kaminen-Ahola et al., 2010b; Rowell and Clark, 1982; Wang et al., 2008). Further-
more, concomitant gestational exposure to both ethanol and tobacco can have greater consequences
on birth-weight than following a single exposure (Aliyu et al., 2009; Brooke et al., 1989; Haste et al.,
1991; Olsen et al., 1991). Whether exposures to ethanol and nicotine restricted to just early gestation
can also impact growth, and whether combined exposure potentiates the effect had yet to be char-
acterised. Consequently, this chapter focused on examining the impact of early gestational nicotine
and/or ethanol exposure on both embryonic and postnatal growth.
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Despite a previous report of a postnatal reduction in body size (from three weeks of age) in the
same model of prenatal ethanol exposure (Kaminen-Ahola et al., 2010a), no effect on body size was
observed in mid-gestational (9.5 dpc) ethanol-exposed embryos (Figure 4.3B). Furthermore, despite
an ethanol-associated postnatal phenotype of microcephaly (Kaminen-Ahola et al., 2010a), head size
at 9.5 dpc was still proportionate to overall body size following the ethanol exposure (Figure 4.2B).
These results suggest that the onset of reduced body size and microcephaly are likely to be between
9.5 dpc and three weeks of age.
Prenatal nicotine exposure resulted in a tendency towards reduced body size, both at 9.5 dpc (Fig-
ure 4.3B, Figure 4.4B) and postnatally (Figure 4.5). At both these ages, the reduced body size was
more apparent in males than in females. When offspring growth was measured at a third, intermediate
time-point shortly prior to birth (17.5 dpc), no such tendency towards reduced body size was detected
(Figure 4.6A). These data suggest that the prenatal and postnatal growth outcomes are distinct and
unconnected parameters, and that the postnatal phenotype is unlikely to simply be a continuation of
an embryonic phenotype. The magnitude of this reduction in body size at 9.5 dpc was greater in
the discovery cohort than in the validation cohort. This difference cannot be explained by housing,
season, age of dams, or any known environmental disturbances and is most likely attributable to natu-
ral biological variation. However, the overall trend towards nicotine-induced reduction in embryonic
size is consistent with previous literature, in which prenatal nicotine exposure has been correlated to
embryonic growth restriction at 10.5 dpc in mouse embryos following culturing in a nicotine solution
for 48 hours (Lin et al., 2013); however, the present study was the first to look at body size following
an in utero exposure. By assaying at multiple ages, this study additionally demonstrates the transient
nature of the prenatal growth restriction.
As there was no evidence for altered somite numbers at 9.5 dpc following any of the exposures
(Figure 4.3A), it is unlikely that the reduced embryonic size can be attributable to developmental
delay. This lack of developmental delay is inconsistent with previous literature in which instances
of developmental delay were detected at mid-gestation following both prenatal ethanol exposure (Liu
et al., 2009; Ogawa et al., 2005) and prenatal nicotine exposure (Lin et al., 2013). These differences
could be attributed to differences in the animal model, with previous literature employing high-dose
whole-embryo culture techniques, in contrast with the more moderate dose in vivo model utilised in
this project.
The dual ethanol/nicotine-exposed offspring appeared to have a phenotype no greater in severity than
the nicotine-exposed offspring, both at 9.5 dpc and postnatally, suggesting that the presence of ethanol
did not potentiate the effect of nicotine on growth. A number of studies have previously identified
a potentiating effect of alcohol on the effect of tobacco products on newborn size in humans (Aliyu
et al., 2009; Brooke et al., 1989; Haste et al., 1991; Olsen et al., 1991). Similar results were reported in
an experimental study using rats, with a greater effect on fetal weight following a combined alcohol
and tobacco exposure than was observed with exposure to ethanol alone (Leichter, 1989). In this
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study, dams were exposed to cigarette smoke and/or ethanol for the four weeks prior to mating until
gestational day 20, resulting in an exposure window considerably longer than that of the models
utilised in this thesis (Leichter, 1989).
Few experimental studies exist on the effect of concomitant exposure to ethanol and nicotine (rather
than tobacco or cigarette smoke) on growth. When pregnant Sprague-Dawley rats were treated with
either nicotine alone or in combination with ethanol from gestational days 9 - 12, there was no greater
effect of a dual ethanol/nicotine treatment when compared to nicotine alone on embryonic growth
(assessed at gestational day 12) (Woo and Persaud, 1988). In both this study and that presented in
this chapter, it appears that ethanol and nicotine do not have an interactive effect on one other in
terms of their effect on growth. It is possible that had a longer exposure window been used, that
potentiative effects on growth may have been detected. Similarly, a different dosage may have also
produced an effect; however, the lack of measurement of blood ethanol or cotinine concentrations in
many studies precludes the direct comparison of effective dosage between studies (Leichter, 1989;
Woo and Persaud, 1988). There is also the possibility that if other (non-growth) parameters were to
be assessed, that a potentiative effect between ethanol and nicotine may be observed. For example, a
potentiative effect in the acquisition of nicotine self-administration in the adult offspring was reported
in a rat model of a dual ethanol/nicotine exposure (Matta and Elberger, 2007).
There was no evidence for any tendency towards an increased susceptibility to obesity on a low-fat
diet or to diet-induced obesity (Figure 4.10) following either the nicotine or dual ethanol/nicotine
exposures. These results are in contrast to experimental studies which have identified associations
between maternal tobacco smoking or prenatal nicotine exposure with later adiposity (reviewed in
Behl et al., 2013). As many of the exposure models reviewed by Behl et al., 2013 spanned a greater
proportion of gestation and/or lactation than did our models, it is possible that exposures restricted to
early gestation may have less impact on adiposity than exposures spanning the entirety of gestation.
Both the embryonic and postnatal phenotypes of reduced body size identified in this chapter were
more apparent in male than female offspring. Postnatally, hormonal differences between the sexes
may contribute to this apparent sex dimorphism. At 9.5 dpc however, gonad development has yet to
occur (Livera et al., 2006) and any differences are unlikely to be a consequence of differential steroid
hormonal status. Sex differences in gene expression have been reported as early as the eight-cell stage
in mice, with many of the differences in expression at this age likely to be driven by the different sex
chromosomes (Lowe et al., 2015). In the following chapter, genome-wide gene expression is assessed
in male embryos at 9.5 dpc. If there are any nicotine-sensitive genes located on the Y-chromosome,
these genes may be involved in the sexually dimorphic growth phenotype observed at this age.
In this chapter I identified a phenotype of reduced growth present transiently at mid-gestation (9.5
dpc) and longer-lasting in postnatal life following a prenatal nicotine exposure. This reduction in
body size was not present shortly prior to birth suggesting the two outcomes are independent. At
both of these time-points, the reduced growth was more apparent in males than in females. Reduced
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growth did not correlate with increased susceptibility to obesity either on a low- or a high-fat diet
at a later age. The experiments presented in this chapter are, to the best of our knowledge, the first
to examine the impact of early gestational in utero exposures to ethanol and/or nicotine on growth,
adiposity, and microcephaly. The following chapter aims to further characterise the impact of these
exposures on the transcriptional profiles of the developing embryo at 9.5 dpc.
5 mRNA and microRNA expressionprofiling at 9.5 dpc
5.1 Introduction
To further characterise the consequences of prenatal ethanol or nicotine exposure on the developing
embryo, transcriptional profiling was conducted on whole embryos at 9.5 dpc. Despite the lack of
overall growth restriction at mid-gestation following the ethanol exposure, in the postnatal offspring
others have previously identified growth restriction and other phenotypic changes. It could therefore
be hypothesised that transcriptional changes may have preceded the development of these phenotypic
changes, and may already be present shortly following the termination of the exposure. In contrast,
nicotine-exposed offspring were identified to be of reduced body size both embryonically, and postna-
tally. Consequently, they too may have transcriptional changes present in the embryo mediating these
phenotypic changes. As the body size of the dual ethanol/nicotine-exposed offspring was indistin-
guishable from that of offspring exposed to nicotine-only, transcriptional profiling was not conducted
on the dual ethanol/nicotine-exposed offspring. To facilitate the identification of early transcriptional
changes which may occur following exposures to ethanol or nicotine, transcription was assayed in
embryos shortly following the termination of the exposures at 9.5 dpc. It was hypothesised that
transcriptional changes at 9.5 dpc may be associated with either the embryonic phenotype (nicotine-
exposed embryos) or the development of later phenotypes (for both ethanol- and nicotine-exposed
embryos).
Traditionally, transcriptional profiling targeted mRNA levels only; however, there is increasing evi-
dence that small, noncoding RNAs such as microRNAs (miRNAs) may also play an important role
in an organism’s response to prenatal exposures (Wang et al., 2009; Soares et al., 2012; Zhang et al.,
2015). As such, the expression of both mRNAs and miRNAs were assayed in ethanol and nicotine-
exposed embryos, and compared to expression in control embryos.
Previously, the expression of mRNAs has been profiled in the mid-gestation mouse embryo following
whole embryo culture in ethanol, using concentrations described as high dose (Liu et al., 2009; Zhou
et al., 2011). However, the very act of culturing can perturb DNA methylation profiles, which in turn
could affect gene expression (Morgan et al., 2008; Leitch et al., 2013). These findings raise concerns
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as to whether the changes identified in vitro are truly representative of changes that may occur in an
in vivo context.
In this chapter, I profile mRNA and miRNA expression following an in utero exposure to either
ethanol or nicotine. I have previously demonstrated (Chapter 3) that the dosages utilised in these
models are a moderate, rather than high dose. These experiments are, to the best of our knowledge,
the first time in which mRNA expression has been profiled in the mid-gestation embryo following a
nicotine exposure, and the first time miRNAs have been assayed in the mid-gestation embryo follow-
ing either an ethanol or nicotine exposure.
5.2 Results
The expression of both miRNAs and mRNAs were assayed in an unbiased manner using TaqMan
array rodent miRNA microfluidic cards and Illumina MouseWG-6 v2.0 BeadChip mRNA microar-
rays, respectively. Many of the previously assayed consequences of ethanol and nicotine exposure
are dependent on the sex of the resultant offspring (Zhang et al., 2015, Chapter 4). For example, the
phenotype of reduced embryonic size in the nicotine-exposed embryos was greater in magnitude in
males than in females at 9.5 dpc. Therefore, to eliminate the possible confounding variable of sex,
only male embryos were assayed in these screens.
In the discovery experiments, 12 male 9.5 dpc embryos from cohort A from each of the control (from
5 litters), ethanol (from 5 litters), and nicotine-only exposure groups (from 6 litters) were assayed
individually. Further, the same 36 embryos were used to profile the expression of both miRNAs and
mRNAs.
To determine whether the results were reproducible, a similar number of male 9.5 dpc embryos from
an independent cohort (cohort B) were subsequently assayed for candidate miRNA or mRNA expres-
sion by qRT-PCR.
5.2.1 Screen: ethanol- and nicotine-sensitive microRNAs in male embryos
TaqMan array rodent miRNA cards (Applied Biosystems, 4444909) are a TaqMan qRT-PCR based
method of assaying miRNA expression. Each set of cards comprises two 384-well microfluidic cards
with pre-plated primers and probes in each well. Together, they allow for the expression profiling of
641 unique miRNAs. Data analysis was conducted on the software recommended by the manufac-
turer (ExpressionSuite Software v1.0.4, Applied Biosystems). For each of the two cards, NormFinder
(Andersen et al., 2004) was used to identify two reference miRNAs, defined as those with the great-
est stability both within, and across treatment groups (data not shown). These reference miRNAs
were then used to normalise the expression of miRNAs between samples. Expression in ethanol- and
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nicotine-exposed embryos were compared to that of the control embryos. MicroRNAs were consid-
ered to be differentially expressed if their absolute fold change (between control and either ethanol
or nicotine) was greater than 1.5 fold, and had an uncorrected p-value of less than 0.05. Only miR-
NAs which met these criteria following normalisation to both reference miRNAs (separately) were
included.
Using these criteria, no miRNAs were identified to be differentially expressed in the ethanol-exposed
embryos. Six miRNAs (miR-99a, miR-9, miR-125a-5p, miR-384-5p, miR-302d, and miR-302b)
were identified to be differentially expressed in the nicotine-exposed embryos when compared to
control embryos (Figure 5.1). These results indicate that, despite miRNAs having regulatory roles
in embryonic development (reviewed in Ivey and Srivastava, 2015), both the ethanol and nicotine
exposures have minimal impact on miRNA expression in whole male embryos at 9.5 dpc.
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Figure 5.1: MicroRNAs differentially expressed in nicotine-exposed compared to control male em-
bryos at 9.5 dpc (1.5 fold, with an uncorrected p-value <0.05), as assayed on the TaqMan array rodent
miRNA cards. Data in this figure were normalised to miR-134. Similar results were obtained when
normalised to miR-17 (Figure A8). Mean ± S.D. is indicated. *: p<0.05, **: p<0.01, ***: p<0.001
as determined by a Student’s t-test . Control males: n=12 (4 litters) and nicotine males: n=12 (6
litters).
5.2.2 Screen: ethanol- and nicotine-sensitive mRNAs in male embryos
Genome-wide gene expression was assayed using the Illumina MouseWG-6 v2.0 BeadChip mRNA
microarray platform (conducted by the Australian Genome Research Facility). Analyses of differen-
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tial gene expression were performed using custom scripts in R project software, which were written
in collaboration with Elizabeth Mason (The Australian Institute of Bioengineering and Nanotechnol-
ogy, The University of Queensland). Probes were filtered based on their detection p-values (p<0.01
in at least 75% of samples in at least one of the two groups being compared). Expression values were
quantile normalised, then a differential gene expression analysis conducted using a Wilcox rank sum
t-test . Probes were considered to be differentially expressed if their absolute fold change (between
ethanol or nicotine and control) was greater than 1.5 fold, and had an uncorrected p-value of less
than 0.05. Confirmation that the probes of interest were specific to their annotated gene was done by
manually inputting probe sequences into BLAT, a BLAST-like alignment tool (Kent, 2002) available
on the University of California, Santa Cruz server. BLAT is a sequence alignment tool which can be
used to identify homology between query sequences, such as probe sequences, and the mouse genome
(Kent, 2002). Sequences displaying homology exclusive to one region in the genome are considered
to be unique.
Differentially expressed genes in ethanol-exposed male embryos
Five genes (assayed by five probes) were identified to be differentially expressed in the ethanol-
exposed embryos when compared to the control embryos (Figure 5.2). Of the five genes identified
to be differentially expressed between the ethanol and control embryos, only the probe for B cell
CLL/lymphoma 11B (Bcl11b) appeared to be specific (Table 5.1).
Figure 5.2: Volcano plot of expression in ethanol-exposed compared to control embryos at 9.5 dpc.
Each black circle represents a probe that passed filtering on detection p-value , with fold change and
uncorrected p-value represented on the X- and Y-axes, respectively. Probes within the red shaded
areas are those that had an absolute fold change ≥ 1.5 fold, with an uncorrected p-value <0.05.
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Gene name Fold change Uncorrectedp-value
p-value after
Bonferroni
correction
Number of
probes
Bcl11b -1.58 0.038 1 1
Table 5.1: Decreased expression of Bcl11b was identified in male ethanol-exposed embryos at 9.5
dpc when compared to control embryos.
Differentially expressed genes in nicotine-exposed male embryos
105 genes (assayed by 117 probes) were identified to be differentially expressed in male nicotine-
exposed embryos when compared to control embryos (Figure 5.3, Table A2). Of these, 62 genes had
decreased expression while 43 had increased expression.
Figure 5.3: Volcano plot of expression in nicotine-exposed compared to control samples at 9.5 dpc.
Each black circle represents a probe that passed filtering on detection p-value , with fold change and
uncorrected p-value represented on the X- and Y-axes, respectively. Probes within the red shaded
areas are those that had an absolute fold change ≥ 1.5 fold, with an uncorrected p-value <0.05.
A functional annotation clustering analysis using the resultant 105 genes was conducted using the
DAVID Bioinformatics Resource 6.7 (Huang et al., 2009a,b). The ten highest scoring gene ontology
terms according to their p-value following Bonferroni correction are listed in Table 5.2. Given the
relatively large number (15/105) of homeobox genes present in the input gene list, it is unsurprising
that many of the highest scoring terms were related to transcriptional regulation and pattern formation.
To generate a list of genes that may be relevant to the phenotype of reduced growth, the 105 genes
were filtered on basis of their correlation with embryonic size (|r2| ≥ 0.5). As phenotypic data was
available for each of the embryos used on the microarray, a Pearson’s correlation coefficient was able
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Gene Ontology term % of totalgene list Count
p-value after Bonferroni
correction
Pattern specification process 21.9 20 2.06 x 10−16
Transcription regulator activity 36.2 33 2.76 x 10−16
Regionalization 19.7 18 5.57 x 10−16
Anterior/posterior pattern formation 17.5 16 1.63 x 10−15
Transcription factor activity 29.6 27 2.36 x 10−15
DNA binding 39.5 36 6.37 x 10−14
Regulation of transcription,
DNA-dependent 36.2 33 1.92 x 10
−13
Sequence-specific DNA binding 24.1 22 2.33 x 10−13
Regulation of RNA metabolic process 36.2 33 2.96 x 10−13
Regulation of transcription 42.8 39 7.22 x 10−13
Table 5.2: Top gene ontology terms from a DAVID functional annotation clustering analysis of genes
differentially expressed in nicotine-exposed male embryos.
to be calculated between the expression of each of the genes identified to be differentially expressed,
and the crown-rump length normalised to somite number of each embryo. This was performed sep-
arately for control and nicotine-exposed embryos (Table 5.3). At this point, probes identified to be
lacking specificity according to BLAT analysis were excluded. Using control embryos the expression
of 20 genes was correlated with normalised crown-rump length. In the nicotine-exposed embryos, the
relationship between these genes and embryonic size appeared to be lost.
The 20 genes that were both differentially expressed between nicotine and control embryos and cor-
related to normalised crown-rump length are involved in a number of biological processes including
those of growth and metabolism. Many (Ptx3, Epha5, Bcl11b, Dcx, Phlda2, Cdx1, Zscan10, and
Ddr2) had a known association with a growth phenotype, though often this was reported postnatally
rather than prenatally (Chawengsaksophak et al., 1997; Katsuragi et al., 2013; Kraus et al., 2014;
Labrador et al., 2001; Mamiya et al., 2008; Tunster et al., 2014; Werner et al., 2012; Witasp et al.,
2014). The presence of genes with known roles in growth in our list provided assurance that the
filtering conducted was valid, and that the resultant gene list was likely to be involved in the growth
phenotype. A number of genes (Ddr2, Insm1, Sst, and Alx3) were also involved in metabolism, with
reported roles in glucose and insulin homeostasis or pancreas development (Cordoba-Chacon et al.,
2013; Gierl et al., 2006; Mirasierra et al., 2011; Zurakowski et al., 2007).
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Uncorrected Correlation with CRL:S
Gene symbol Gene name Fold change p-value Control Nicotine
Bcl11a B cell CLL/lymphoma 11A -2.43 0.0036 0.73 -0.34
-1.81 0.0023 0.68 -0.12
Cdx1 Caudal type homeobox 1 1.53 0.0056 -0.66 -0.02
1.80 0.0018 -0.53 0.23
Dcx Doublecortin -1.89 0.0332 0.64 -0.51
Ptx3 Pentaxtrin related gene -1.94 0.0173 0.63 -0.53
-2.59 0.0045 0.59 -0.26
Lamc3 Laminin gamma 3 -2.26 0.0036 0.62 -0.59
Phlda2 Pleckstrin homology-like domain, family A, member 2 1.82 0.0205 -0.62 0.25
Insm1 Insulinoma-associated 1 -1.55 0.0173 0.61 -0.36
Alx3 Aristaless-like homeobox 3 -1.51 0.0068 0.61 0.21
Gp5 Glycoprotein 5 (platelet) -1.55 0.0332 0.60 -0.60
Barx1 BarH-like homeobox 1 -2.00 0.0100 0.60 -0.10
-2.00 0.0205 0.55 -0.21
Nef3 Neurofilament, medium polypeptide -1.92 0.0449 0.58 -0.33
EphA5 Eph receptor A5 2.25 0.0036 -0.55 -0.24
Inmt Indolethylamine N-methyltransferase -1.69 0.0145 0.54 0.28
Bcl11b B cell CLL/lymphoma 11B -2.05 0.0009 0.54 -0.16
Mapt Microtubule-associated tau -1.52 0.0121 0.53 0.04
Sst Somatostatin -2.32 0.0051 0.53 -0.12
Prtn3 Proteinase 3 -1.67 0.0121 0.52 -0.07
Ddr2 Discoidin domain receptor family, member 2 -1.57 0.0242 0.51 -0.68
Zscan10 Zinc finger and SCAN domain containing 10 1.73 0.0173 -0.51 0.42
Vtn Vitronectin -1.98 0.0449 0.51 -0.30
Table 5.3: Genes identified to be both differentially expressed in the nicotine-exposed embryos and correlated in control embryos with crown-
rump length normalised to somite number (|r2| ≥ 0.5).
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5.2.3 Validation: nicotine-sensitive miRNAs in male embryos
To test the reproducibility of the differential expression of the six miRNAs identified to be sensitive
to nicotine in male 9.5 dpc embryos in the discovery experiment, expression of these miRNAs was
assayed in male embryos generated in an independent validation cohort. The same TaqMan assays as
were used on the microfluidic cards were used to measure expression in male embryos from the vali-
dation cohort using qRT-PCR in 384-well plates. In the independent validation cohort, the differential
expression of none of the miRNAs of interest validated (Figure 5.4).
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Figure 5.4: qRT-PCR validation assays for 6 miRNAs identified to be differentially expressed using
the TaqMan array rodent miRNA cards. Data in this figure were normalised to miR-134. Similar
results were obtained when normalised to miR-17 (Figure A9). Mean ± S.D. is indicated. Control
males: n=18 (10 litters) and nicotine males: n=16-17 (7 litters).
5.2.4 Validation: nicotine-sensitive mRNAs in male embryos
As the nicotine-exposed embryos had both a stronger phenotype (Chapter 4) and had a considerably
greater number of genes identified to be differentially expressed (105 genes) than the ethanol exposure
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(one gene), the remainder of this chapter and project focuses on characterising the changes identified
following the nicotine rather than the ethanol exposure.
The expression of a subset (18) of these genes identified to be both nicotine-sensitive and correlated
with embryonic size (selected on basis of fold change, uncorrected p-value and reported function in
previous literature) were assayed in male embryos derived from the validation cohort. SYBR-based
qRT-PCR was conducted using primers designed to assay the same transcripts as those assayed by
the microarray (Table A1). Of the genes assayed, the differential expression of one gene, Zinc finger
SCAN domain containing 10 (Zscan10), was successfully validated (p = 0.04, Figure 5.5). Zscan10
was previously known as Zinc finger protein 206 (Zfp206).
The magnitude of the Zscan10 expression change identified in the validation qRT-PCR (fold change:
1.18 (Gapdh) and 1.22 (Hsp90ab1); Figure 5.5) was less than that identified in the microarray (fold
change: 1.73; Table 5.3). The qRT-PCR results also showed that while on average, the nicotine-
exposed embryos had increased expression of Zscan10, there were individual nicotine-exposed em-
bryos with similar expression levels to that of the control embryos, i.e., only a subpopulation of the
nicotine-exposed embryos had Zscan10 expression levels greater than that in the controls (Figure 5.5).
Therefore, the effect of nicotine on Zscan10 expression appears to be stochastic.
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Figure 5.5: qRT-PCR validation assays for 18 genes identified in the microarray experiment (Ta-
ble 5.3) in male 9.5 dpc embryos. Data in this figure were normalised to Gapdh. Similar results
were obtained when normalised to Hsp90ab1 (Figure A10). Mean ± S.D. is indicated. *: p<0.05,
as determined by a Student’s t-test . Control males: n=17-18 (10 litters) and nicotine males: n=17 (7
litters).
Nicotine-induced increase in Zscan10 expression is stronger in males
To determine whether this increased expression of Zscan10 following nicotine exposure also occurred
in females, Zscan10 expression was assayed in female embryos from both the discovery and validation
cohorts (Figure 5.6). Female sample sizes in both cohorts were similar to those used for the male
assays. In the discovery cohort, increased Zscan10 expression was observed in the female nicotine-
exposed embryos (p = 0.04), consistent with the results from the male embryos (Figure 5.6A). In
the validation cohort, there was no change in Zscan10 expression in the nicotine-exposed embryos
(p = 0.70), despite originating from the same cohort in which male embryos were identified to have
altered Zscan10 expression (Figure 5.6B). These results suggest that male embryos appear to be more
sensitive to nicotine-induced alterations in Zscan10 expression than female embryos.
A B
Figure 5.6: Zscan10 expression was assayed by qRT-PCR in female 9.5 dpc embryos from both the
(A) discovery (control females: n=18 (10 litters) and nicotine females: n=17 (8 litters)) and the (B)
validation (control females: n=12 (6 litters) and nicotine females: n=12 (6 litters)) cohorts. Data in
this figure were normalised to Gapdh. Similar results were obtained when normalised to Hsp90ab1
(Figure A11). Mean ± S.D. is indicated. *: p<0.05, as determined by a Student’s t-test .
Increased Zscan10 expression at 9.5 dpc does not persist into adulthood
The expression of Zscan10 has previously been assayed in 13 adult mouse tissues (brain, heart, lung,
liver, spleen, kidney, stomach, small intestine, skeletal muscle, thymus, testis, uterus and placenta)
(Wang et al., 2007a). Within these tissues, Zscan10 expression was strongest in the testis (Wang
et al., 2007a). To determine whether the nicotine-induced increase in Zscan10 expression persisted
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into postnatal life, Zscan10 expression was assayed by qRT-PCR using RNA isolated from the testes
of control and nicotine-exposed mice at 11 months of age. Gapdh and Actb were selected for use as
reference genes (Fullston et al., 2013; Gong et al., 2014).
Figure 5.7: Zscan10 expression was assayed by qRT-PCR in testes of control and nicotine-exposed
mice. Data in this figure were normalised to Gapdh. Similar results were obtained when normalised
to Actb (Figure A12). Mean ± S.D. is indicated. Control males: n=11 (4 litters) and nicotine males:
n=17 (3 litters).
There was no difference in Zscan10 expression in the testes between control and nicotine-exposed
mice (Figure 5.7). These data suggest that the nicotine-induced increase in Zscan10 expression is
specific to the 9.5 dpc embryo.
There are multiple nicotine-sensitive Zscan10 transcripts in the male 9.5 dpc embryo
Multiple Zscan10 transcripts, proposed to be generated by alternative splicing, have previously been
reported in mouse embryonic stem cells (Zhang et al., 2006). It was unknown whether the nicotine-
induced differential expression of Zscan10 was reflective of changes in the expression of all of these
transcripts or specific to a subset of transcripts. To investigate this further, RT-PCR was used to am-
plify a region from exon 2 - 6 as previously described (Zhang et al., 2006). Within this amplified
region (highlighted in Figure 5.8A) there is considerable variation in exonic structure between tran-
scripts (UCSC Genome Browser NCBI37/mm9, accessed March 2016) (Rosenbloom et al., 2015).
When PCR of this region was conducted on cDNA from male 9.5 dpc embryos, three main transcripts
were identified (Figure 5.8B). No difference was observed in either the number or size of PCR prod-
ucts between control or nicotine-exposed embryos. As not every individual nicotine-exposed embryo
displayed Zscan10 expression dissimilar to that of the controls, two nicotine-exposed subgroups were
assayed: embryos with basal Zscan10 expression levels similar to that of the control embryos, and
those with relatively high levels. Even between these two nicotine-exposed subgroups, there was
no differences in the number or size of PCR products (Figure 5.8B). To definitively identify each of
these PCR products, representatives of each band were subcloned and Sanger sequenced. The re-
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sultant exon structure of each of the three transcripts (Figure 5.8C) is consistent with some of the
transcripts described previously (Zhang et al., 2006).
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Figure 5.8: (A) Screenshot from the UCSC Genome Browser illustrating the multiple reported tran-
scripts of Zscan10 (UCSC Genome Browser NCBI37/mm9, accessed March 2016; Rosenbloom
et al., 2015). The region assayed by RT-PCR is highlighted in blue, with the location of primers
(Zfp206_F_Zhang2006 and Zfp206_R_Zhang2006) previously described (Zhang et al., 2006) indi-
cated. (B) RT-PCR identified three putative Zscan10 transcripts in the 9.5 dpc male embryo. (C)
Schematic of the exonic structure of Zscan10 exons 2 - 6 present in the 9.5 dpc embryo, as deter-
mined by Sanger sequencing of the three PCR products.
The microarray probe for Zscan10 targeted its 3’UTR and the qRT-PCR primers utilised for subse-
quent validations spanned exons 5 and 6. Both of these regions are common to all three transcripts
82 EXPRESSION AT 9.5 DPC
detailed in Figure 5.8, and as such results obtained using these assays (Table 5.3 and Figure 5.5) are
likely to reflect the average expression of these three transcripts. To determine the relative contribu-
tion of each of these three transcripts to the results, qRT-PCR was conducted using primers designed
to be specific to each transcript (Figure 5.9A; Table A1). A trend for increased expression of all
three transcripts (significant for transcripts II and III) was identified in the nicotine-exposed embryos
(Figure 5.9B). These results suggest that the nicotine-associated differential expression of Zscan10 is
likely to be driven by multiple transcripts, rather than any one transcript in isolation.
A
B
Figure 5.9: (A) Location of primers designed to assay specific transcripts of Zscan10. Dashed line
indicates where an individual primer spans two exons. (B) Relative expression of each of the three
transcripts identified in the 9.5 dpc male embryo. Data in this figure were normalised to Gapdh.
Similar results observed when normalised to Hsp90ab1 (Figure A13). *: p<0.05, **: p<0.01, as
determined by a Student’s t-test . Control males: n=18 (10 litters) and nicotine males: n=17 (7
litters).
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5.3 Discussion
In this chapter, the expression of miRNAs and mRNAs were successfully profiled in male 9.5 dpc
embryos following either an ethanol or a nicotine exposure.
The expression of one gene, B cell CLL/lymphoma 11B (Bcl11b), was identified to be sensitive to
ethanol exposure in male embryos at 9.5 dpc. Bcl11b encodes for a transcription factor with roles
in embryonic tooth development (Katsuragi et al., 2013) and the development of T lymphocytes
(Wakabayashi et al., 2003). It was not identified to be differentially expressed in any of the other
tissues previously assayed in this ethanol model (Kaminen-Ahola et al., 2010a; Marjonen et al., 2015;
Zhang et al., 2015), nor has it been identified in association with other models of prenatal ethanol
exposure. Consequently, the differential expression of Bcl11b following ethanol exposure has not
been further characterised in this project.
Aside from Bcl11b, no other transcriptional changes (either miRNA or mRNA) were identified in
the ethanol-exposed embryos. These findings, while perhaps unsurprising given the absence of any
apparent phenotype at 9.5 dpc, are seemingly at odds with those using the same ethanol model that
identified numerous phenotypic outcomes and changes in the expression of various mRNAs and
miRNAs in the adolescent and adult offspring (Kaminen-Ahola et al., 2010a; Marjonen et al., 2015;
Zhang et al., 2015). Slc17a6 is one of the genes previously identified to be differentially expressed in
the adult male hippocampus in the ethanol model (Zhang et al., 2015). What was intriguing about this
however, was that there was no differential expression in the adolescent offspring (postnatal day 21);
instead, the increase in Slc17a6 expression was not observed until later in adulthood, at both postnatal
days 87 and 120 (Zhang et al., 2015). Collectively, these results suggest that despite the lack of
transcriptional changes in male 9.5 dpc embryos, ethanol exposure can have consequences later in life.
This apparent delay in onset of ethanol-induced consequences could be mediated by a number
of mechanisms. A morphological abnormality may have been present in the embryo, which may
have consequences on the developmental trajectory of the affected tissue, in turn resulting in
expression changes later in life; however, no gross morphological abnormalities were observed in
the ethanol-exposed embryos (Chapter 4). Another possibility is that the ethanol exposure may have
resulted in perturbations in preimplantation epigenetic reprogramming, the functional consequences
of which may be dormant until the affected loci are expressed in later life. Certainly, changes to
DNA methylation have previously been reported in the hippocampi of offspring of this ethanol model
(Marjonen et al., 2015; Zhang et al., 2015). In future, either a targeted analysis of these previously
reported DNA methylation changes or a genome-wide screen for DNA methylation conducted in
the 9.5 dpc embryo could discern whether changes to the methylome may be occurring, and in fact
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preceding changes to expression.
Relative to the ethanol-exposed embryos, a considerably greater number of both miRNAs and
mRNAs were identified to be differentially expressed in the nicotine-exposed embryos in the
discovery cohort. When the differential expression of a subset of these genes were attempted to be
validated in an independent cohort, the differential expression of only one (Zinc finger and SCAN
domain containing 10, or Zscan10) was robust across cohorts. One possibility is that these changes in
the discovery cohort were indeed false positives. However, it must be noted that the nicotine-induced
reduction in embryonic size was greater in the discovery than in the validation cohort. As the
mRNAs selected for validation were selected on the basis of their association with this phenotype,
the consequence of this diminished phenotype could be a parallel reduction in the magnitude of the
differential expression of these genes.
Increased expression of Zscan10 was identified in both males (Table 5.3) and females (Figure 5.6A)
of the discovery cohort. In the validation cohort, however, the differential expression was present
only in the male embryos (Figure 5.5, Figure 5.6B). There appears to be an association between
the presence of the reduced embryonic size and increased Zscan10 expression; that is, an increase
in Zscan10 expression was present in all groups with reduced embryonic size (male and female
discovery cohorts, and male validation cohort). The exact nature of this relationship and the
mechanism by which it is more apparent in males than females requires further study.
The increased Zscan10 expression identified in the whole 9.5 dpc embryo is not ubiquitous through
all ages, in all tissues (Figure 5.7). Zscan10 expression was unchanged between control and
prenatally nicotine-exposed adult testes (Figure 5.7). The absence of differential Zscan10 expression
in the testes does not preclude the possibility that Zscan10 expression may still be perturbed in
other adult tissues following a prenatal nicotine exposure. Similarly, gene expression patterns can
be dynamic through postnatal life; for example, following a prenatal ethanol exposure Slc17a6 was
differentially expressed in the hippocampus in adulthood, but not adolescence (Zhang et al., 2015).
Zscan10 encodes for a transcription factor expressed throughout development (Wang et al., 2007a).
Zscan10 is best known for its role in regulating embryonic stem cell development (Zhang et al.,
2006), but it has been proposed that it may continue to regulate progenitor cells for the remainder
of embyronic development and postnatal life (Kraus et al., 2014). Mice homozygous for a Zscan10
loss-of-function mutation exhibited pleiotropic outcomes, affecting numerous physiological systems
including but not limited to the renal, cardiovascular, respiratory, and the immune systems (Kraus
et al., 2014). However, there have yet to be any reports of the functional consequences of Zscan10
overexpression, and as such the link to embryonic growth identified in this chapter is novel.
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Consistent with previous literature (Zhang et al., 2006), the presence of multiple Zscan10 transcripts
was detected in the male 9.5 dpc embryo; however, the experiment was limited by its ability to only
assay a subset of the exons present in each transcript. Despite this limitation, these results suggest
that multiple transcripts of Zscan10 are increased in expression following nicotine exposure. Further,
nicotine-induced differential expression of Zscan10 is unlikely to be a result of perturbations in
alternate splicing, but rather the disruption of mechanisms controlling transcription.
The mechanism by which Zscan10 expression increases following a nicotine exposure is not known.
Given that the period of nicotine exposure is identical to that of the period of exposure in the ethanol
model, and consequently also covers the major period of somatic epigenetic reprogramming in the
embryo (reviewed in Reik et al., 2001), there is a possibility that like for the ethanol model, nicotine
exposure may too be resulting in changes to DNA methylation. Previous literature has identified
associations between DNA methylation of a CpG island within the final exon of Zscan10 and its
expression (Kawashima et al., 2012). It is possible that the increased Zscan10 expression identified
in the nicotine-exposed embryos may be associated with differential Zscan10 methylation at cis-
regulatory elements.
The experiments presented in this chapter successfully profiled both miRNA and mRNA expression in
the mid-gestational mouse embryo following either an ethanol or a nicotine exposure in utero. In the
ethanol model, the mid-gestational transcriptional profile was unable to explain phenotypes observed
at later ages (Zhang et al., 2015; Marjonen et al., 2015). In the nicotine model, considerably more
transcriptional changes were identified, with the expression of Zscan10 able to be validated across
cohorts. This perturbation in Zscan10 expression is further explored in the following chapter, the
focus of which is investigations into DNA methylation in nicotine-exposed 9.5 dpc male embryos.
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6 DNA methylation changes followingnicotine exposure
6.1 Introduction
One of the ways by which prenatal environmental exposures can affect offspring health is through
the modulation of epigenetic mechanisms, which can result in altered gene expression and in turn,
phenotype. Epigenetic modifications include DNA methylation, histone modifications, and the
expression of non-coding RNAs (reviewed in Yamada and Chong, 2016). Agouti viable yellow
(Avy) is a metastable epiallele that has been extensively studied as an epigenetic biosensor in
various models of prenatal environmental exposures, including those of ethanol, soy protein isolate,
bisphenol A, genistein, methyl supplementation, and even in vitro culturing of zygotes (Badger et al.,
2008; Rosenfeld et al., 2013; Anderson et al., 2012; Dolinoy et al., 2007, 2006; Kaminen-Ahola
et al., 2010b; Cooney et al., 2002; Morgan et al., 2008). The Agouti gene contributes to coat colour
in mice (Morgan et al., 1999). Avy, which is an allele of Agouti, displays variable expressivity in
mice, with resultant coat colours ranging from completely yellow to mottled to completely agouti
(brown) (Morgan et al., 1999). The variable expression of Avy is linked to DNA methylation within an
Intracisternal-A Particle (IAP) retrotransposon insertion ∼100 kb upstream of the hair-cycle specific
promoters. It is this distribution of coat colours, which are used as a proxy marker for methylation at
this locus, that has been reported to be altered following various prenatal exposures (Badger et al.,
2008; Rosenfeld et al., 2013; Anderson et al., 2012; Dolinoy et al., 2007, 2006; Kaminen-Ahola
et al., 2010b; Blewitt et al., 2006; Cooney et al., 2002; Morgan et al., 2008).
Altered DNA methylation in offspring following adverse prenatal environmental conditions is not
unique to the Avy allele, with changes to DNA methylation also reported at other genomic loci in
both humans and experimental animal models following various prenatal exposures (Tobi et al.,
2009; Kaminen-Ahola et al., 2010b; Downing et al., 2011; Bekdash et al., 2013; Laufer et al., 2013;
Kile et al., 2014; Tobi et al., 2014; Amarasekera et al., 2014). Maternal tobacco smoking throughout
pregnancy has been extensively associated with changes to DNA methylation in the blood of children
(Joubert et al., 2012; Breton et al., 2014; Kupers et al., 2015; Lee et al., 2015; Joubert et al., 2016;
Ladd-Acosta et al., 2016). These changes to DNA methylation may have functional consequences,
with one of these studies identifying changes in gene expression associated with these methylation
changes (Joubert et al., 2016). There is also some evidence from a rat model for the capacity
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for prenatal nicotine exposure (from gestational day 4) to impact on both DNA methylation and
expression of protein kinase C epsilon (PKCε) - a gene which encodes for a protein associated with
cardiac injury in the fetal heart (Lawrence et al., 2010; Murriel and Mochly-Rosen, 2003). Whether
an in utero exposure to nicotine restricted to early gestation also has the potential to affect DNA
methylation is unknown.
The window of exposure utilised in the models used in this thesis (0.5 - 8.5 dpc) encompasses
preimplantation epigenetic reprogramming in the embryo, during which time it may be hypothesised
that the somatic epigenome is at increased susceptibility to adverse environmental conditions (re-
viewed in Yamada and Chong, 2016). Consistent with this hypothesis, we have previously identified
changes to DNA methylation at several loci following maternal ethanol consumption during this
exposure window (Kaminen-Ahola et al., 2010b; Zhang et al., 2015). These previously observed
methylation changes had associated changes in expression at Avy and other genes (Kaminen-Ahola
et al., 2010b; Zhang et al., 2015). These observations together lend further support to the hypothesis
that environmental perturbations during this early gestational window may result in changes to DNA
methylation, resulting in functional consequences in gene expression.
In this chapter, I first examine the capacity for early gestational nicotine exposure to impact on the
expression of the environmentally sensitive Avy allele. I further investigate whether the nicotine-
induced increase in Zscan10 expression identified in the previous chapter is associated with changes
in DNA methylation.
6.2 Results
6.2.1 Impact of prenatal nicotine exposure on Agouti viable yellow expression
In this section, the consequences of early gestational maternal nicotine consumption on DNA methy-
lation and expression of the Avy allele was investigated. Agouti is a gene which encodes for a yellow
pigment, and its expression is regulated by hair cycle-specific promoters (black arrows; Figure 6.1A)
(Morgan et al., 1999). Expression in this manner results in a sub-apical yellow band on an other-
wise black hair shaft, giving the overall appearance of a brown (agouti) coat colour (Morgan et al.,
1999). The Avy allele has an IAP retrotransposon insertion ∼100 kb upstream of the hair-cycle spe-
cific promoters (Figure 6.1A) (Morgan et al., 1999). When unmethylated, a cryptic promoter located
at the 3’UTR of the IAP insertion (dashed arrows) can drive the constitutive and ectopic expression
of Agouti in all tissues, resulting in a yellow coat colour (Figure 6.1B) (Morgan et al., 1999). The
cryptic promoter can also be variably methylated in different cells, resulting in varying degrees of
silencing; mice with the IAP methylated and silenced in all cells have agouti-coloured coats (termed
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pseudoagouti) with expression driven instead by the hair cycle-specific promoters, whereas those with
the IAP methylated in only some cells having patches of agouti fur (mottled) (Figure 6.1B) (Morgan
et al., 1999). Consequently, the resultant coat-colour of each mouse can be used as a measure of both
Agouti expression and methylation status at the associated IAP (Morgan et al., 1999).
A
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Figure 6.1: (A) The Avy allele has an Intracisternal-A Particle (IAP) retrotransposon insertion within
pseudoexon 1a of the agouti gene. Dashed and solid arrows indicate the cryptic promoter within
the IAP insertion and the hair cycle-specific promoters, respectively. Figure adapted from Blewitt
et al., 2006. (B) Isogenic mice, each carrying one Avy allele. Coat colours ranging from yellow to
pseudoagouti correlate with the methylation of the cryptic promoter within the IAP insertion and in
turn the expression of Agouti viable yellow.
The capacity for early gestational nicotine exposure to affect Avy expression, and by extension,
methylation was assessed in heterozygous (Avy/a) offspring. Epigenetic modifications of the Avy
allele can be inherited through the female germline (Morgan et al., 1999). Consequently, to ensure
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that any effect observed following prenatal nicotine exposure was not confounded by Avy DNA
methylation patterns inherited from the dam, matings were carried out such that male heterozygous
(Avy/a) studs were mated with congenic (a/a) dams not carrying the Avy allele. Coat colour, used as a
proxy marker for Avy methylation and expression, was recorded in Avy/a offspring exposed to either
prenatal nicotine or water on postnatal day 21.
When females consumed water throughout pregnancy, 14% of the Avy/a offspring were yellow, 68%
were mottled, and 18% were pseudoagouti (Figure 6.2A). Although slightly more yellow (18%) and
pseudoagouti (27%) offspring were observed following prenatal nicotine exposure, the distribution of
coat colours of mice prenatally exposed to nicotine were not significantly different to those from dams
provided with water throughout gestation (Figure 6.2A; p = 0.39, Chi-squared test). No differences
in coat colour distribution were observed even when males (Figure 6.2C; p = 0.51, Chi-squared test)
and females (Figure 6.2B; p = 0.70, Chi-squared test) were analysed separately.
A B C
Figure 6.2: Distribution of coat colours in mice carrying the Agouti viable yellow allele following
prenatal exposure to nicotine. Offspring coat colours were categorised as either yellow, mottled,
or pseudoagouti by one observer (LY). Results are shown as (A) all male and female Avy offspring
combined (control: n=108 (28 litters) and nicotine: n=106 (31 litters)), (B) female offspring only
(control: n=58 (27 litters) and nicotine: n=57 (26 litters)), or (C) males only (control: n=50 (26
litters) and nicotine: n=49 (27 litters)).
6.2.2 DNA methylation at Zscan10
Previously, DNA methylation at the CpG island within the final exon of ZSCAN10 was inversely
associated with ZSCAN10 protein expression in human neuroblastoma samples (Kawashima et al.,
2012). Consequently, there was a possiblity that the nicotine-induced increase in Zscan10 mRNA
expression in male 9.5 dpc embryos (Chapter 5) was associated with altered DNA methylation at
the same region. In addition to the previously described CpG island (CGI region) in the final exon
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(Kawashima et al., 2012), DNA methylation at two putative promoter regions (P1 and P2) - each sur-
rounding transcription start sites - were also assayed using clonal bisulfite sequencing (Figure 6.5A,
Figure 6.6A, and Figure 6.4A). Only a subset of offspring were assayed, due to the labour-intensive
nature of the clonal bisulfite sequencing technique used. Selection of samples for bisulfite sequencing
was based on Zscan10 expression (Figure 6.3); these embryos included control embryos (n=8), as
well as nicotine-exposed embryos with either basal (n=4) or high (n=4) Zscan10 expression levels.
All samples assayed were from cohort B.
Figure 6.3: Male 9.5 dpc embryos from cohort B were selected for analysis of Zscan10 DNA methy-
lation on the basis of their Zscan10 mRNA expression. Eight control embryos (from seven litters) rep-
resenting the full range of Zscan10 expression levels within the control group (black), four nicotine-
exposed embryos (from four litters) with basal levels of Zscan10 expression (blue), and four nicotine-
exposed embryos (from two litters) with relatively high levels of Zscan10 expression (red) were se-
lected for analysis of DNA methylation. Embryos indicated by grey circles represent those in which
DNA methylation was not assayed. Expression in this figure was normalised to Gapdh. Expres-
sion levels of Zscan10 when normalised to Hsp90ab1 in the embryos selected for DNA methylation
analysis is represented in Figure A14.
Methylation at 34 CpGs across 581 bp and spanning the CpG island (as defined by UCSC Genome
Browser, NCBI37/mm9) within the final exon of Zscan10 (Figure 6.4A) was assayed in all samples.
Generally, the CpG island was hypermethylated in all samples (Figure 6.4B, Figure 6.4C) No differ-
ences were observed in average methylation levels between clones from controls (91.5%), and clones
from either group of nicotine-exposed embryos (basal: 92.7%, high-expressing: 93.3%) (Figure 6.4B,
Figure 6.4C). Similarly, when methyation of individual CpG sites was compared between groups, no
difference in methylation was observed at any of the individual CpG sites (Figure 6.4D).
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Figure 6.4: DNA methylation at the Zscan10 CpG island (CGI region) in whole male 9.5 dpc em-
bryos following prenatal nicotine exposure. (A) A schematic of the Zscan10 gene drawn to scale.
Exons and introns are represented by thicker and thinner lines, respectively. The CpG island at which
methylation was assayed is shown, with individual CpGs indicated below (to scale). (B) Clonal bisul-
fite sequencing results: each row of circles represents CpG methylation at an individual clone or
allele, with black and white circles representing methylated and non-methylated cytosines, respec-
tively. (C) Percentage cytosine methylation of each clone from control, basal Zscan10-expressing
nicotine-exposed embryos, and high Zscan10-expressing nicotine-exposed embryos. Mean ± S.D. is
indicated. (D) Average methylation of individual cytosines within the region assayed.
A putative promoter region (P1), spanning -299 to +140 bp relative to the first transcriptional start site
in exon one (as defined by UCSC Genome Browser, NCBI37/mm9, Figure 6.5A), was also assayed
for DNA methylation (Figure 6.5B). This 439 bp region contains eight CpG sites and was found to be
less heavily methylated overall compared to the CpG island (Figure 6.5B). No differences in average
methylation levels (Figure 6.5C) were detected between controls (33.7%) and either of the nicotine-
exposed subgroups (basal: 39.8%, high: 32.8%). When the methylation of individual CpG sites
was analysed, the second CpG site had significantly greater levels of methylation in basal-expressing
nicotine-exposed samples (75.0%) when compared to controls (40.6%) (Figure 6.5D). Methylation
levels of the high-expressing nicotine-exposed samples were not significantly changed from controls
at this site (Figure 6.5D).
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Figure 6.5: DNA methylation at an upstream putative Zscan10 promoter region 1 (P1) in whole
male 9.5 dpc embryos following prenatal nicotine exposure. (A) A schematic of the Zscan10 gene
drawn to scale. Exons and introns are represented by thicker and thinner lines, respectively. The
putative promoter region 1 (P1) at which methylation was assayed is shown, with individual CpGs
indicated below (to scale). (B) Clonal bisulfite sequencing results: each row of circles represents
CpG methylation at an individual clone or allele, with black and white circles representing methylated
and non-methylated cytosines, respectively. (C) Percentage cytosine methylation of each clone from
control, basal Zscan10-expressing nicotine-exposed embryos, and high Zscan10-expressing nicotine-
exposed embryos. Mean ± S.D. is indicated. (D) Average methylation of individual cytosines within
the region assayed. Blue *: p<0.05, as determined by a Student’s t-test between clones from control
and nicotine (basal) samples.
Methylation was also assayed at a second putative promoter region (P2, Figure 6.6B), spanning -337
to +189 bp of a transcription start site located 5’ of exon two (as defined by UCSC Genome Browser,
NCBI37/mm9, +4650 bp relative to the P1 transcription start site, Figure 6.6A). This 526 bp region
contains ten CpG sites which were heavily methylated in the majority of clones (Figure 6.6B). There
was a trend towards reduced methylation over the whole region between control (91.0%) and high-
expressing nicotine-exposed embryos (84.3%) (p = 0.05, Figure 6.6C). Further, site-specific analy-
sis revealed significant reductions in methylation at CpG sites 4 and 8 in high-expressing nicotine-
exposed embryos (68.7% and 81.2%, respectively) when compared to control embryos (93.3% and
100.0%, respectively) (Figure 6.6D).
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Figure 6.6: DNA methylation at a downstream putative Zscan10 promoter region 2 (P2) in whole
male 9.5 dpc embryos following prenatal nicotine exposure. (A) A schematic of the Zscan10 gene
drawn to scale. Exons and introns are represented by thicker and thinner lines, respectively. The
putative promoter region 2 (P2) at which methylation was assayed is shown, with individual CpGs
indicated below (to scale). (B) Clonal bisulfite sequencing results: each row of circles represents CpG
methylation of an individual clone or allele, with black and white circles representing methylated
and non-methylated cytosines, respectively. (C) Percentage cytosine methylation of each clone from
control, basal Zscan10-expressing nicotine-exposed embryos, and high Zscan10-expressing nicotine-
exposed embryos. Mean± S.D. is indicated. p-value determined using a Student’s t-test. (D) Average
methylation of individual cytosines within the region assayed. Red *: p<0.05, as determined by a
Student’s t-test between clones from control and nicotine (high) samples.
6.3 Discussion
In this chapter, the expression and therefore methylation of an environmentally-sensitive metastable
epiallele (Avy) and DNA methylation at Zscan10 were assayed following prenatal nicotine exposure.
Prenatal nicotine exposure did not influence coat colour distributions in mice carrying the Avy
allele (Figure 6.2), suggesting no effect on DNA methylation at this locus. At time of writing, this
study is the first to investigate the effect of nicotine on the Avy allele. While the lack of effect of a
prenatal exposure on Avy expression and methylation is not common, it is also not unheard of; at
least two published studies have also identified no effect on Avy following early-life exposures (each
spanning preconception, gestation and lactation) to soy protein isolate (Badger et al., 2008), or to
ethinyl estradiol, or various combinations of bisphenol-A and genistein (Rosenfeld et al., 2013).
The exposures studied in these previous studies (soy protein isolate, ethinyl estradiol, bisphenol-A
and genistein) and the nicotine used in this chapter are all known or suspected endocrine disruptors
(Badger et al., 2008; Kanungo et al., 2012; Rosenfeld et al., 2013), suggesting that as a group,
these chemicals do not impact Avy expression. However, conflicting reports that bisphenol-A and
genistein can impact Avy expression (Dolinoy et al., 2006, 2007; Anderson et al., 2012) also suggest
that early-life programming by environmental exposures of the the Avy allele is more complex than
currently appreciated. A limitation of this experiment was the lack of direct measurement of DNA
methylation at the the Avy allele following nicotine exposure, which would have validated that the
lack of coat colour change was indeed reflective of an absence of change in DNA methylation at the
Avy IAP.
Although Avy methylation was not affected by prenatal nicotine exposure, it was still possible that
the Zscan10 expression changes were linked to a change in epigenetic state. Indeed, methylation of
a CpG island located in the final exon of Zscan10 has previously been associated with expression
(Kawashima et al., 2012). DNA methylation at this CpG island as well as two other putative promoter
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regions within Zscan10 was assayed using clonal bisulfite sequencing. Clonal bisulfite sequencing is
a technique in which sequences from individual clones are, in theory, representative of methylation
states of one allele within a single cell. As would be expected when assaying heterogeneous cell
populations such as in whole embryos in which not all cells would express Zscan10, inter-clone
variability in methylation patterns were observed (Figure 6.4B, Figure 6.5B, Figure 6.6B). To discern
the true magnitude of difference in methylation in cells expressing Zscan10 following the nicotine
exposure, those cells expressing Zscan10 should be isolated first in future.
Within the intragenic CpG island, methylation levels were on average, relatively high (91.5% within
the control embryos, Figure 6.4C). This is consistent with previous literature which identified that in
both mouse and human tissues, intragenic non-promoter-associated CpG islands are more likely to
be methylated than promoter-associated CpG islands (Illingworth et al., 2010). The function of CpG
islands not associated with promoters is poorly understood; however, it has been proposed that some
of these CpG islands may be associated with undetected promoters (Illingworth et al., 2010).
The nicotine-induced changes in Zscan10 expression were not associated with methylation dif-
ferences within the intragenic CpG island (Figure 6.4C, Figure 6.4D). This lack of association
is seemingly inconsistent with the observations by Kawashima et al., 2012, who identified that
DNA methylation of this region was associated with protein expression. Possible reasons for this
discrepancy include the differences inherent in measuring mRNA versus protein, differences in
species (mouse and human), and differences in tissue-type (whole 9.5 dpc embryo and neuroblastoma
samples). Furthermore, this particular locus has previously been identified to be differentially
methylated in different tissues (Song et al., 2009), raising the possibility that the relationship between
Zscan10 methylation and expression may in fact be tissue-specific.
Methylation in the vicinity of transcriptional start sites can affect transcriptional initiation, and is
typically inversely associated with gene expression (reviewed in Jones, 2012). For the first time,
two regions (P1 and P2) surrounding putative Zscan10 transcriptional start sites were assayed for
methylation (Figure 6.5A, Figure 6.6A) in order to assess whether differential methylation of these
regions were associated with differential Zscan10 expression. Interestingly, in both putative promoter
regions assayed, the CpG site closest to each of the reported transcription start sites displayed the
lowest methylation levels when compared to surrounding sites (P1: CpG 4, Figure 6.5D; and P2:
CpG 5, Figure 6.6D), suggestive of an epigenetic landscape permissive of transcription factor binding
and allowing for transcriptional initiation from these sites.
There was no association between average methylation across eight CpG sites at the first putative
promoter region (P1) and Zscan10 expression (Figure 6.5C). Within P1, methylation at CpG site 2
was significantly higher in nicotine-exposed samples with basal levels of Zscan10 expression when
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compared to control samples; however, no such difference was observed in the nicotine-exposed
samples with high levels of Zscan10 expression (Figure 6.5D). There appears to be no association
between methylation at CpG site 2 with either nicotine exposure, or Zscan10 expression level and as
such, the functional significance of this change in methylation, if any, is unclear.
In contrast, there was a trend towards reduced average methylation (p=0.05) at a region containing
ten CpG sites surrounding the second putative promoter region (P2) in nicotine-exposed samples
with high levels of Zscan10 expression when compared to control samples (Figure 6.6C) - that
is, methylation at this region was inversely associated with expression. Further, a reduction in
methylation in the high-expressing nicotine samples was significant at two individual CpG sites
assayed (sites 4 and 8) (Figure 6.6D).
The mechanism by which this reduction in DNA methylation at P2 impacts Zscan10 expression
is unknown; however, it may regulate transcription factor binding. Interestingly, P2 contains
experimentally validated binding sites for OCT4 and SOX2, which are transcription factors involved
in the regulation of embryonic stem cell pluripotency (Figure 6.7, Wang et al., 2007b). While these
reported binding sites do not directly overlap with any of the CpGs assayed, others have shown that
OCT4 fails to bind target sequences when CpG sites within 100 bp are methylated (You et al., 2011).
The SOX/OCT binding site within P2 has previously been reported to not influence the activity of
the promoter upstream of exon 1 (P1) in luciferase reporter assays (Wang et al., 2007b). Whether
this SOX/OCT binding site can direct activity at the putative promoter 5’ of exon 2 (P2) has yet
to be investigated. As such, further work is required to understand the functional consequences
of differential methylation at this region. One possible hypothesis is that the nicotine-associated
reduction in DNA methylation at this region may be associated with increased binding of OCT4 and
transcriptional activation of Zscan10. Future experiments could investigate whether this is indeed
the case by assessing OCT/SOX occupancy in the P2 region following prenatal nicotine exposure by
means of chromatin immunoprecipitation-PCR.
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Figure 6.7: Location of OCT4/SOX2 binding site in the vicinity of the putative Zscan10 promoter
region 2 (P2).
The data presented in this chapter is the first time that the impact of prenatal nicotine exposure on
the Avy allele has been assessed. Furthermore, I have described the DNA methylation landscape
surrounding two putative transcription start sites within Zscan10 - regions which were previously
uncharacterised. Methylation at one of these regions, P2, was found to be associated with the expres-
sion changes at Zscan10. These data provide a proof of concept that nicotine exposure, even when
restricted to very early gestation has the potential to affect epigenetic state and gene expression in a
locus-specific manner.
7 General discussion and conclusion
The potential for early-life environments to influence long-term health is well characterised in both
humans and animal models (Ravelli et al., 1976; Barker and Osmond, 1986; Kwong et al., 2000;
Holloway et al., 2005; Golan and Huleihel, 2006; Kaminen-Ahola et al., 2010b; Moritz et al., 2011;
Ganu et al., 2012; Hanson and Gluckman, 2014; Heindel et al., 2016). However, comparatively little
is known as to whether exposure to an adverse environment restricted to just early gestation can also
impact future health. Furthermore, our knowledge of the mechanisms underlying the relationships
between gestational maternal environment and subsequent fetal health are still in their infancy. In this
thesis, the consequences on the offspring of early gestational exposure to two of the most commonly
used substances in pregnancy (ethanol and nicotine) were characterised in mouse models. In
addition to characterising the long-term postnatal consequences, embryos were also assayed shortly
following the termination of the exposures (at 9.5 dpc) in an attempt to better understand the immedi-
ate embryonic response to these exposures and the possible mechanisms by which these exposures act.
The ethanol-only model used in this thesis was previously established by our laboratory (Kaminen-
Ahola et al., 2010b,a; Sanchez Vega et al., 2013; Zhang et al., 2015). One of the mechanisms by
which gestational environment is hypothesised to program subsequent health is by the impairment
of organogenesis, leading to impaired organ function and thus disease later in life (Desai and Hales,
1997; Ingelfinger and Woods, 2002; Hyatt et al., 2008). We therefore expected the growth restriction
and microcephaly phenotypes previously identified postnatally (Kaminen-Ahola et al., 2010a,b) to
be present from the time of exposure. However, shortly following the termination of the ethanol
exposure at 9.5 dpc, there was no evidence for embryonic growth restriction or microcephaly or any
gross dysmorphology in embryos exposed to ethanol compared to their control counterparts in either
sex. These data collectively suggest that the growth phenotype is not contiguous from the time of
exposure; instead, there appears to be a delay or latency between the ethanol exposure and the onset
of adverse outcomes. In order for these delayed-onset phenotypes to occur, the developing embryo
must be able to somehow remember the ethanol exposure, in a non-anatomical manner.
Previously, a number of gene and miRNA expression changes were identified in the postnatal
hippocampus and liver following the prenatal ethanol exposure (Kaminen-Ahola et al., 2010a;
Marjonen et al., 2015; Zhang et al., 2015). Given the potential for this exposure to induce tran-
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scriptional changes in the offspring, one possible mechanism for these delayed-onset phenotypes
is the perturbation of molecular pathways that may be involved in the later development of these
phenotypes. However, unbiased screens of both mRNA and miRNA expression identified few
transcriptional changes at 9.5 dpc; out of a total ∼45, 000 probes on the microarray (annotated to 30,
855 genes) and the 641 miRNAs assayed, only one gene (Bcl11b) was identified to be differentially
expressed following the ethanol exposure. The absence of wide-spread transcriptional changes in
the 9.5 dpc embryo suggest that changes in the expression of embryonic mRNAs and miRNAs are
unlikely to be a major contributor to the memory of the ethanol exposure.
Our laboratory has previously identified changes to DNA methylation at the Avy allele in response
to the same ethanol exposure (Kaminen-Ahola et al., 2010b). Since DNA methylation at the Avy
allele is established between implantation and mid-gestation (Blewitt et al., 2006), changes to
DNA methylation are likely present in the embryo by the end of the exposure, and as such, DNA
methylation may contribute to both the phenotypic and transcriptional memory observed. In the
future, DNA methylation should be assessed in the embryo across the entire genome or at loci
previously determined to be differentially methylated in the postnatal offspring to determine whether
this may contribute to the molecular memory.
In animal models, in utero nicotine exposure for the entirety of gestation has been demonstrated to
reduce fetal growth (Rowell and Clark, 1982; Wang et al., 2008); however, less clear is whether an
exposure restricted to just early gestation is also capable of affecting growth and development. To
investigate whether an early gestational exposure to nicotine has the capacity to affect offspring in
this manner, a mouse model of prenatal nicotine exposure was established in this thesis.
This thesis provides for the first time, a proof-of-principle that early gestational exposure to nicotine
is sufficient to induce a reduction in body size at mid-gestation and body weight postnatally in
the mouse. Interestingly, the effect on embryonic growth is transient while the effect on postnatal
growth does not appear until nine weeks of age but persists, suggesting that again, there is likely to
be a non-anatomical memory of the exposure programmed into the developing embryo, allowing
for the development of the postnatal phenotype. At mid-gestation, a locus-specific change in DNA
methylation within a putative promoter region of Zscan10 was identified, along with an associated
change in expression. What role, if any, that Zscan10 has on growth at mid-gestation is unknown,
but is a possible avenue for further study. It is possible, that should DNA methylation be assayed
on a genome-wide scale, that more extensive DNA methylation changes may be identified - some
of which may persist into postnatal life and and in turn be associated with the changes in postnatal
growth. The findings from this thesis demonstrate the capacity for nicotine (at a dosage equivalent
to smoking 10 - 15 cigarettes per day [Lawson et al., 1998]) to have both molecular and phenotypic
consequences in the offspring, raising questions as to the safety of nicotine usage during early
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pregnancy. Further work is required both in animal models and humans in order to better characterise
not only these phenotypic consequences, but also the underlying molecular mechanisms.
A number of studies have identified that women who smoke are more likely to drink during pregnancy
(Cameron et al., 2013; Flynn et al., 2003). Furthermore, given the relatively high rate of co-exposure
of these two drugs in children diagnosed with Fetal Alcohol Syndrome (Elliott et al., 2008), in
addition to understanding the consequences associated with each drug in isolation, it is imperative to
understand what interaction, if any, there is between the two to allow women to make more informed
decisions during pregnancy. To further investigate the consequences of a dual ethanol/nicotine
exposure, a mouse model of early gestational concomitant ethanol and nicotine exposure was newly
established in this thesis.
In this thesis, there was no evidence for an exacerbation of the reduced body size phenotype in
the dual exposure model when compared to the nicotine-only model. While it is possible that
ethanol and nicotine at these dosages (average concentrations of serum alcohol: 12 mg/dl, and
cotinine: 172 ng/ml) during this particular window of development (0.5 - 8.5 dpc) do not have an
interactive effect on fetal development, there is every possibility that should other phenotypes be
assayed that a discordance in the severity of the phenotype may be observed between the dual and
single-exposure models. Further work is required to characterise other phenotypes in the offspring
to more comprehensively assess the presence or lack thereof of interaction in this model. Previous
literature describing the consequences of co-exposure to ethanol and nicotine are conflicting; while
a dual exposure (gestational days 9 - 12: ethanol [1.41 g/kg intraperitoneal injection] and nicotine
[16.7 mg/kg subcutaneous injection]) had no interactive effect on mid-gestational embryo size in
the rat (Woo and Persaud, 1988), a potentiative effect of the dual exposure (gestational days 1 -
21: ad libitum access to liquid diet containing 10% (v/v) ethanol and twice daily subcutaneous
injections of 3.0 mg/kg nicotine) was reported on rates of stillbirth and neonatal death in rats (Martin
et al., 1982), and on the acquisition of nicotine self-administration in adult rat offspring (Matta and
Elberger, 2007). The exact conditions under which a dual exposure to ethanol and nicotine can result
in interactive effects on offspring phenotype are at present unclear; however, the individual dosages
of ethanol and nicotine, as well as the timing of the exposure are likely to be of importance. Should
these characteristics be able to be elucidated in future, it would be of value in contributing to the
identification of children at greatest risk of harm from prenatal exposures to ethanol and/or nicotine.
A recent review of the literature identified greater than 400 conditions to be comorbid with Fetal
Alcohol Spectrum Disorders (Popova et al., 2016), highlighting the broad range of phenotypic
consequences possible following prenatal ethanol exposure. Relative to ethanol, the consequences
of prenatal nicotine exposure are even more poorly understood, but it is entirely possible that it
too is associated with an array of conditions yet to be associated with a prenatal nicotine exposure.
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Consequently, it is important to continue a comprehensive phenotypic characterisation of each of the
three models presented in this thesis - assaying for phenotypes both known to be associated with each
exposure, but also assaying for novel outcomes. Should more phenotypic changes be identified in the
offspring, then further transcriptional assays should be conducted in the relevant organs to identify
genes or pathways associated with these pertubations in phenotype. A greater understanding of the
molecular mechanisms behind such phenotypes allows for the potential to develop interventions to
counter these adverse outcomes.
The concept that early-life conditions can influence adult health is not new; many studies of both
animal models and humans have provided evidence that exposures spanning the majority of gestation
can influence fetal outcomes (Barker and Osmond, 1986; Leichter, 1989; Esposito et al., 2008;
Holloway et al., 2005). More recently, there are an emerging number of studies arguing that even
exposures restricted to the periconceptional or early gestational period can affect future health
(Kwong et al., 2006; Heijmans et al., 2008; Gardebjer et al., 2014; Williams-Wyss et al., 2014;
Silver et al., 2015). The results from this thesis provide for the first time, a proof-of-principle that
nicotine exposure, even when restricted to early gestation can influence offspring phenotype. The
findings from the ethanol model highlighted that the absence of an overt embryonic phenotype
does not preclude the development of other phenotypes later in life. The high rate of women who
cease drinking alcohol and smoking tobacco upon pregnancy confirmation within the Australian
community (Australian Institute of Health and Welfare, 2014) highlights the willingness of women
to make lifestyle modifications to protect the health of their baby. If the potentially detrimental
impact of early-gestational exposures were better understood, this would enable not only women
planning a pregnancy to make more informed decisions as to the lifestyle choices they make during
the peri-conceptional period, but would also allow for better risk mitigation in individuals who were
inadvertently exposed prior to pregnancy recognition.
7.1 Future directions
This thesis began the characterisation of phenotypes associated with prenatal nicotine exposure;
however, there is scope for a more comprehensive phenotypic characterisation. Specifically, a number
of phenotypes have previously been associated with other models of prenatal nicotine exposure,
including those of alterations in behaviour (Klein et al., 2003; Pauly et al., 2004), respiratory function
(Rehan et al., 2012), and immune function (Basta et al., 2000). These phenotypes have largely been
identified following nicotine exposure either for the entirety of gestation, or late in gestation. It
would therefore be of interest to investigate whether these phenotypic changes can also be induced
following an exposure restricted to early gestation.
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It may also be informative to further validate the differential expression of the other genes identified
in the initial screen to be sensitive to nicotine in independent cohorts. Given the number of homeobox
genes that were identified to be differentially expressed in this screen, should their perturbation be
independently validated, it is possible that body pattern formation may have been perturbed, with
axial changes apparent later in life (reviewed in Mallo et al., 2010).
A finding of particular intrigue in this thesis was the absence of phenotypes such as growth restriction
and microcephaly at mid-gestation following the ethanol exposure, despite previous studies utilis-
ing the same mouse model identifying both of these phenotypes in later life (Kaminen-Ahola et al.,
2010a,b; Zhang et al., 2015). Furthermore, a greater number of genes were identified to be differen-
tially expressed in both the adult liver and hippocampus following this ethanol exposure than were
identified in the whole embryo at 9.5 dpc (Kaminen-Ahola et al., 2010a; Zhang et al., 2015). These
findings suggest that the embryo may have developed a memory of the ethanol exposure, allowing
for this latency in the onset of both phenotype and gene expression. The nature of this memory is
still uncertain; however, it is possible that changes in DNA methylation and/or histone modifications
may be involved. Consequently, future studies could examine the genome-wide methylation and/or
histone modifications in both the embryo at mid-gestation, and in adult life to assess the persistence
and/or permanence of any change identified.
106 GENERAL DISCUSSION AND CONCLUSION
Reference List
Ahlgren, S. C., Thakur, V., and Bronner-Fraser, M. (2002). Sonic hedgehog rescues cranial neu-
ral crest from cell death induced by ethanol exposure. Proceedings of the National Academy of
Sciences, 99(16):10476–10481.
Aliyu, M. H., Wilson, R. E., Zoorob, R., Brown, K., Alio, A. P., Clayton, H., and Salihu, H. M.
(2009). Prenatal alcohol consumption and fetal growth restriction: potentiation effect by concomi-
tant smoking. Nicotine & Tobacco Research, 11(1):36 – 43.
Alkam, T., Kim, H.-C., Mamiya, T., Yamada, K., Hiramatsu, M., and Nabeshima, T. (2013). Evalua-
tion of cognitive behaviors in young offspring of C57BL/6J mice after gestational nicotine exposure
during different time-windows. Psychopharmacology, 230(3):451–463.
Amarasekera, M., Martino, D., Ashley, S., Harb, H., Kesper, D., Strickland, D., Saffery, R., and
Prescott, S. L. (2014). Genome-wide DNA methylation profiling identifies a folate-sensitive re-
gion of differential methylation upstream of ZFP57-imprinting regulator in humans. The FASEB
Journal, 28(9):4068–4076.
Andersen, C. L., Jensen, J. L., and Orntoft, T. F. (2004). Normalization of real-time quantitative re-
verse transcription-PCR data: a model-based variance estimation approach to identify genes suited
for normalization, applied to bladder and colon cancer data sets. Cancer Research, 64(15):5245–
5250.
Anderson, M. E., Johnson, D. C., and Batal, H. A. (2005). Sudden infant death syndrome and prenatal
maternal smoking: rising attributed risk in the back to sleep era. BMC Medicine, 3(4).
Anderson, O. S., Nahar, M. S., Faulk, C., Jones, T. R., Liao, C., Kannan, K., Weinhouse, C., Rozek,
L. S., and Dolinoy, D. C. (2012). Epigenetic responses following maternal dietary exposure to phys-
iologically relevant levels of bisphenol A. Environmental and Molecular Mutagenesis, 53(5):334–
342.
107
108 REFERENCE LIST
Anthony, B., Vinci-Booher, S., Wetherill, L., Ward, R., Goodlett, C., and Zhou, F. C. (2010). Alcohol-
induced facial dysmorphology in C57BL/6 mouse models of fetal alcohol spectrum disorder. Al-
cohol, 44(7 - 8):659 – 671.
Anway, M. D., Cupp, A. S., Uzumcu, M., and Skinner, M. K. (2005). Epigenetic transgenerational
actions of endocrine disruptors and male fertility. Science, 308(5727):1466–1469.
Aros, S., Mills, J. L., Iniguez, G., Avila, A., Conley, M. R., Troendle, J., Cox, C., and Cassorla, F.
(2011). Effects of prenatal ethanol exposure on postnatal growth and the insulin-like growth factor
axis. Hormone Research in Paediatrics, 75(3):166–173.
Astley, S. J. (2004). Diagnostic Guide for Fetal Alcohol Spectrum Disorders: The 4-Digit Diagnostic
Code. University of Washington, School of Public Health and Community Medicine, University of
Washington, Seattle, Washington, 98195, 3 edition.
Australian Institute of Health and Welfare (2014). National drug strategy household survey detailed
report 2013. Drug Statistics Series, PHE 183(28).
Badger, T. M., Ronis, M. J. J., Wolff, G., Stanley, S., Ferguson, M., Shankar, K., Simpson, P., and
Jo, C.-H. (2008). Soy protein isolate reduces hepatosteatosis in yellow Avy/a mice without altering
coat color phenotype. Experimental Biology and Medicine, 233(10):1242–1254.
Baker, J., Liu, J.-P., Robertson, E. J., and Efstratiadis, A. (1993). Role of insulin-like growth factors
in embryonic and postnatal growth. Cell, 75(1):73–82.
Barker, D. J. and Osmond, C. (1986). Infant mortality, childhood nutrition, and ischaemic heart
disease in England and Wales. The Lancet, 327(8489):1077–1081.
Barlow, N., Phillips, S., Wallace, D., Sar, M., Gaido, K., and Foster, P. (2003). Quantitative changes
in gene expression in fetal rat testes following exposure to di(n-butyl) phthalate. Toxicological
Sciences, 73(2):431–441.
Basta, P., Basham, K., Ross, W., Brust, M., and Navarro, H. (2000). Gestational nicotine exposure
alone or in combination with ethanol down-modulates offspring immune function. International
Journal of Immunopharmacology, 22(2):159 – 169.
Behl, M., Rao, D., Aagaard, K., Davidson, T. L., Levin, E. D., Slotkin, T. A., Srinivasan, S., Wallinga,
D., White, M. F., Walker, V. R., Thayer, K. A., and Holloway, A. C. (2013). Evaluation of the
association between maternal smoking, childhood obesity, and metabolic disorders: a national
toxicology program workshop review. Environmental Health Perspectives, 121(2):170–180.
109
Bekdash, R. A., Zhang, C., and Sarkar, D. K. (2013). Gestational choline supplementation normal-
ized fetal alcohol-induced alterations in histone modifications, DNA methylation, and proopiome-
lanocortin (POMC) gene expression in β -endorphin-producing POMC neurons of the hypothala-
mus. Alcoholism: Clinical and Experimental Research, 37(7):1133–1142.
Bhutani, N., Brady, J. J., Damian, M., Sacco, A., Corbel, S. Y., and Blau, H. M. (2010). Reprogram-
ming towards pluripotency requires AID-dependent DNA demethylation. Nature, 463(7284):1042–
1047.
Blewitt, M. E., Vickaryous, N. K., Paldi, A., Koseki, H., and Whitelaw, E. (2006). Dynamic re-
programming of DNA methylation at an epigenetically sensitive allele in mice. PLoS Genetics,
2(4):e49.
Bock, C., Reither, S., Mikeska, T., Paulsen, M., Walter, J., and Lengauer, T. (2005). BiQ analyzer:
visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinfor-
matics, 21(21):4067–4068.
Bose, M., Oliván, B., and Laferrère, B. (2009). Stress and obesity: the role of the hypothalamic–
pituitary–adrenal axis in metabolic disease. Current opinion in endocrinology, diabetes, and obe-
sity, 16(5):340.
Breton, C. V., Siegmund, K. D., Joubert, B. R., Wang, X., Qui, W., Carey, V., Nystad, W., Haberg,
S. E., Ober, C., Nicolae, D., Barnes, K. C., Martinez, F., Liu, A., Lemanske, R., Strunk, R., Weiss,
S., London, S., Gilliland, F., Raby, B., and on behalf of the Asthma BRIDGE consortium (2014).
Prenatal Tobacco Smoke Exposure Is Associated with Childhood DNA CpG Methylation. PLoS
ONE, 9(6):e99716.
Brooke, O. G., Anderson, H. R., Bland, J. M., Peacock, J. L., and Stewart, C. M. (1989). Effects on
birth weight of smoking, alcohol, caffeine, socioeconomic factors, and psychosocial stress. BMJ:
British Medical Journal, 298(6676):795–801.
Buelke-Sam, J., Holson, J. F., and Nelson, C. J. (1982). Blood flow during pregnancy in the rat: II.
dynamics of and litter variability in uterine flow. Teratology, 26(3):279–288.
Buka, S. L., Shenassa, E. D., and Niaura, R. (2003). Elevated risk of tobacco dependence among off-
spring of mothers who smoked during pregnancy: A 30-year prospective study. American Journal
of Psychiatry, 160(11):1978–1984.
Butler, N. R., Goldstein, H., and Ross, E. M. (1972). Cigarette smoking in pregnancy: Its influence
on birth weight and perinatal mortality. BMJ: British Medical Journal, 2(5806):127–130.
Callinan, S. and Room, R. (2012). Alcohol consumption during pregnancy: results from the 2010
national drug strategy household survey. Foundation for Alcohol Research & Education.
110 REFERENCE LIST
Cameron, C. M., Davey, T. M., Kendall, E., Wilson, A., and McClure, R. J. (2013). Changes in
alcohol consumption in pregnant Australian women between 2007 and 2011. Medical Journal of
Australia, 199(5):355 – 357.
Cartwright, M. M., Tessmer, L. L., and Smith, S. M. (1998). Ethanol-induced neural crest apoptosis
is coincident with their endogenous death, but is mechanistically distinct. Alcohol: Clinical and
Experimental Research, 22(1):142–149.
Chan, B. W., Chan, K.-S., Koide, T., Yeung, S.-M., Leung, M. B., Copp, A. J., Loeken, M. R.,
Shiroishi, T., and Shum, A. S. (2002). Maternal diabetes increases the risk of caudal regression
caused by retinoic acid. Diabetes, 51(9):2811–2816.
Chawengsaksophak, K., James, R., Hammond, V. E., Kontgen, F., and Beck, F. (1997). Homeosis
and intestinal tumours in Cdx2 mutant mice. Nature, 386(6620):84–87. 10.1038/386084a0.
Chen, H., Parker, S. L., Matta, S. G., and Sharp, B. M. (2005). Gestational nicotine exposure reduces
nicotinic cholinergic receptor (nAChR) expression in dopaminergic brain regions of adolescent
rats. European Journal of Neuroscience, 22(2):380–388.
Chen, W.-J. A., Parnell, S. E., and West, J. R. (2001). Nicotine decreases blood alcohol concentration
in neonatal rats. Alcoholism: Clinical and Experimental Research, 25(7):1072–1077.
Chudley, A. E., Conry, J., Cook, J. L., Loock, C., Rosales, T., and LeBlanc, N. (2005). Fetal alcohol
spectrum disorder: Canadian guidelines for diagnosis. Canadian Medical Association Journal,
172(5 suppl):S1–S21.
Clark, M., Bishop, A., vom Saal, F., and Galef, B. (1993). Responsiveness to testosterone of male
gerbils from known intrauterine positions. Physiology & Behavior, 53:1183–1187.
Colvin, L., Payne, J., Parsons, D., Kurinczuk, J. J., and Bower, C. (2007). Alcohol consumption dur-
ing pregnancy in nonindigenous west Australian women. Alcoholism: Clinical and Experimental
Research, 31(2):276–284.
Cooney, C. A., Dave, A. A., and Wolff, G. L. (2002). Maternal methyl supplements in mice affect
epigenetic variation and DNA methylation of offspring. Journal of Nutrition, 132(8 Suppl):2393S–
2400S.
Cordoba-Chacon, J., Gahete, M. D., Pozo-Salas, A. I., Castano, J. P., Kineman, R. D., and Luque,
R. M. (2013). Endogenous somatostatin is critical in regulating the acute effects of l-Arginine on
growth hormone and insulin release in mice. Endocrinology, 154(7):2393–2398. PMID: 23696563.
Czoli, C. D., Fong, G. T., Mays, D., and Hammond, D. (2016). How do consumers perceive dif-
ferences in risk across nicotine products? A review of relative risk perceptions across smokeless
111
tobacco, e-cigarettes, nicotine replacement therapy and combustible cigarettes. Tobacco Control,
pages 1F–10.
Da Lee, R., An, S., Kim, S., Rhee, G., Kwack, S., Seok, J., Chae, S., Park, C., Choi, Y., Kim, H., Cho,
H., Lee, B., and Park, K. (2005). Neurotoxic effects of alcohol and acetaldehyde during embryonic
development. Journal of Toxicology and Environmental Health - Part A - Current Issues, 68(23-
24):2147–2162.
Day, N., Cornelius, M., Goldschmidt, L., Richardson, G., Robles, N., and Taylor, P. (1992). The
effects of prenatal tobacco and marijuana use on offspring growth from birth through 3 years of
age. Neurotoxicology and teratology, 14(6):407–414.
Day, N., Leech, S., Richardson, G. A., Cornelius, M., Robles, N., and Larkby, C. (2002). Prenatal al-
cohol exposure predicts continued deficits in offspring size at 14 years of age. Alcoholism: Clinical
and Experimental Research, 26(10):1584–1591.
Day, N. L., Jasperse, D., Richardson, G., Robles, N., Sambamoorthi, U., Taylor, P., Scher, M., Stoffer,
D., and Cornelius, M. (1989). Prenatal exposure to alcohol: effect on infant growth and morpho-
logic characteristics. Pediatrics, 84(3):536–541.
Day, N. L., Zuo, Y., Richardson, G. A., Goldschmidt, L., Larkby, C. A., and Cornelius, M. D. (1999).
Prenatal alcohol use and offspring size at 10 years of age. Alcoholism: Clinical and Experimental
Research, 23(5):863–869.
Dean, W., Bowden, L., Aitchison, A., Klose, J., Moore, T., Meneses, J. J., Reik, W., and Feil, R.
(1998). Altered imprinted gene methylation and expression in completely ES cell-derived mouse
fetuses: association with aberrant phenotypes. Development, 125(12):2273–2282.
Dejmek, J., Solansk, I., Podrazilová, K., and Srám, R. J. (2002). The exposure of nonsmoking and
smoking mothers to environmental tobacco smoke during different gestational phases and fetal
growth. Environmental Health Perspectives, 110(6):601.
Delpisheh, A., Brabin, L., Drummond, S., and Brabin, B. J. (2008). Prenatal smoking exposure and
asymmetric fetal growth restriction. Annals of Human Biology, 35(6):573–583.
Denny, K. J., Coulthard, L. G., Jeanes, A., Lisgo, S., Simmons, D. G., Callaway, L. K., Wlodarczyk,
B., Finnell, R. H., Woodruff, T. M., and Taylor, S. M. (2013). C5a receptor signaling prevents folate
deficiency-induced neural tube defects in mice. The Journal of Immunology, 190(7):3493–3499.
DeRoo, L. A., Wilcox, A. J., Drevon, C. A., and Lie, R. T. (2008). First-trimester maternal alcohol
consumption and the risk of infant oral clefts in Norway: a population-based case-control study.
American journal of epidemiology, 168(6):638–646.
112 REFERENCE LIST
Desai, M. and Hales, C. N. (1997). Role of fetal and infant growth in programming metabolism in
later life. Biological Reviews of the Cambridge Philosophical Society, 72(02):329–348.
DiPadova, C., Worner, T. M., Julkunen, R. J., and Lieber, C. S. (1987). Effects of fasting and chronic
alcohol consumption on the first-pass metabolism of ethanol. Gastroenterology, 92(5 Pt 1):1169–
1173.
Dobson, C. C., Mongillo, D. L., Brien, D. C., Stepita, R., Poklewska-Koziell, M., Winterborn, A.,
Holloway, A. C., Brien, J. F., and Reynolds, J. N. (2012). Chronic prenatal ethanol exposure
increases adiposity and disrupts pancreatic morphology in adult guinea pig offspring. Nutrition
and Diabetes, 2(12):e57.
Dole, V. P. and Gentry, R. T. (1984). Toward an analogue of alcoholism in mice: scale factors in the
model. Proceedings of the National Academy of Sciences, 81(11):3543–3546.
Dolinoy, D. C., Huang, D., and Jirtle, R. L. (2007). Maternal nutrient supplementation counteracts
bisphenol A-induced DNA hypomethylation in early development. Proceedings of the National
Academy of Sciences, 104(32):13056–13061.
Dolinoy, D. C., Weidman, J. R., Waterland, R. A., and Jirtle, R. L. (2006). Maternal genistein al-
ters coat color and protects Avy mouse offspring from obesity by modifying the fetal epigenome.
Environmental Health Perspectives, 114(4):567–572.
Downing, C., Johnson, T. E., Larson, C., Leakey, T. I., Siegfried, R. N., Rafferty, T. M., and Cooney,
C. A. (2011). Subtle decreases in DNA methylation and gene expression at the mouse Igf2 locus
following prenatal alcohol exposure: effects of a methyl-supplemented diet. Alcohol, 45(1):65 –
71.
Elliott, E. J., Payne, J., Morris, A., Haan, E., and Bower, C. (2008). Fetal alcohol syndrome: a
prospective national surveillance study. Archives of Diseases in Childhood, 93(9):732–737.
Elswick, B. A., Welsch, F., and Janszen, D. B. (2000). Effect of different sampling designs on outcome
of endocrine disruptor studies. Reproductive Toxicology, 14(4):359–367.
Ernst, M., Moolchan, E. T., and Robinson, M. L. (2001). Behavioral and neural consequences of
prenatal exposure to nicotine. Journal of the American Academy of Child & Adolescent Psychiatry,
40(6):630 – 641.
Esposito, E. R., Horn, K. H., Greene, R. M., and Pisano, M. M. (2008). An animal model of cigarette
smoke-induced in utero growth retardation. Toxicology, 246(2-3):193 – 202.
Even, M., Dhar, M., and vom Saal, F. (1992). Transport of steroids between fetuses via amniotic fluid
in relation to the intrauterine position phenomenon in rats. Journal of Reproduction and Fertility,
96:709–716.
113
Fast, D. K., Conry, J., and Loock, C. A. (1999). Identifying fetal alcohol syndrome among youth in
the criminal justice system. Journal of Developmental and Behavioral Pediatrics, 20(5):370–372.
Fazel, A. (1996). Cigarette smoke/ethanol-induced limb defects in mouse embryos. Medical Journal
of the Islamic Republic of Iran, 9(4):333 – 340.
Feldman, H. S., Jones, K. L., Lindsay, S., Slymen, D., Klonoff-Cohen, H., Kao, K., Rao, S., and
Chambers, C. (2012). Prenatal alcohol exposure patterns and alcohol-related birth defects and
growth deficiencies: A prospective study. Alcoholism: Clinical and Experimental Research,
36(4):670–676.
Flynn, H. A., Marcus, S. M., Barry, K. L., and Blow, F. C. (2003). Rates and correlates of alcohol
use among pregnant women in obstetrics clinics. Alcoholism: Clinical and Experimental Research,
27(1):81–87.
Fullston, T., Ohlsson Teague, E. M. C., Palmer, N. O., DeBlasio, M. J., Mitchell, M., Corbett, M.,
Print, C. G., Owens, J. A., and Lane, M. (2013). Paternal obesity initiates metabolic disturbances in
two generations of mice with incomplete penetrance to the F2 generation and alters the transcrip-
tional profile of testis and sperm microRNA content. The FASEB Journal, 27(10):4226–4243.
Furtado, M. B., Solloway, M. J., Jones, V. J., Costa, M. W., Biben, C., Wolstein, O., Preis, J. I.,
Sparrow, D. B., Saga, Y., Dunwoodie, S. L., Robertson, E. J., Tam, P. P., and Harvey, R. P. (2008).
BMP/SMAD1 signaling sets a threshold for the left/right pathway in lateral plate mesoderm and
limits availability of SMAD4. Genes and Development, 22(21):3037–3049.
Gamieldien, K. and Maritz, G. (2004). Postnatal expression of cytochrome P450 1A1, 2A3, and
2B1 mRNA in neonatal rat lung: influence of maternal nicotine. Experimental Lung Research,
30(2):121–133.
Ganu, R. S., Harris, R. A., Collins, K., and Aagaard, K. M. (2012). Early origins of adult disease:
approaches for investigating the programmable epigenome in humans, nonhuman primates, and
rodents. ILAR Journal, 53(3-4):306–321.
Gao, Y.-J., Holloway, A. C., Zeng, Z.-H., Lim, G. E., Petrik, J. J., Foster, W. G., and Lee, R. M.
(2005). Prenatal exposure to nicotine causes postnatal obesity and altered perivascular adipose
tissue function. Obesity Research, 13(4):687–692.
Gardebjer, E., Cuffe, J., Pantaleon, M., Wlodek, M., and Moritz, K. (2014). Periconceptional alco-
hol consumption causes fetal growth restriction and increases glycogen accumulation in the late
gestation rat placenta. Placenta, 35(1):50–57.
Gardebjer, E. M., Anderson, S. T., Pantaleon, M., Wlodek, M. E., and Moritz, K. M. (2015). Maternal
alcohol intake around the time of conception causes glucose intolerance and insulin insensitivity in
114 REFERENCE LIST
rat offspring, which is exacerbated by a postnatal high-fat diet. The FASEB Journal, 29(7):2690–
2701.
Garro, A. J., McBeth, D. L., Lima, V., and Lieber, C. S. (1991). Ethanol consumption inhibits fetal
DNA methylation in mice: implications for the fetal alcohol syndrome. Alcohol: Clinical and
Experimental Research, 15(3):395–398.
Gierl, M. S., Karoulias, N., Wende, H., Strehle, M., and Birchmeier, C. (2006). The Zinc-finger factor
Insm1 (IA-1) is essential for the development of pancreatic β cells and intestinal endocrine cells.
Genes & Development, 20(17):2465–2478.
Godin, E., O’Leary-Moore, S., Khan, A., Parnell, S., Ament, J., Dehart, D., Johnson, B., Allan John-
son, G., Styner, M., and Sulik, K. (2010). Magnetic resonance microscopy defines ethanol-induced
brain abnormalities in prenatal mice: Effects of acute insult on gestational day 7. Alcoholism:
Clinical and Experimental Research, 34(1):98–111.
Golan, H. and Huleihel, M. (2006). The effect of prenatal hypoxia on brain development: short- and
long-term consequences demonstrated in rodent models. Developmental Science, 9(4):338–349.
Gong, Z.-K., Wang, S.-J., Huang, Y.-Q., Zhao, R.-Q., Zhu, Q.-F., and Lin, W.-Z. (2014). Identifica-
tion and validation of suitable reference genes for RT-qPCR analysis in mouse testis development.
Molecular Genetics and Genomics, 289(6):1157–1169.
Gray, S. P., Denton, K. M., Cullen-McEwen, L., Bertram, J. F., and Moritz, K. M. (2010). Prenatal
exposure to alcohol reduces nephron number and raises blood pressure in progeny. Journal of the
American Society of Nephrology, 21(11):1891–1902.
Gritz, E. R., Ippoliti, A., Jarvik, M. E., Rose, J. E., Shiffman, S., Harrison, A., and Van Vunakis, H.
(1988). The effect of nicotine on the delay of gastric emptying. Alimentary Pharmacology and
Therapeutics, 2(2):173–178.
Gyekis, J., Anthony, K., Foreman, J. E., Klein, L. C., and Vandenbergh, D. J. (2010). Perinatal
nicotine exposure delays genital development in mice. Reproductive Toxicology, 29(3):378 – 380.
Han, M., Evsikov, A. V., Zhang, L., Lastra-Vicente, R., and Linask, K. K. (2016). Embryonic ex-
posures of lithium and homocysteine and folate protection affect lipid metabolism during mouse
cardiogenesis and placentation. Reproductive Toxicology, 61:82–96.
Hanson, M. and Gluckman, P. (2014). Early developmental conditioning of later health and disease:
physiology or pathophysiology? Physiological reviews, 94(4):1027–1076.
Harper, K. M., Tunc-Ozcan, E., Graf, E. N., and Redei, E. E. (2014). Intergenerational effects of
prenatal ethanol on glucose tolerance and insulin response. Physiological Genomics, 46(5):159–
168.
115
Harri, M., Lindblom, J., Malinen, H., Hyttinen, M., Lapveteläinen, T., Eskola, S., and Helminen, H. J.
(1999). Effect of access to a running wheel on behavior of C57BL/6J mice. Laboratory Animal
Science, 49(4):401–405.
Haseman, J. K. and Hogan, M. D. (1975). Selection of the experimental unit in teratology studies.
Teratology, 12(2):165–171.
Haste, F., Anderson, H., Brooke, O., Bland, J., and Peacock, J. (1991). The effects of smoking and
drinking on the anthropometric measurements of neonates. Paediatric and Perinatal Epidemiology,
5(1):83–92.
Heijmans, B. T., Tobi, E. W., Stein, A. D., Putter, H., Blauw, G. J., Susser, E. S., Slagboom, P. E., and
Lumey, L. H. (2008). Persistent epigenetic differences associated with prenatal exposure to famine
in humans. Proceedings of the National Academy of Sciences of the United States of America,
105(44):17046–17049.
Heindel, J. J., Skalla, L. A., Joubert, B. R., Dilworth, C. H., and Gray, K. A. (2016). Review of devel-
opmental origins of health and disease publications in environmental epidemiology. Reproductive
Toxicology.
Hellström, A., Jansson, C., Boguszewski, M., Olegård, R., Laegreid, L., and Albertsson-Wikland,
K. (1996). Growth hormone status in six children with fetal alcohol syndrome. Acta Paediatrica,
85(12):1456–1462.
Henderson, G. I., Devi, B. G., Perez, A., and Schenker, S. (1995). In utero ethanol exposure elicits
oxidative stress in the rat fetus. Alcoholism: Clinical and Experimental Research, 19(3):714–720.
Holloway, A. C., Lim, G. E., Petrik, J. J., Foster, W. G., Morrison, K. M., and Gerstein, H. C. (2005).
Fetal and neonatal exposure to nicotine in wistar rats results in increased beta cell apoptosis at birth
and postnatal endocrine and metabolic changes associated with type 2 diabetes. Diabetologia,
48(12):2661–2666.
Howard, L. A., Micu, A. L., Sellers, E. M., and Tyndale, R. F. (2001). Low doses of nicotine and
ethanol induce CYP2E1 and chlorzoxazone metabolism in rat liver. Journal of Pharmacology and
Experimental Therapeutics, 299(2):542–550.
Howard, L. A., Miksys, S., Hoffmann, E., Mash, D., and Tyndale, R. F. (2003). Brain CYP2E1 is
induced by nicotine and ethanol in rat and is higher in smokers and alcoholics. British Journal of
Pharmacology, 138(7):1376–1386.
Howdeshell, K. and Saal, F. (2000). Developmental exposure to bisphenol A: interaction with en-
dogenous estradiol during pregnancy in mice. American Zoologist, 40(3):429–437.
116 REFERENCE LIST
Hoyme, H. E., May, P. A., Kalberg, W. O., Kodituwakku, P., Gossage, J. P., Trujillo, P. M., Buckley,
D. G., Miller, J. H., Aragon, A. S., Khaole, N., Viljoen, D. L., Jones, K. L., and Robinson, L. K.
(2005). A practical clinical approach to diagnosis of fetal alcohol spectrum disorders: clarification
of the 1996 Institute of Medicine criteria. Pediatrics, 115(1):39–47.
Huang, D. W., Sherman, B. T., and Lempicki, R. A. (2009a). Bioinformatics enrichment tools: paths
toward the comprehensive functional analysis of large gene lists. Nucleic Acids Research, 37(1):1–
13.
Huang, D. W., Sherman, B. T., and Lempicki, R. A. (2009b). Systematic and integrative analysis of
large gene lists using DAVID bioinformatics resources. Nature Protocols, 4(1):44 – 57.
Huang, P., Abbott, L., and Winzer-Serhan, U. (2015). Evaluation of chronic oral nicotine treatment in
food consumption, body weight and [125i] epibatidine binding in adult mice. Open Access Journal
of Toxicology, 1(1):555552.
Hutter, D., Kingdom, J., and Jaeggi, E. (2010). Causes and mechanisms of intrauterine hypoxia and its
impact on the fetal cardiovascular system: A review. International Journal of Pediatrics, 2010:1–9.
Hyatt, M. A., Budge, H., and Symonds, M. E. (2008). Early developmental influences on hepatic
organogenesis. Organogenesis, 4(3):170–175.
Illingworth, R. S., Gruenewald-Schneider, U., Webb, S., Kerr, A. R. W., James, K. D., Turner, D. J.,
Smith, C., Harrison, D. J., Andrews, R., and Bird, A. P. (2010). Orphan CpG islands identify
numerous conserved promoters in the mammalian genome. PLoS Genetics, 6(9):e1001134.
Ingelfinger, J. R. and Woods, L. L. (2002). Perinatal programming, renal development, and adult
renal function. American journal of hypertension, 15(S2):46S–49S.
Ivey, K. N. and Srivastava, D. (2015). microRNAs as developmental regulators. Cold Spring Harbour
Perspectives in Biology, 7(7):a008144.
Jaakkola, J. J. and Gissler, M. (2004). Maternal smoking in pregnancy, fetal development, and child-
hood asthma. American Journal of Public Health, 94(1):136–140.
Jacobson, J. L., Jacobson, S. W., Sokol, R. J., Martier, S. S., Ager, J. W., and Shankaran, S. (1994).
Effects of alcohol use, smoking, and illicit drug use on fetal growth in black infants. The Journal
of pediatrics, 124(5):757–764.
Jensen, J. A. (1991). Cigarette smoking decreases tissue oxygen. Archives of Surgery, 126(9):1131.
Jing, H. and Li, Y. (2004). Effects of ethanol on mouse embryonic brain development and Heat Shock
Protein 73 expression. Toxicology in Vitro, 18(5):601–607.
117
Johnson, R. D., Horowitz, M., Maddox, A. F., Wishart, J. M., and Shearman, D. J. C. (1991). Cigarette
smoking and rate of gastric emptying: effect on alcohol absorption. BMJ: British Medical Journal,
302(6767):20 – 23.
Jones, P. A. (2012). Functions of DNA methylation: islands, start sites, gene bodies and beyond.
Nature Reviews. Genetics, 13(7):484–492.
Joubert, B., Felix, J., Yousefi, P., Bakulski, K., Just, A., Breton, C., Reese, S. E., Markunas, C.,
Richmond, R., and Xu, C.-J. (2016). DNA methylation in newborns and maternal smoking in
pregnancy: Genome-wide consortium meta-analysis. The American Journal of Human Genetics,
98(4):680–696.
Joubert, B. R., Haberg, S. E., Nilsen, R. M., Wang, X., Vollset, S. E., Murphy, S. K., Huang, Z., Hoyo,
C., Midttun, i., Cupul-Uicab, L. A., and et al. (2012). 450K epigenome-wide scan identifies differ-
ential DNA methylation in newborns related to maternal smoking during pregnancy. Environmental
Health Perspectives, 120(10):1425–1431.
Julkunen, R., Tannenbaum, L., Baraona, E., and Lieber, C. (1985). First pass metabolism of ethanol:
An important determinant of blood levels after alcohol consumption. Alcohol, 2(3):437–441.
Julvez, J., Ribas-Fito, N., Torrent, M., Forns, M., Garcia-Esteban, R., and Sunyer, J. (2007). Maternal
smoking habits and cognitive development of children at age 4 years in a population-based birth
cohort. International Journal of Epidemiology, 36(4):825–832.
Kaminen-Ahola, N., Ahola, A., Flatscher-Bader, T., Wilkins, S. J., Anderson, G. J., Whitelaw, E., and
Chong, S. (2010a). Postnatal growth restriction and gene expression changes in a mouse model
of fetal alcohol syndrome. Birth Defects Research Part A: Clinical and Molecular Teratology,
88(10):818–826.
Kaminen-Ahola, N., Ahola, A., Maga, M., Mallitt, K. A., Fahey, P., Cox, T. C., Whitelaw, E., and
Chong, S. (2010b). Maternal ethanol consumption alters the epigenotype and the phenotype of
offspring in a mouse model. PLoS Genetics, 6(1):e1000811.
Kang, P. and Svoboda, K. K. (2003). Nicotine inhibits palatal fusion and modulates nicotinic receptors
and the PI-3 kinase pathway in medial edge epithelia. Orthodontics & Craniofacial Research,
6(3):129–142.
Kanungo, J., Cuevas, E., Guo, X., Lopez, A. G., Ramirez-Lee, M. A., Trickler, W., Paule, M. G., and
Ali, S. F. (2012). Nicotine alters the expression of molecular markers of endocrine disruption in
zebrafish. Neuroscience Letters, 526(2):133–137.
Katsuragi, Y., Anraku, J., Nakatomi, M., Ida-Yonemochi, H., Obata, M., Mishima, Y., Sakuraba, Y.,
Gondo, Y., Kodama, Y., Nishikawa, A., Takagi, R., Ohshima, H., and Kominami, R. (2013). Bcl11b
118 REFERENCE LIST
transcription factor plays a role in the maintenance of the ameloblast-progenitors in mouse adult
maxillary incisors. Mechanisms of Development, 130(9 - 10):482 – 492.
Kawashima, H., Sugito, K., Yoshizawa, S., Uekusa, S., Furuya, T., Ikeda, T., Koshinaga, T., Shino-
jima, Y., Hasegawa, R., Mishra, R., Igarashi, J., Kimura, M., Wang, X., Fujiwara, K., Gosh, S., and
Nagase, H. (2012). DNA hypomethylation at the ZNF206-exon 5 CpG island associated with neu-
ronal differentiation in mice and development of neuroblastoma in humans. International Journal
of Oncology, 40(1):31–39.
Kent, W. J. (2002). BLAT-The BLAST-Like Alignment Tool. Genome Research, 12(4):656–664.
Kietzman, H. W., Everson, J. L., Sulik, K. K., and Lipinski, R. J. (2014). The teratogenic effects
of prenatal ethanol exposure are exacerbated by Sonic Hedgehog or Gli2 haploinsufficiency in the
mouse. PLoS ONE, 9(2):e89448.
Kile, M. L., Houseman, E. A., Baccarelli, A. A., Quamruzzaman, Q., Rahman, M., Mostofa, G.,
Cardenas, A., Wright, R. O., and Christiani, D. C. (2014). Effect of prenatal arsenic exposure on
DNA methylation and leukocyte subpopulations in cord blood. Epigenetics, 9(5):774–782.
Klein, L. C., Stine, M. M., Pfaff, D. W., and Vandenbergh, D. J. (2003). Laternal nicotine exposure
increases nicotine preference in periadolescent male but not female C57B1/6J mice. Nicotine and
Tobacco Research, 5(1):117–124.
Kline, J., Stein, Z. A., Susser, M., and Warburton, D. (1977). Smoking: a risk factor for spontaneous
abortion. New England Journal of Medicine, 297(15):793–796.
Kraus, P., V, S., Yu, H. B., Xing, X., Lim, S. L., Adler, T., Pimentel, J. A. A., Becker, L., Bohla,
A., Garrett, L., Hans, W., Holter, S. M., Janas, E., Moreth, K., Prehn, C., Puk, O., Rathkolb, B.,
Rozman, J., Adamski, J., Bekeredjian, R., Busch, D. H., Graw, J., Klingenspor, M., Klopstock, T.,
Neff, F., Ollert, M., Stoeger, T., Yildrim, A. O., Eickelberg, O., Wolf, E., Wurst, W., Fuchs, H.,
Gailus-Durner, V., de Angelis, M. H., Lufkin, T., and Stanton, L. W. (2014). Pleiotropic Functions
for Transcription Factor Zscan10. PLoS ONE, 9(8):e104568.
Kupers, L. K., Xu, X., Jankipersadsing, S. A., Vaez, A., la Bastide-van Gemert, S., Scholtens, S.,
Nolte, I. M., Richmond, R. C., Relton, C. L., and Felix, J. F. (2015). DNA methylation mediates
the effect of maternal smoking during pregnancy on birthweight of the offspring. International
Journal of Epidemiology, 44(4):1224–1237.
Kwong, W. Y., Miller, D. J., Ursell, E., Wild, A. E., Wilkins, A. P., Osmond, C., Anthony, F. W., and
Fleming, T. P. (2006). Imprinted gene expression in the rat embryo-fetal axis is altered in response
to periconceptional maternal low protein diet. Reproduction, 132(2):265–277.
119
Kwong, W. Y., Wild, A. E., Roberts, P., Willis, A. C., and Fleming, T. P. (2000). Maternal under-
nutrition during the preimplantation period of rat development causes blastocyst abnormalities and
programming of postnatal hypertension. Development, 127(19):4195–4202.
Labrador, J. P., Azcoitia, V., Tuckermann, J., Lin, C., Olaso, E., Manes, S., Brucker, K., Georgen,
J.-L., Lemke, G., Yancopoulos, G., Angel, P., Martinez-A, C., and Klein, R. (2001). The colla-
gen receptor DDR2 regulates proliferation and its elimination leads to dwarfism. EMBO Reports,
2(5):446 – 452.
Ladd-Acosta, C., Shu, C., Lee, B. K., Gidaya, N., Singer, A., Schieve, L. A., Schendel, D. E., Jones,
N., Daniels, J. L., and Windham, G. C. (2016). Presence of an epigenetic signature of prenatal
cigarette smoke exposure in childhood. Environmental Research, 144(Pt A):139–148.
Lan, N., Yamashita, F., Halpert, A. G., Sliwowska, J. H., Viau, V., and Weinberg, J. (2009). Effects
of prenatal ethanol exposure on hypothalamic-pituitary-adrenal function across the estrous cycle.
Alcoholism: Clinical and Experimental Research, 33(6):1075–1088.
Lassen, T. H., Madsen, M., Skovgaard, L. T., Strandberg-Larsen, K., Olsen, J., and Andersen, A.-
M. N. (2010). Maternal use of nicotine replacement therapy during pregnancy and offspring birth-
weight: a study within the Danish National Birth Cohort. Paediatric and Perinatal Epidemiology,
24(3):272–281.
Laufer, B. I., Mantha, K., Kleiber, M. L., Diehl, E. J., Addison, S. M. F., and Singh, S. M. (2013).
Long-lasting alterations to DNA methylation and ncRNAs could underlie the effects of fetal alcohol
exposure in mice. Disease Models & Mechanisms, 6(4):977 – 992.
Lauing, K., Himes, R., Rachwalski, M., Strotman, P., and Callaci, J. J. (2008). Binge alcohol treat-
ment of adolescent rats followed by alcohol abstinence is associated with site-specific differences
in bone loss and incomplete recovery of bone mass and strength. Alcohol, 42(8):649 – 656.
Lawrence, J., Chen, M., Xiong, F., Xiao, D., Zhang, H., Buchholz, J. N., and Zhang, L. (2010). Foetal
nicotine exposure causes PKCε gene repression by promoter methylation in rat hearts. Cardiovas-
cular Research, 89(1):89–97.
Laws, P., Grayson, N., and Sullivan, E. A. (2006). Smoking and pregnancy. AIHW National Perinatal
Statistics Unit, 33.
Lawson, G. M., Hurt, R. D., Dale, L. C., Offord, K. P., Croghan, I. T., Schroeder, D. R., and Jiang,
N.-S. (1998). Application of serum nicotine and plasma cotinine concentrations to assessment of
nicotine replacement in light, moderate, and heavy smokers undergoing transdermal therapy. The
Journal of Clinical Pharmacology, 38(6):502–509.
120 REFERENCE LIST
Lee, K. W. K., Richmond, R., Hu, P., French, L., Shin, J., Bourdon, C., Reischl, E., Waldenberger,
M., Zeilinger, S., and Gaunt, T. (2015). Prenatal exposure to maternal cigarette smoking and DNA
methylation: Epigenome-wide association in a discovery sample of adolescents and replication
in an independent cohort at birth through 17 years of age. Environmental Health Perspectives,
123(2):193–199.
Lee, Y., Osumi-Yamashita, N., Ninomiya, Y., Moon, C., Eriksson, U., and Eto, K. (1995). Retinoic
acid stage-dependently alters the migration pattern and identity of hindbrain neural crest cells.
Development, 121(3):825–837.
Leichter, J. (1989). Growth of fetuses of rats exposed to ethanol and cigarette smoke during gestation.
Growth, Development and Aging, 53(3):129 – 134.
Leitch, H. G., McEwen, K. R., Turp, A., Encheva, V., Carroll, T., Grabole, N., Mansfield, W., Nashun,
B., Knezovich, J. G., Smith, A., and et al. (2013). Naive pluripotency is associated with global DNA
hypomethylation. Nature Structural & Molecular Biology, 20(3):311–316.
Li, L.-C. and Dahiya, R. (2002). MethPrimer: designing primers for methylation PCRs. Bioinformat-
ics, 18(11):1427–1431.
Li, Y., Xiao, D., Dasgupta, C., Xiong, F., Tong, W., Yang, S., and Zhang, L. (2012). Perinatal
nicotine exposure increases vulnerability of hypoxic-ischemic brain injury in neonatal rats: Role
of angiotensin II receptors. Stroke, 43(9):2483–2490.
Li, Y.-X., Yang, H.-T., Zdanowicz, M., Sicklick, J., Qi, Y., Camp, T., and Diehl, A. M. (2007). Fetal
alcohol exposure impairs hedgehog cholesterol modification and signaling. Laboratory Investiga-
tion, 87(3):231–240.
Lieberman, E., Gremy, I., Lang, J. M., and Cohen, A. P. (1994). Low birthweight at term and the
timing of fetal exposure to maternal smoking. American Journal of Public Health, 84(7):1127–
1131.
Lin, C., Yon, J.-M., Jung, A. Y., Lee, J. G., Jung, K. Y., Lee, B. J., Yun, Y. W., and Nam, S.-Y. (2013).
Antiteratogenic effects of β -carotene in cultured mouse embryos exposed to nicotine. Evidence-
Based Complementary and Alternative Medicine, 2013(575287):doi: 10.1155/2013/575287.
Little, R. E., Asker, R. L., Sampson, P. D., and Renwick, J. (1986). Fetal growth and moderate
drinking in early pregnancy. American Journal of Epidemiology, 123(2):270–278.
Liu, Y., Balaraman, Y., Wang, G., Nephew, K. P., and Zhou, F. C. (2009). Alcohol exposure alters
DNA methylation profiles in mouse embryos at early neurulation. Epigenetics, 4(7):500–11.
Livak, K. J. and Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time
quantitative PCR and the 2-∆∆CT method. Methods, 25(4):402–408.
121
Livera, G., Delbes, G., Pairault, C., Rouiller-Fabre, V., and Habert, R. (2006). Organotypic culture,
a powerful model for studying rat and mouse fetal testis development. Cell and Tissue Research,
324(3):507–521.
Lowe, R., Gemma, C., Rakyan, V. K., and Holland, M. L. (2015). Sexually dimorphic gene expres-
sion emerges with embryonic genome activation and is dynamic throughout development. BMC
Genomics, 16(295):doi: 10.1186/s12864–015–1506–4.
Ma, N., Nicholson, C. J., Wong, M., Holloway, A. C., and Hardy, D. B. (2014). Fetal and neonatal
exposure to nicotine leads to augmented hepatic and circulating triglycerides in adult male offspring
due to increased expression of fatty acid synthase. Toxicology and Applied Pharmacology, 275(1):1
– 11.
Maier, C. R., Hollander, M. C., Hobbs, E. A., Dogan, I., Linnoila, R. I., and Dennis, P. A. (2011).
Nicotine does not enhance tumorigenesis in mutant k-ras-driven mouse models of lung cancer.
Cancer Prevention Research, 4(11):1743–1751.
Maier, S. E., Chen, W.-J. A., Miller, J. A., and West, J. R. (1997). Fetal alcohol exposure and temporal
vulnerability: regional differences in alcohol-induced microencephaly as a function of the timing of
binge-like alcohol exposure during rat brain development. Alcoholism: Clinical and Experimental
Research, 21(8):1418–1425.
Mallo, M., Wellik, D. M., and Deschamps, J. (2010). Hox genes and regional patterning of the
vertebrate body plan. Developments in Biologicals, 344(1):7 – 15.
Mamiya, P. C., Hennesy, Z., Zhou, R., and Wagner, G. C. (2008). Changes in attack behavior and
activity in EphA5 knockout mice . Brain Research, 1205(0):91 – 99.
Mangubat, M., Lutfy, K., Lee, M. L., Pulido, L., Stout, D., Davis, R., Shin, C.-S., Shahbazian, M.,
Seasholtz, S., and Sinha-Hikim, A. (2012). Effect of nicotine on body composition in mice. Journal
of Endocrinology, 212(3):317–326.
Marjonen, H., Sierra, A., Nyman, A., Rogojin, V., Grohn, O., Linden, A.-M., Hautaniemi, S., and
Kaminen-Ahola, N. (2015). Early maternal alcohol consumption alters hippocampal DNA methy-
lation, gene expression and volume in a mouse model. PLoS ONE, 10(5):e0124931.
Martin, J. C., Martin, D. C., Chao, S., and Shores, P. (1982). Interactive effects of chronic mater-
nal ethanol and nicotine exposure upon offspring development and function. Neurobehavioural
Toxicology and Teratology, 4(3):293 – 298.
Marufu, T. C., Ahankari, A., Coleman, T., and Lewis, S. (2015). Maternal smoking and the risk of
still birth: systematic review and meta-analysis. BMC Public Health, 15(1):doi: 10.1186/s12889–
015–1552–5.
122 REFERENCE LIST
Matta, S. G. and Elberger, A. J. (2007). Combined exposure to nicotine and ethanol throughout full
gestation results in enhanced acquisition of nicotine self-administration in young adult rat offspring.
Psychopharmacology, 193(2):199 – 213.
May, P. A., Gossage, J. P., Kalberg, W. O., Robinson, L. K., Buckley, D., Manning, M., and Hoyme,
H. E. (2009). Prevalence and epidemiologic characteristics of FASD from various research meth-
ods with an emphasis on recent in-school studies. Developmental Disabilities Research Reviews,
15(3):176–192.
McFarlane, L., Truong, V., Palmer, J., and Wilhelm, D. (2013). Novel PCR assay for determining the
genetic sex of mice. Sexual Development, 7(4):207–211.
McGrath, K. E., Koniski, A. D., Malik, J., and Palis, J. (2003). Circulation is established in a stepwise
pattern in the mammalian embryo. Blood, 101(5):1669–1676.
Meliska, C. J., Bartke, A., McGlacken, G., and Jensen, R. A. (1995). Ethanol, nicotine, amphetamine,
and aspartame consumption and preferences in C57BL/6 and DBA/2 mice. Pharmacology Bio-
chemistry and Behavior, 50(4):619 – 626.
Michalk, A., Stricker, S., Becker, J., Rupps, R., Pantzar, T., Miertus, J., Botta, G., Naretto, V. G.,
Janetzki, C., Yaqoob, N., Ott, C.-E., Seelow, D., Wieczorek, D., Fiebig, B., Wirth, B., Hoopmann,
M., Walther, M., Korber, F., Blankenburg, M., Mundlos, S., Heller, R., and Hoffmann, K. (2008).
Acetylcholine receptor pathway mutations explain various fetal akinesia deformation sequence dis-
orders. American Journal of Human Genetics, 82(2):464–476.
Mirasierra, M., Fernandez-Perez, A., Diaz-Prieto, N., and Vallejo, M. (2011). Alx3-deficient mice
exhibit decreased insulin in beta cells, altered glucose homeostasis and increased apoptosis in pan-
creatic islets. Diabetologia, 54(2):403–414.
Mitchell, J. A. and Hammer, R. E. (1985). Effects of nicotine on oviducal blood flow and embryo
development in the rat. Journal of Reproduction and Fertility, 74(1):71–76.
Monk, M., Boubelik, M., and Lehnert, S. (1987). Temporal and regional changes in DNA methyla-
tion in the embryonic, extraembryonic and germ cell lineages during mouse embryo development.
Development, 99(3):371–382.
Morales-Suárez-Varela, M. M., Bille, C., Christensen, K., and Olsen, J. (2006). Smoking habits,
nicotine use, and congenital malformations. Obstetrics and Gynecology, 107(1):51–57.
Moreno-Gonzalez, I., Estrada, L. D., Sanchez-Mejias, E., and Soto, C. (2013). Smoking exacerbates
amyloid pathology in a mouse model of Alzheimer’s disease. Nature Communications, 4(1495):1
– 10.
123
Morgan, H. D., Jin, X. L., Li, A., Whitelaw, E., and O’Neill, C. (2008). The culture of zygotes to
the blastocyst stage changes the postnatal expression of an epigentically labile allele, agouti viable
yellow, in mice. Biology of Reproduction, 79(4):618–623.
Morgan, H. D., Sutherland, H. G., Martin, D. I., and Whitelaw, E. (1999). Epigenetic inheritance at
the agouti locus in the mouse. Nature Genetics, 23(3):314–318.
Moritz, K. M., De Matteo, R., Dodic, M., Jefferies, A. J., Arena, D., Wintour, E. M., Probyn, M. E.,
Bertram, J. F., Singh, R. R., and Zanini, S. (2011). Prenatal glucocorticoid exposure in the sheep
alters renal development in utero: implications for adult renal function and blood pressure control.
AJP: Regulatory, Integrative and Comparative Physiology, 301(2):R500–R509.
Mund, M., Louwen, F., Klingelhoefer, D., and Gerber, A. (2013). Smoking and pregnancy – a review
on the first major environmental risk factor of the unborn. International Journal of Environmental
Research and Public Health, 10(12):6485–6499.
Murriel, C. L. and Mochly-Rosen, D. (2003). Opposing roles of δ and εPKC in cardiac ischemia
and reperfusion: targeting the apoptotic machinery. Archives of Biochemistry and Biophysics,
420(2):246–254.
Mychasiuk, R., Muhammad, A., and Kolb, B. (2014). Environmental enrichment alters structural
plasticity of the adolescent brain but does not remediate the effects of prenatal nicotine exposure.
Synapse, 68(7):293–305.
Naruse-Nakajima, C., Asano, M., and Iwakura, Y. (2001). Involvement of EphA2 in the formation of
the tail notochord via interaction with ephrinA1. Mechanisms of Development, 102(1–2):95 – 105.
Ni, Q., Tan, Y., Zhang, X., Luo, H., Deng, Y., Magdalou, J., Chen, L., and Wang, H. (2015). Prenatal
ethanol exposure increases osteoarthritis susceptibility in female rat offspring by programming a
low-functioning IGF-1 signaling pathway. Scientific Reports, 5(14711):doi: 10.1038/srep14711.
Nicholas, L. M., Rattanatray, L., MacLaughlin, S. M., Ozanne, S. E., Kleemann, D. O., Walker, S. K.,
Morrison, J. L., Zhang, S., Muhlhäusler, B. S., Martin-Gronert, M. S., et al. (2013). Differential ef-
fects of maternal obesity and weight loss in the periconceptional period on the epigenetic regulation
of hepatic insulin-signaling pathways in the offspring. The FASEB Journal, 27(9):3786–3796.
Noakes, P. S., Hale, J., Thomas, R., Lane, C., Devadason, S. G., and Prescott, S. L. (2006). Mater-
nal smoking is associated with impaired neonatal toll-like-receptor-mediated immune responses.
European Respiratory Journal, 28(4):721–729.
Ogawa, T., Kuwagata, M., Ruiz, J., and Zhou, F. C. (2005). Differential teratogenic effect of alcohol
on embryonic development between C57BL/6 and DBA/2 mice: a new view. Alcoholism: Clinical
and Experimental Research, 29(5):855–863.
124 REFERENCE LIST
Oldenburg, P. J., Wyatt, T. A., Factor, P. H., and Sisson, J. H. (2009). Alcohol feeding blocks
methacholine-induced airway responsiveness in mice. American Journal of Physiology - Lung
Cellular and Molecular Physiology, 296(1):L109–L114.
Olsen, J., Pereira, A. d. C., and Olsen, S. F. (1991). Does maternal tobacco smoking modify the effect
of alcohol on fetal growth? American Journal of Public Health, 81(1):69–73.
Oncken, C. A., Hatsukami, D. K., Lupo, V. R., Lando, H. A., Gibeau, L. M., and Hansen, R. J.
(1996). Effects of short-term use of nicotine gum in pregnant smokers. Clinical Pharmacology &
Therapeutics, 59(6):654–661.
Otis, E. M. and Brent, R. (1954). Equivalent ages in mouse and human embryos. The Anatomical
Record, 120(1):33–63.
Parnell, S. E., Dehart, D. B., Wills, T. A., Chen, S.-y., Hodge, C. W., Besheer, J., Waage-Baudet,
H. G., Charness, M. E., and Sulik, K. K. (2006). Maternal oral intake mouse model for fetal alcohol
spectrum disorders: ocular defects as a measure of effect. Alcoholism: Clinical and Experimental
Research, 30(10):1791–1798.
Pauly, J. R., Sparks, J. A., Hauser, K. F., and Pauly, T. H. (2004). In utero nicotine exposure causes
persistent, gender-dependant changes in locomotor activity and sensitivity to nicotine in C57BL/6
mice. International Journal of Developmental Neuroscience, 22(5 - 6):329 – 337.
Peterson, K. L., Heniger, R. W., and Seegmiller, R. E. (1981). Fetotoxicity following chronic prenatal
treatment of mice with tobacco smoke and ethanol. Bulletin of Environmental Contamination and
Toxicology, 26(6):813 – 819.
Pollak, K. I., Oncken, C. A., Lipkus, I. M., Lyna, P., Swamy, G. K., Pletsch, P. K., Peterson, B. L.,
Heine, R. P., Brouwer, R. J. N., Fish, L., et al. (2007). Nicotine replacement and behavioral therapy
for smoking cessation in pregnancy. American Journal of Preventive Medicine, 33(4):297–305.
Popova, S., Lange, S., Shield, K., Mihic, A., Chudley, A. E., Mukherjee, R. A. S., Bekmuradov, D.,
and Rehm, J. (2016). Comorbidity of fetal alcohol spectrum disorder: a systematic review and
meta-analysis. The Lancet, 387(10022):978–987.
Prabhu, N., Smith, N., Campbell, D., Craig, L. C., Seaton, A., Helms, P. J., Devereux, G., and Turner,
S. W. (2010). First trimester maternal tobacco smoking habits and fetal growth. Thorax, 65(3):235–
240.
Probyn, M. E., Cuffe, J. S. M., Zanini, S., and Moritz, K. M. (2013). The effects of low-moderate dose
prenatal ethanol exposure on the fetal and postnatal rat lung. Journal of Developmental Origins of
Health and Disease, 4(05):358–367.
125
Probyn, M. E., Zanini, S., Ward, L. C., Bertram, J. F., and Moritz, K. M. (2012). A rodent model
of low- to moderate-dose ethanol consumption during pregnancy: patterns of ethanol consumption
and effects on fetal and offspring growth. Reproduction, Fertility and Development, 24(6):859.
Queensland Government (2013). Alcohol limits. https://www.qld.gov.au/transport/safety/
road-safety/drink-driving/blood-alcohol/. Accessed: 2016-09-23.
Ramachandran, V., Perez, A., Chen, J., Senthil, D., Schenker, S., and Henderson, G. I. (2001). In utero
ethanol exposure causes mitochondrial dysfunction, which can result in apoptotic cell death in fetal
brain: a potential role for 4-hydroxynonenal. Alcoholism: Clinical and Experimental Research,
25(6):862–871.
Ramanathan, R., Wilkemeyer, M. F., Mittal, B., Perides, G., and Charness, M. E. (1996). Alcohol
inhibits cell-cell adhesion mediated by human L1. The Journal of Cell Biology, 133(2):381–90.
Raval, A. P., Bhatt, A., and Saul, I. (2009). Chronic nicotine exposure inhibits 17β -estradiol-mediated
protection of the hippocampal CA1 region against cerebral ischemia in female rats. Neuroscience
Letters, 458(2):65 – 69.
Ravelli, G.-P., Stein, Z. A., and Susser, M. W. (1976). Obesity in young men after famine exposure in
utero and early infancy. New England Journal of Medicine, 295(7):349–353.
Rehan, V., Liu, J., Naeem, E., Tian, J., Sakurai, R., Kwong, K., Akbari, O., and Torday, J. (2012). Peri-
natal nicotine exposure induces asthma in second generation offspring. BMC Medicine, 10(1):1–14.
Reik, W., Dean, W., and Walter, J. (2001). Epigenetic reprogramming in mammalian development.
Science, 293(5532):1089–1093.
Ren, J., Wold, L. E., Natavio, M., Ren, B. H., Hannigan, J. H., and Brown, R. A. (2002). Influence of
prenatal alcohol exposure on myocardial contractile function in adult rat hearts: role of intracellular
calcium and apoptosis. Alcohol and Alcoholism, 37(1):30–37.
Richards, E. J. (2006). Inherited epigenetic variation - revisiting soft inheritance. Nature Reviews.
Genetics, 7(5):395 – 401.
Robinson, R. S. and Seelig, L. L. (2002). Effects of maternal ethanol consumption on hematopoietic
cells in the rat fetal liver. Alcohol, 28(3):151–156.
Robinson, S., Marks, M., and Collins, A. (1996). Inbred mouse strains vary in oral self-selection of
nicotine. Psychopharmacology, 124(4):332–339.
Rodgers, D. A. (1966). Factors underlying differences in alcohol preference among inbred strains of
mice. Psychosomatic Medicine, 28(4):498–513.
126 REFERENCE LIST
Rosenbloom, K. R., Armstrong, J., Barber, G. P., Casper, J., Clawson, H., Diekhans, M., Dreszer,
T. R., Fujita, P. A., Guruvadoo, L., Haeussler, M., Harte, R. A., Heitner, S., Hickey, G., Hinrichs,
A. S., Hubley, R., Karolchik, D., Learned, K., Lee, B. T., Li, C. H., Miga, K. H., Nguyen, N.,
Paten, B., Raney, B. J., Smit, A. F. A., Speir, M. L., Zweig, A. S., Haussler, D., Kuhn, R. M., and
Kent, W. J. (2015). The UCSC Genome Browser database: 2015 update. Nucleic Acids Research,
43(Database issue):D670–D681.
Rosenfeld, C. S., Sieli, P. T., Warzak, D. A., Ellersieck, M. R., Pennington, K. A., and Roberts, R. M.
(2013). Maternal exposure to bisphenol A and genistein has minimal effect on Avy/a offspring
coat color but favors birth of agouti over nonagouti mice. Proceedings of the National Academy of
Sciences, 110(2):537–542.
Rowell, P. P. and Clark, M. J. (1982). The effect of chronic oral nicotine administration on fetal
weight and placental amino acid accumulation in mice. Toxicology and Applied Pharmacology,
66(1):30 – 38.
Roy, T., Andrews, J., Seidler, F., and Slotkin, T. (1998). Nicotine evokes cell death in embryonic rat
brain during neurulation. Journal of Pharmacology and Experimental Therapeutics, 287(3):1136–
1144.
Rozen, S. and Skaletsky, H. (1999). Primer3 on the WWW for General Users and for Biologist
Programmers. 132:365–386.
Sagone, A. L., Lawrence, T., and Balcerzak, S. P. (1973). Effect of smoking on tissue oxygen supply.
Blood, 41(6):845–851.
Sanchez Vega, M. C., Chong, S., and Burne, T. H. (2013). Early gestational exposure to moderate
concentrations of ethanol alters adult behaviour in C57BL/6J mice. Behavioural Brain Research,
252:326 – 333.
Sathyan, P., Golden, H. B., and Miranda, R. C. (2007). Competing interactions between micro-RNAs
determine neural progenitor survival and proliferation after ethanol exposure: evidence from an ex
vivo model of the fetal cerebral cortical neuroepithelium. Journal of Neuroscience, 27(32):8546–
8557.
Schneider, A., Thiel, C., Rindermann, J., DeRossi, C., Popovici, D., Hoffmann, G. F., Grone, H.-
J., and Korner, C. (2012). Successful prenatal mannose treatment for congenital disorder of
glycosylation-Ia in mice. Nature Medicine, 18(1):71 – 73.
Seller, M. J. and Perkins-Cole, K. J. (1987). Sex difference in mouse embryonic development at
neurulation. Journal of Reproduction and Fertility, 79(1):159–161.
127
Serrano, M., Han, M., Brinez, P., and Linask, K. K. (2010). Fetal alcohol syndrome: cardiac birth
defects in mice and prevention with folate. American Journal of Obstetrics and Gynecology,
203(1):e7–e15.
Silver, M. J., Kessler, N. J., Hennig, B. J., Dominguez-Salas, P., Laritsky, E., Baker, M. S., Coarfa,
C., Hernandez-Vargas, H., Castelino, J. M., Routledge, M. N., and et al. (2015). Independent
genomewide screens identify the tumor suppressor VTRNA2-1 as a human epiallele responsive to
periconceptional environment. Genome Biology, 16(1):doi: 10.1186/s13059–015–0660–y.
Singh, S. P., Snyder, A. K., and Pullen, G. L. (1989). Maternal alcohol ingestion inhibits fetal glucose
uptake and growth. Neurotoxicology and Teratology, 11(3):215–9.
Slotkin, T., McCook, E., and Seidler, F. (1997). Cryptic brain cell injury caused by fetal nicotine
exposure is associated with persistent elevations of c-fos protooncogene expression. Brain research,
750(1):180–188.
Slotkin, T. A., Stadler, A., Skavicus, S., Card, J., Ruff, J., Levin, E. D., and Seidler, F. J. (2016). Is
there a critical period for the developmental neurotoxicity of low-level tobacco smoke exposure?
Toxicological Sciences.
Soares, A. R., Pereira, P. M., Ferreira, V., Reverendo, M., Simoes, J., Bezerra, A. R., Moura, G. R.,
and Santos, M. A. S. (2012). Ethanol exposure induces upregulation of specific microRNAs in
zebrafish embryos. Toxicological Sciences, 127(1):18–28.
Sokol, R. J., Miller, S. I., and Reed, G. (1980). Alcohol abuse during pregnancy: an epidemiologic
study. Alcoholism: Clinical and Experimental Research, 4(2):135–145.
Somm, E., Schwitzgebel, V. M., Vauthay, D. M., Aubert, M. L., and Hüppi, P. S. (2009). Prenatal
nicotine exposure and the programming of metabolic and cardiovascular disorders. Molecular and
Cellular Endocrinology, 304(1-2):69–77.
Somm, E., Schwitzgebel, V. M., Vauthay, D. M., Camm, E. J., Chen, C. Y., Giacobino, J.-P., Sizo-
nenko, S. V., Aubert, M. L., and Hüppi, P. S. (2008). Prenatal nicotine exposure alters early
pancreatic islet and adipose tissue development with consequences on the control of body weight
and glucose metabolism later in life. Endocrinology, 149(12):6289–6299.
Song, F., Mahmood, S., Ghosh, S., Liang, P., Smiraglia, D. J., Nagase, H., and Held, W. A. (2009).
Tissue specific differentially methylated regions (TDMr): Changes in DNA methylation during
development. Genomics, 93(2):130–139.
Sparks, J. A. and Pauly, J. R. (1999). Effects of continuous oral nicotine administration on brain nico-
tinic receptors and responsiveness to nicotine in C57Bl/6 mice. Psychopharmacology, 141(2):145–
153.
128 REFERENCE LIST
Stratton, K., Howe, C., Battaglia, F., of Medicine (U.S.). Division of Biobehavioral Sciences, I.,
to Study Fetal Alcohol Syndrome, M. D. C., on Alcohol Abuse, N. I., and (U.S.), A. (1996). Fetal
alcohol syndrome: diagnosis, epidemiology, prevention, and treatment. National Academy Press.
Streissguth, A., Clarren, S., and Jones, K. (1985). Natural history of the fetal alcohol syndrome: A
10-year follow-up of eleven patients. The Lancet, 326(8446):85–91.
Streissguth, A., Martin, D., Barr, H., and Sandman, B. (1984). Intrauterine alcohol and nicotine ex-
posure: attention and reaction time in 4-year-old children. Developmental Psychology, 20(4):533–
541.
Streissguth, A. P., Bookstein, F. L., Barr, H. M., Sampson, P. D., O’Malley, K., and Young, J. K.
(2004). Risk factors for adverse life outcomes in fetal alcohol syndrome and fetal alcohol effects.
Journal of Developmental and Behavioral Pediatrics, 25(4):228–238.
Sulik, K. K., Johnston, M. C., and Webb, M. A. (1981). Fetal alcohol syndrome: embryogenesis in a
mouse model. Science, 214(4523):936–938.
Talhout, R., Schulz, T., Florek, E., Van Benthem, J., Wester, P., and Opperhuizen, A. (2011). Haz-
ardous compounds in tobacco smoke. International Journal of Environmental Research and Public
Health, 8(12):613–628.
Tobi, E. W., Goeman, J. J., Monajemi, R., Gu, H., Putter, H., Zhang, Y., Slieker, R. C., Stok, A. P.,
Thijssen, P. E., Muller, F., and et al. (2014). DNA methylation signatures link prenatal famine
exposure to growth and metabolism. Nature Communications, 5(5592):doi: 10.1038/ncomms6592.
Tobi, E. W., Lumey, L. H., Talens, R. P., Kremer, D., Putter, H., Stein, A. D., Slagboom, P. E.,
and Heijmans, B. T. (2009). DNA methylation differences after exposure to prenatal famine are
common and timing- and sex-specific. Human Molecular Genetics, 18(21):4046–4053.
Tong, M., Ziplow, J., Chen, W. C., Nguyen, Q.-G., Kim, C., and de la Monte, S. M. (2013). Mo-
tor function deficits following chronic prenatal ethanol exposure are linked to impairments in in-
sulin/IGF, Notch and Wnt signaling in the cerebellum. Journal of Diabetes & Metabolism, 4(1):doi:
10.4172/2155–6156.1000238.
Tunster, S. J., Van De Pette, M., and John, R. M. (2014). Isolating the role of elevated Phlda2 in
asymmetric late fetal growth restriction in mice. Disease Models & Mechanisms, 7(10):1185–
1191.
U.S. Food and Drug Administration (2012). Harmful and potentially harmful constituents in tobacco
products and tobacco smoke; established list. Federal Register, FDA2012N0143.
van der Schoot, P. (1992). Disturbed testicular descent in the rat after prenatal exposure to the antian-
drogen flutamide. Reproduction, 96(2):483–496.
129
Vangipuram, S. D. and Lyman, W. D. (2012). Ethanol affects differentiation-related pathways and
suppresses Wnt signaling protein expression in human neural stem cells. Alcoholism: Clinical and
Experimental Research, 36(5):788–797.
Viljoen, D. L., Gossage, J. P., Brooke, L., Adnams, C. M., Jones, K. L., Robinson, L. K., Hoyme,
H. E., Snell, C., Khaole, N. C., Kodituwakku, P., Asante, K. O., Findlay, R., Quinton, B., Marais,
A. S., Kalberg, W. O., and May, P. A. (2005). Fetal alcohol syndrome epidemiology in a South
African community: a second study of a very high prevalence area. Journal of Studies on Alcohol,
66(5):593–604.
Wakabayashi, Y., Watanabe, H., Inoue, J., Takeda, N., Sakata, J., Mishima, Y., Hitomi, J., Yamamoto,
T., Utsuyama, M., Niwa, O., Aizawa, S., and Kominami, R. (2003). Bcl11b is required for differ-
entiation and survival of αβ T lymphocytes. Nature Immunology, 4(4):533 – 539.
Wang, G. and Bieberich, E. (2010). Prenatal alcohol exposure triggers ceramide-induced apoptosis in
neural crest-derived tissues concurrent with defective cranial development. Nature Cell Death and
Disease, 1(e46):doi: 10.1038/cddis.2010.22.
Wang, L. L., Zhang, Z., Li, Q., Yang, R., Pei, X., Xu, Y., Wang, J., Zhou, S. F., and Li, Y. (2009).
Ethanol exposure induces differential microRNA and target gene expression and teratogenic effects
which can be suppressed by folic acid supplementation. Human Reproduction, 24(3):562–79.
Wang, T., Chen, M., Yan, Y.-E., Xiao, F.-Q., Pan, X.-L., and Wang, H. (2008). Growth retardation
of fetal rats exposed to nicotine in utero: possible involvement of CYP1A1, CYP2E1, and P-
glycoprotein. Environmental Toxicology, 24(1):33–42.
Wang, Z.-X., Kueh, J. L., Teh, C. H.-L., Rossbach, M., Lim, L., Li, P., Wong, K.-Y., Lufkin, T.,
Robson, P., and Stanton, L. W. (2007a). Zfp206 is a transcription factor that controls pluripotency
of embryonic stem cells. Stem Cells, 25(9):2173–2182.
Wang, Z.-X., Teh, C. H.-L., Kueh, J. L. L., Lufkin, T., Robson, P., and Stanton, L. W. (2007b).
Oct4 and Sox2 directly regulate expression of another pluripotency transcription factor, Zfp206, in
embryonic stem cells. Journal of Biological Chemistry, 282(17):12822–12830.
Ward, C., Lewis, S., and Coleman, T. (2007). Prevalence of maternal smoking and environmental
tobacco smoke exposure during pregnancy and impact on birth weight: retrospective study using
millennium cohort. BMC Public Health, 7(1):1.
Waterland, R. A. and Jirtle, R. L. (2003). Transposable elements: targets for early nutritional effects
on epigenetic gene regulation. Molecular and Cellular Biology, 23(15):5293–300.
Weitzman, M., Gortmaker, S., and Sobol, A. (1992). Maternal smoking and behavior problems of
children. Pediatrics, 90(3):342–349.
130 REFERENCE LIST
Werner, L., Muller-Fielitz, H., Ritzal, M., Werner, T., Rossner, M., and Schwaninger, M. (2012).
Involvement of doublecortin-expressing cells in the arcuate nucleus in body weight regulation.
Endocrinology, 153(6):2655–2664.
Williams, L., Seki, Y., Vuguin, P. M., and Charron, M. J. (2014). Animal models of in utero exposure
to a high fat diet: A review. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease,
1842(3):507–519.
Williams-Wyss, O., Zhang, S., MacLaughlin, S. M., Kleemann, D., Walker, S. K., Suter, C. M.,
Cropley, J. E., Morrison, J. L., Roberts, C. T., and Caroline McMillen, I. (2014). Embryo number
and periconceptional undernutrition in the sheep have differential effects on adrenal epigenotype,
growth, and development. AJP: Endocrinology and Metabolism, 307(2):E141–150.
Wisborg, K., Henriksen, T. B., Jespersen, L. B., and Secher, N. J. (2000). Nicotine patches for
pregnant smokers: a randomized controlled study. Obstetrics & Gynecology, 96(6):967–971.
Witasp, A., Carrero, J. J., Michaelsson, K., Ahlstrom, H., Kullberg, J., Adamsson, V., Riserus, U.,
Larsson, A., Helmersson-Karlqvist, J., Lind, L., Stenvinkel, P., and Arnlov, J. (2014). Inflammatory
biomarker pentraxin 3 (PTX3) in relation to obesity, body fat depots and weight loss. Obesity,
22(5):1373–1379.
Witek-Janusek, L. (1986). Maternal ethanol ingestion: effect on maternal and neonatal glucose bal-
ance. American Journal of Physiology-Endocrinology and Metabolism, 251(2):E178–E184.
Wongtrakool, C., Grooms, K., Ping, X.-D., Rivera, H., Ward, J., Roser-Page, S., Roman, J., Brown, L.
A. S., and Gauthier, T. W. (2012a). In utero nicotine exposure promotes M2 activation in neonatal
mouse alveolar macrophages. Pediatric Research, 72(2):147–153.
Wongtrakool, C., Wang, N., Hyde, D. M., Roman, J., and Spindel, E. R. (2012b). Prenatal nico-
tine exposure alters lung function and airway geometry through α7 nicotinic receptors. American
Journal of Respiratory Cell and Molecular Biology, 46(5):695–702.
Woo, N. D. and Persaud, T. V. N. (1988). Rat embryogenesis following exposure to alcohol and
nicotine. Acta Anatomica, 131(2):122 – 126.
Wright, J., Barrison, I., Lewis, I., MacRae, K., Waterson, E., Toplis, P., Gordon, M., Morris, N.,
and Murray-Lyon, I. (1983). Alcohol consumption, pregnancy, and low birthweight. The Lancet,
321(8326):663–665.
Xu, D., Bai, J., Zhang, L., Shen, L., Wang, L., Liu, Z., Xia, L., and Wang, H. (2015). Prenatal
nicotine exposure-induced intrauterine programming alteration increases the susceptibility of high-
fat diet-induced non-alcoholic simple fatty liver in female adult offspring rats. Toxicology Research,
4(1):doi: 10.1039/C4TX00092G.
131
Xu, D., Liang, G., Yan, Y., He, W., Liu, Y., Chen, L., Magdalou, J., and Wang, H. (2013). Nicotine-
induced over-exposure to maternal glucocorticoid and activated glucocorticoid metabolism causes
hypothalamic–pituitary–adrenal axis-associated neuroendocrine metabolic alterations in fetal rats.
Toxicology Letters, 209(3):282–290.
Yamada, L. and Chong, S. (2016). Epigenetic studies in developmental origins of health and dis-
ease: pitfalls and key considerations for study design and interpretation. Journal of Developmental
Origins of Health and Disease, Epub ahead of print:doi: 10.1017/S2040174416000507.
Yong, H.-H., Borland, R., Balmford, J., McNeill, A., Hitchman, S., Driezen, P., Thompson, M. E.,
Fong, G. T., and Cummings, K. M. (2015). Trends in e-cigarette awareness, trial, and use under
the different regulatory environments of Australia and the United Kingdom. Nicotine & Tobacco
Research, 17(10):1203–1211.
Yoshinaga, K., Rice, C., Krenn, J., and Pilot, R. L. (1979). Effects of nicotine on early pregnancy in
the rat. Biology of Reproduction, 20(2):294–303.
You, J. S., Kelly, T. K., De Carvalho, D. D., Taberlay, P. C., Liang, G., and Jones, P. A. (2011). Oct4
establishes and maintains nucleosome-depleted regions that provide additional layers of epigenetic
regulation of its target genes. Proceedings of the National Academy of Sciences, 108(35):14497–
14502.
Zhang, C. R., Ho, M.-F., Vega, M. C. S., Burne, T. H. J., and Chong, S. (2015). Prenatal ethanol ex-
posure alters adult hippocampal VGLUT2 expression with concomitant changes in promoter DNA
methylation, H3K4 trimethylation and miR-467b-5p levels. Epigenetics & Chromatin, 8(1):doi:
10.1186/s13072–015–0032–6.
Zhang, H. H., Huang, J., Duvel, K., Boback, B., Wu, S., Squillace, R. M., Wu, C.-L., and Manning,
B. D. (2009). Insulin stimulates adipogenesis through the Akt-TSC2-mTORc1 Pathway. PLoS
ONE, 4(7):e6189.
Zhang, W., Walker, E., Tamplin, O. J., Rossant, J., Stanford, W. L., and Hughes, T. R. (2006). Zfp206
regulates ES cell gene expression and differentiation. Nucleic Acids Research, 34(17):4780–4790.
Zhao, Z. and Reece, E. A. (2005). Nicotine-induced embryonic malformations mediated by apop-
tosis from increasing intracellular calcium and oxidative stress. Birth Defects Research Part B:
Developmental and Reproductive Toxicology, 74(5):383–391.
Zhou, F. C., Zhao, Q., Liu, Y., Goodlett, C. R., Liang, T., McClintick, J. N., Edenberg, H. J., and Li,
L. (2011). Alteration of gene expression by alcohol exposure at early neurulation. BMC Genomics,
12(124):doi: 10.1186/1471–2164–12–124.
132 REFERENCE LIST
Zurakowski, H., Gagnon, A., Landry, A., Layne, M. D., and Sorisky, A. (2007). Discoidin domain
receptor 2 impairs insulin- stimulated insulin receptor substrate-1 tyrosine phosphorylation and
glucose uptake in 3T3-L1 adipocytes. Hormone and Metabolic Research, 39(8):575 – 581.
Appendix
Table A1: List of oligonucleotides used in this project. Primers were obtained from previous liter-
ature, or pre-designed and purchased through KiCqStart (Sigma Aldrich, Australia), or designed for
this project using Primer3 (Rozen and Skaletsky, 1999) or MethPrimer (Li and Dahiya, 2002), based
on RefSeq sequences accessed from the UCSC database (Kent, 2002).
Primer name Sequence 5’ to 3’ Source
SX_F GAT GAT TTG AGT GGA AAT GTG AGG TA McFarlane et al., 2013
SX_R CTT ATG TTT ATA GGC ATG CAC CAT GTA
Hsp90ab1-F AGA ATC CGA CAC CAA ACT GC Primer3
Hsp90ab1-R CAT TGC TAA GTC TGG CAC GA
Gapdh-F CCC TGT TGC TGT AGC CGT AT Primer3
Gapdh-R GGC ATT GCT CTC AAT GAC AA
Actb_F CCT TCT GAC CCA TTC CCA CC Primer3
Actb_R GGC TGT ATT CCC CTC CAT CG
FM1_Bcl11a CGT CAT CTA GAG GAA TTT GC KiCqStart, Sigma Aldrich
RM1_Bcl11a CTC ATC TTT ACA AAT ACC CTG C
FM1_Bcl11b ATG AAG ATG ACC ACC TAC TG KiCqStart, Sigma Aldrich
RM1_Bcl11b GCT CAT CTT TAC CTG CAA TG
FM1_Cdx1 GAA AAG GAG TTT CAC TAC AGC KiCqStart, Sigma Aldrich
RM1_Cdx1 TGG AAC CAG ATC TTT ACC TG
FM1_Dcx GGA TGA GAA TGA ATG CAG AG KiCqStart, Sigma Aldrich
RM1_Dcx CTT TGA CTT AGG TGT TGA GAG
FM1_Lamc3 CTA GAG GGA ATG AAG CTG AG KiCqStart, Sigma Aldrich
RM1_Lamc3 CTG CTT CTT TGC TTT TCT TC
FM1_Insm1 CTG TAT ACG TTT GTC TCG TG KiCqStart, Sigma Aldrich
RM1_Insm1 ACA TAG AGA GCA GAG ATT GG
FM1_Alx3 TCT TCC AGA AAA CCC ACT AC KiCqStart, Sigma Aldrich
RM1_Alx3 CAG TAC GGA GAT GTC ATA GG
FM1_Gp5 GAA CTG CTT CAG ACA TGC KiCqStart, Sigma Aldrich
RM1_Gp5 ATG TGT GTG AGG TTC GTA G
FM1_Barx1 AAT AGA TCT AGC TGA GTC CC KiCqStart, Sigma Aldrich
Continued on next page
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Primer name Sequence 5’ to 3’ Source
RM1_Barx1 TTG CAG CAC TAT TTT CTT CC
FM1_Epha5 TCA TAA CGG GCA CAT TAA AC KiCqStart, Sigma Aldrich
RM1_Epha5 GCA AAC TTC ACC AAA TTC AC
FM1_Inmt CAT AGG AGG TGA GGA CTA TG KiCqStart, Sigma Aldrich
RM1_Inmt AAC TTT ACG ATT TCC TGC TC
FM1_Mapt CAG GTG GAA GTA AAA TCA GAG KiCqStart, Sigma Aldrich
RM1_Mapt GGG TTT CAA TCT TCT TAT TCC C
FM1_Ddr2 CGA GAT CAC TTT CCA ATC AG KiCqStart, Sigma Aldrich
RM1_Ddr2 ACA GGA TGA TGA CGA TGA TAG
FM1_Ptx3 GGT TGT GAA ACA GCA ATT TTC KiCqStart, Sigma Aldrich
RM1_Ptx3 TAC AGC TGA ATC TCA TAG GG
Phlda2_Tunster_F TCA GCG CTC TGA GTC TGA AA Tunster et al., 2014
Phlda2_Tunster_R TCC TGG GCT CCT GTC TGA T
Nefm_L GTG CGA GGC ACT AAG GAG TC Primer3
Nefm_R ATT TTC CAA CTG CTG GAT GG
FM1_Sst CAA CCA GAC AGA GAA TGA TG KiCqStart, Sigma Aldrich
RM1_Sst AAC AGG ATG TGA ATG TCT TC
FM1_Zscan10 GAT ACC TCA GAG AAG AGA GC KiCqStart, Sigma Aldrich
RM1_Zscan10 GTC ACT TTA GGC TCT TCA AC
Zfp206_F_Zhang2006 GAC GGA GAG GAG GTG GTA CA Zhang et al., 2006
Zfp206_R_Zhang2006 AGC TGC GTC CAA AAG TCT TC
Zscan10_F1-2 ATA CTC CAG GAC CCA CGA GA Primer3
Zscan10_R1 GCA TCG GAA GCT CCT CTA AC Primer3
Zscan10_R2 ACT GGT GGG CTT CAC AAC TT Primer3
Zscan10_F3b GGT AGA GAC CCT TCC CAG Primer3
Zscan10_R3 ACT CTG CTC CAA TGA CGA CA Primer3
Zscan10-BS-P1-L1 TTA TGT TTT TAG AGT TTG TTG TTT AAT AAA MethPrimer
Zscan10-BS-P1-L2 TAT GAA TGA AAA GTT AAG TAA AGA GGT TTA MethPrimer
Zscan10-BS-P1-R1/2 AAT ACT ATA AAC CTA CAC CCC AAC C MethPrimer
Zscan10-BS-P2-L1 TAT TAT GTG GTT GTT GGG AAT TG MethPrimer
Zscan10-BS-P2-L2 TTT TTA ATT TTT GAG TTA TTT TTT TT MethPrimer
Zscan10-BS-P2-R1/2 ACC TCA AAC CTA AAC CTA AAC TCT MethPrimer
Zscan10-BS-3CGI-L1 TTT TAT TTA AAA TTT TTA GTT GAT TAG TTA MethPrimer
Zscan10-BS-3CGI-L2 TTT TTA GTT GAT TAG TTA TTA GTA GAT TTA MethPrimer
Zscan10-BS-3CGI-R1/2 ACA ATA CAC AAA AAT AAA ACC TTA C MethPrimer
M13 reverse primer CAG GAA ACA GCT ATG ACC
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Table A2: Genes identified to be differentially expressed in the nicotine-exposed embryos following
a genome-wide gene expression microarray (absolute fold change ≥ 1.5 fold, with an uncorrected
p-value <0.05.)
Probe Id Gene Fold change p-value
ILMN_2543198 0610030P10Rik 1.62 0.0241
ILMN_1222219 2610528A11Rik 2.57 0.0144
ILMN_2869623 6330503C03Rik 1.6 0.0023
ILMN_2470131 6720475J19Rik -1.58 0.0332
ILMN_2724194 9030425E11Rik -1.62 0.0055
ILMN_1256238 A430103B12Rik -1.64 0.0241
ILMN_1228804 A430106G13Rik -1.53 0.0284
ILMN_2482662 A730036E13Rik -1.81 0.01
ILMN_2650115 Adamtsl2 1.56 0.0068
ILMN_3052026 Alx3 -1.51 0.0068
ILMN_2728038 Arhgap24 1.67 0.0023
ILMN_2433635 AW125296 2.25 0.0036
ILMN_2831618 Barx1 -2 0.0204
ILMN_1259956 Barx1 -2 0.01
ILMN_2712044 Bcl11a -2.43 0.0036
ILMN_1257463 Bcl11a -1.81 0.0023
ILMN_2611022 Bcl11b -2.05 0.0008
ILMN_2721466 Bnc2 -1.57 0.0172
ILMN_1255869 Catnb -1.58 0.0172
ILMN_1226329 Cd93 -1.61 0.0241
ILMN_2694175 Cd97 -1.78 0.0144
ILMN_2863641 Cdx1 1.53 0.0055
ILMN_2725801 Cdx1 1.8 0.0018
ILMN_2725853 Cdx2 2.59 0.012
ILMN_1241829 Cdx4 2.13 0.0241
ILMN_2681321 Cntnap2 1.66 0.0449
ILMN_1241768 Col23a1 -2.05 0.01
ILMN_2650447 Col23a1 -1.57 0.0172
ILMN_2913563 Crym -1.61 0.0387
ILMN_2801891 Cygb -1.54 0.0449
ILMN_2573159 D130047L08Rik -1.55 0.0332
ILMN_1220958 D930002M03Rik -1.86 0.0172
ILMN_2522345 D930014N22Rik -1.75 0.0284
ILMN_2596346 Dcn -1.79 0.0055
ILMN_2747959 Dcn -1.65 0.0144
ILMN_1228206 Dcx -1.89 0.0332
ILMN_2926480 Diras2 -1.6 0.0387
ILMN_2699621 Dlk2 -1.5 0.0045
ILMN_2800505 Dlx1 -1.8 0.0001
ILMN_3140871 Dmbx1 1.62 0.0449
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Probe Id Gene Fold change p-value
ILMN_1230366 Dmrt3 1.61 0.0172
ILMN_1255731 Dnm3os -1.72 0.0068
ILMN_1222451 Dst -1.51 0.012
ILMN_1221523 E330027M22Rik 1.97 0.0144
ILMN_1251248 Ebf2 -1.56 0.0449
ILMN_2714455 Ebf3 -1.64 0.0204
ILMN_2422615 Ebf3 -1.53 0.0284
ILMN_2890915 EG331493 -1.56 0.0172
ILMN_1228497 Esrrb 1.55 0.0172
ILMN_2731113 Evx1 2.47 0.0204
ILMN_2639788 Fgf17 1.9 0.0172
ILMN_3163279 Foxe1 -1.88 0.0241
ILMN_1249766 Gbx2 1.61 0.0001
ILMN_1224859 Gimap6 -1.53 0.0284
ILMN_2840975 Gls2 1.65 0.0011
ILMN_1259653 Gng8 -1.55 0.0082
ILMN_1236762 Gp5 -1.55 0.0332
ILMN_3006587 Greb1 1.55 0.0018
ILMN_1258462 Hoxa9 1.67 0.0204
ILMN_1240198 Hoxb1 1.69 0.0014
ILMN_2818750 Hoxb1 1.71 0.0006
ILMN_2836888 Hoxc10 3.06 0.0144
ILMN_2836885 Hoxc10 2.41 0.0082
ILMN_1217328 Hoxc6 1.55 0.0055
ILMN_2702687 Hoxd10 1.99 0.0068
ILMN_2693052 Hoxd8 1.9 0.0036
ILMN_1216475 Hoxd9 1.95 0.0029
ILMN_2800183 Hoxd9 2.01 0.0055
ILMN_2731265 Hsd11b2 -1.53 0.01
ILMN_1214071 Ifitm1 1.85 0.0045
ILMN_2769884 Igf1 -1.68 0.0029
ILMN_1231445 Inmt -1.69 0.0144
ILMN_2859558 Insm1 -1.55 0.0172
ILMN_3040693 Lamc3 -2.26 0.0036
ILMN_1217849 Laptm5 -1.6 0.0144
ILMN_1225672 Lhx1 1.62 0.01
ILMN_1245007 LOC100045413 1.55 0.0014
ILMN_2536687 LOC383077 -1.59 0.0144
ILMN_2446405 LOC98434 -1.57 0.0241
ILMN_2997494 Lox -1.61 0.0055
ILMN_2740020 Mapt -1.52 0.012
ILMN_2474596 Mllt3 1.51 0
ILMN_2769777 Msc -2.03 0.0172
Continued on next page
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ILMN_2594039 Nat8l 1.66 0.0011
ILMN_2632416 Nef3 -1.92 0.0449
ILMN_1224128 Nfe2l2 -1.68 0.012
ILMN_2726585 Nfib -1.53 0.0006
ILMN_1216381 Nfic -1.53 0.0068
ILMN_1216442 Nkx1-2 3.13 0.0144
ILMN_2659630 Nkx1-2 2.31 0.0055
ILMN_2755578 Nnat -1.56 0.0055
ILMN_3076625 Nr2f2 -1.72 0.0204
ILMN_2756023 Pcsk9 1.69 0.0036
ILMN_2425029 Phlda2 1.82 0.0204
ILMN_1247753 Ppap2b -1.55 0.012
ILMN_2760001 Ppfibp2 -1.71 0.0045
ILMN_1256317 Prl3b1 -1.53 0.01
ILMN_2758029 Prtn3 -1.67 0.012
ILMN_2662802 Ptx3 -2.59 0.0045
ILMN_2662803 Ptx3 -1.94 0.0172
ILMN_1216781 Rab11fip5 -1.52 0.006
ILMN_2664202 Rarres1 -1.51 0.0172
ILMN_2643443 Sall1 1.62 0.0018
ILMN_3001398 Sall3 1.78 0.0204
ILMN_1252794 Sall3 1.57 0.0014
ILMN_2729826 Sst -2.32 0.005
ILMN_1244340 T 2.11 0.0332
ILMN_2696903 Tal2 1.66 0.01
ILMN_1249014 Tbx6 3.03 0.01
ILMN_2907214 Tcea3 1.66 0.0018
ILMN_1237948 Tes -1.75 0.0241
ILMN_2727663 Tgfbi -1.6 0.01
ILMN_2817714 Tspan17 -1.86 0.0144
ILMN_1234111 Vtn -1.98 0.0449
ILMN_2469090 Wnt1 1.67 0.0172
ILMN_1220516 Wnt3a 1.58 0.0001
ILMN_2858050 Zscan10 1.73 0.0172
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A
B
Figure A1: (A) Crown-rump length (µm) and (B) head length (µm) normalised to crown-rump length
(µm) of embryos at 9.5 dpc following prenatal exposure to ethanol and/or nicotine. Embryos in
this figure were generated from cohort A (Chapter 3). Morphometric measurements in this figure
were obtained by SC, with similar results obtained from a second investigator unblinded to embryo
treatment group (LY) (Figure 4.2). Mean± S.D. is indicated. **: p<0.01, ***: p<0.001 as determined
by a Student’s t-test. Control males: n=17 (6 litters), ethanol males: n=22 (7 litters), nicotine males:
n=22 (6 litters), EtOH/NIC males: n=13 (5 litters), control females: n=24 (7 litters), ethanol females:
n=20 (7 litters), nicotine females: n=16 (6 litters), and EtOH/NIC females: n=21 (6 litters).
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Figure A2: Crown-rump length normalised to the somite number for each embryo at 9.5 dpc. Embryos
in this figure were generated from cohort A (Chapter 3). Morphometric measurements in this figure
were obtained by SC who was blinded to embryo treatment group, with similar results obtained from
a second investigator unblinded to embryo treatment group (LY) (Figure 4.3). Mean± S.D. indicated.
*: p<0.05, ***: p<0.001 as determined by a Student’s t-test. Control males: n=17 (6 litters), ethanol
males: n=22 (7 litters), nicotine males: n=22 (6 litters), EtOH/NIC males: n=13 (5 litters), control
females: n=24 (7 litters), ethanol females: n=20 (7 litters), nicotine females: n=16 (6 litters), and
EtOH/NIC females: n=21 (6 litters).
Figure A3: Representative image of an embryo at 9.5 dpc following whole mount in situ hybridisation
with a probe for a somitic marker, Uncx4.1. Scale bar represents 1 mm.
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Figure A4: Number of somites in control and ethanol-exposed embryos at 9.5 dpc . Somite counts
in unstained embryos was compared to the average somite count of two investigators after staining
using whole mount in situ hybridisation for a somitic marker, Uncx4.1. n=33 control, and 29 ethanol-
exposed embryos. Each point represents an individual embryo. A linear regression line showing the
correlation between the two methodologies is displayed (r2=0.75).
Figure A5: Crown-rump length normalised to the somite number for each embryo at 9.5 dpc. Embryos
in this figure were generated from cohort B (Chapter 3). Morphometric measurements in this figure
were obtained by SC who was blinded to embryo treatment group, with similar results obtained from
a second investigator unblinded to embryo treatment group (LY) (Figure 4.3). Mean± S.D. indicated.
*: p<0.05 as determined by a Student’s t-test. Control males: n=43 (12 litters), nicotine males: n=28
(9 litters), control females: n=40 (13 litters), and nicotine females: n=28 (8 litters).
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Figure A6: Body composition parameters in female offspring following prenatal exposure to nicotine
or dual ethanol/nicotine, then either a postnatal high-fat or low-fat diet. Body weight (g) ((A), lean
mass (g) (B), fat mass (g) (C), and bone mineral density (g/cm2) (D). Mean ± S.D. is indicated. *:
p<0.05, as determined by a Student’s t-test . Control LFD: n=4 (2 litters), nicotine LFD: n=4 (3
litters), EtOH/NIC LFD: n=4 (4 litters), control HFD: n=4 (2 litters), nicotine HFD: n=4 (3 litters),
and EtOH/NIC HFD: n=4 (2 litters).
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Figure A7: Body composition parameters in male offspring following prenatal exposure to nicotine
or dual ethanol/nicotine, then either a postnatal high-fat or low-fat diet. Body weight (g) ((A), lean
mass (g) (B), fat mass (g) (C), and bone mineral density (g/cm2) (D). Mean ± S.D. is indicated. *:
p<0.05, as determined by a Student’s t-test . Control LFD: n=4 (4 litters), nicotine LFD: n=4 (2
litters), EtOH/NIC LFD: n=4 (2 litters), control HFD: n=4 (3 litters), nicotine HFD: n=4 (3 litters),
and EtOH/NIC HFD: n=4 (3 litters).
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Figure A8: MicroRNAs identified in nicotine-exposed compared to control male embryos at 9.5 dpc
to be differentially expressed by at least 1.5 fold, with an uncorrected p<0.05, as assayed on the
TaqMan array rodent miRNA cards. Data in this figure were normalised to miR-17. Similar results
were obtained when normalised to miR-134 (Figure 5.1). Mean ± S.D. is indicated. *: p<0.05, ***:
p<0.001 as determined by a Student’s t-test . Control males: n=12 (4 litters) and nicotine males: n=12
(6 litters)
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Figure A9: qRT-PCR validation assays for 6 miRNAs identified to be differentially expressed using
the TaqMan array rodent miRNA cards. Data in this figure were normalised to miR-17. Similar results
were obtained when normalised to miR-134 (Figure 5.4). Mean ± S.D. is indicated. Control males:
n=18 (10 litters) and nicotine males: n=16-17 (7 litters).
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Figure A10: qRT-PCR validation assays for 18 genes identified in the microarray experiment (Ta-
ble 5.3) in male 9.5 dpc embryos. Data in this figure were normalised to Hsp90ab1. Similar results
were obtained when normalised to Gapdh (Figure 5.5). Mean ± S.D. is indicated. *: p<0.05, as
determined by a Student’s t-test . Control males: n=17-18 (10 litters) and nicotine males: n=17 (7
litters).
A B
Figure A11: Zscan10 expression was assayed by qRT-PCR in female 9.5 dpc embryos from both the
(A) discovery (cohort A) (control females: n=18 (10 litters) and nicotine females: n=17 (8 litters))
and the (B) validation (cohort B) (control females: n=12 (6 litters) and nicotine females: n=12 (6
litters)) cohorts. Data in this figure were normalised to Hsp90ab1. Similar results were obtained
when normalised to Gapdh (Figure 5.6). Mean ± S.D. is indicated.
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Figure A12: Zscan10 expression was assayed by qRT-PCR in testes of control and nicotine-exposed
mice. Data in this figure were normalised to Actb. Similar results were obtained when normalised to
Gapdh (Figure 5.7). Mean ± S.D. is indicated. Control males: n=11 (4 litters) and nicotine males:
n=17 (3 litters).
Figure A13: Relative expression of each of the three transcripts identified in the 9.5 dpc male embryo.
Data in this figure were normalised to Hsp90ab1. Similar results observed when normalised to Gapdh
(Figure 5.9B). Mean ± S.D. is indicated. *:p<0.05, as determined by a Student’s t-test . Control
males: n=18 (10 litters) and nicotine males: n=17 (7 litters).
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Figure A14: Male 9.5 dpc embryos from cohort B were selected for analysis of Zscan10 DNA
methylation on the basis of their Zscan10 mRNA expression. Eight control embryos (from seven
litters) representing the full range of Zscan10 expression levels within the control group (black), four
nicotine-exposed embryos (from four litters) with basal levels of Zscan10 expression (blue), and four
nicotine-exposed embryos (from two litters) with relatively high levels of Zscan10 expression (red)
were selected for analysis of DNA methylation. Embryos indicated by grey circles represent those in
which DNA methylation was not assayed. Expression in this figure was normalised to Hsp90ab1. Ex-
pression levels of Zscan10 when normalised to Gapdh in the embryos selected for DNA methylation
analysis is represented in Figure 6.3.
